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ABSTRACT  
Hannah Patricia Thompson  
EXPLORING THE SENSITIVITY OF MANTLE CELL LYMPHOMA TO INHIBITORS OF   
BRUTON’S TYROSINE KINASE 
 
Mantle cell lymphoma (MCL) is an incurable B-cell lymphoma which responds poorly to 
conventional chemotherapy. Inhibitors of Bruton’s tyrosine kinase (BTKi) have shown a 
significant clinical effect; despite this success however, approximately one third of MCL 
patients have primary resistance to the drug, and patients who initially respond to 
treatment frequently acquire secondary resistance with aggressive relapse of the 
disease. The purpose of this study was to understand how BTKi-resistance or sensitivity 
is mediated, aiming to identify new targets for therapy or predictive biomarkers of 
response.  
 
Combining a range of cell culture, biochemical and molecular techniques, the work 
presented describes the development of in vitro models of MCL with different 
sensitivity or resistance to BTKi. These models identify distinct functional and signalling 
responses of sensitive or resistant cell lines during BTKi treatment in the presence or 
absence of stromal cell support. The REC-1 cell line demonstrated reduced survival, 
proliferation, inhibition of BTK and ERK signalling, and downregulation of IRF4 
expression in response to BTK inhibition. In contrast, resistant cell lines (G519, JEKO-1 
and JVM2) or REC-1 cells with acquired resistance to BTKi did not downregulate IRF4.  
The stromal microenvironment also supported BTKi resistance and opposed IRF4 
downregulation. These findings were reproduced using ex vivo primary MCL cells taken 
before and during clinical BTKi therapy, identifying IRF4 as a potential mediator and 
biomarker of BTKi treatment sensitivity or resistance in a clinical setting.  
 
Further detailed assessment of IRF4 protein interactions using molecular and 
proteomic approaches in BTKi sensitive cells identified a novel potential association 
with proteins involved in mitochondrial function that may be involved in resistance to 
treatment with BTKi. Further investigation of these interactions may indicate novel 
targets for the design of therapeutic combinations which can overcome BTKi resistance 
in MCL. 
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1.1 Mantle cell lymphoma 
Mantle cell lymphoma (MCL) is currently classified by the World Health Organisation 
(WHO) as a mature B-cell neoplasm which represents up to 10% of all cases of Non-
Hodgkin’s Lymphoma (NHL).1,2  The incidence of MCL is approximately 1 in 100,000 in 
Europe and the USA3 and is marginally higher among Caucasians (~0.6 in 100,000) than 
among black and Asian populations (~0.3 in 100,000).4 MCL can develop at a young 
age, but diagnosis of the disease is more common in elderly individuals with a median 
age of 65 years,5 and the frequency of males diagnosed is greater than that of females 
(3:1 ratio, respectively).2,6 
The majority of MCL patients (75%) are diagnosed at a late clinical stage (stage III-IV) 
with an aggressive form of MCL, characterised by progressive nodal disease indicated 
by widespread dissemination of MCL cells to the lymph nodes (>90%), bone-marrow 
(70-80%), spleen (60%), liver (30%), peripheral blood (30%) and gastrointestinal tract 
(lymphomatous polyposis) (20-30%).1,7,8 Patients with aggressive MCL have the worst 
long term survival of all NHL subtypes with a median overall survival of 3-5 years and 
require immediate treatment.8-10  
However, a minority of MCL patients display a more indolent form of the disease, 
characterised by a non-nodal leukaemic presentation with only bone marrow 
involvement and an enlarged spleen.11,12 These indolent cases are less common but 
have a progression free survival ranging from 7 to 10 years in the absence of 
treatment.8,13,14 
3 
 
1.1.1 The biological characteristics of mantle cell lymphoma  
MCL is a heterogeneous disease and has several different phenotypes. However, the 
characteristic hallmark of MCL and the primary oncogenic mechanism in the 
development of MCL, is the t(11; 14) (q13; q32) translocation which occurs at the pre-
B stage of differentiation, during recombination of the V(D)J genes of the 
immunoglobulin heavy chain variable region (IGHV) in the bone marrow.15,16 This 
translocation event joins the IGHV enhancer-promotor on chromosome 14 (14q32), to 
the transcription unit of the proto-oncogene CCND1 on chromosome 11 (11q13) which 
encodes the protein cyclin D1.  
Cyclin D1 is a key regulator of the G1/S transition of the cell cycle.17,18 In normal B-cells, 
cyclin D1 is transiently expressed and binds to cyclin dependant kinase (CDK)4 and 
CDK6 to form a CDK/cyclin complex which phosphorylates the tumour suppressor 
retinoblastoma (RB1) gene. This leads to activation of E2F transcription factors which 
promote cyclin E/CDK2 activation to trigger entry into the S phase of the cell cycle.1,17  
In MCL, cyclin D1 is overexpressed which enables cells to bypass these cell cycle 
control mechanisms and leads to uncontrolled cell proliferation.19  
Although the t(11; 14) (q13; q32) translocation is found in the majority of MCL cases, a 
small number of cases lack cyclin D1 overexpression and instead overexpress cyclin D2 
or D3.20,21 In addition, the translocation exists in blood cells in approximately 2% of 
healthy individuals.1,22 This suggests that deregulation via CCND1 and cyclin D1 
overexpression is not the only cause for MCL development.  
MCL has a high degree of genomic instability. Several genomic aberrations are 
frequently observed in MCL which can increase cyclin D1 expression and are thought 
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to contribute to disease progression. Some of these include mutations in ATM and 
TP53 genes 23 causing alterations in DNA damage response, mutations in epigenetic 
modifiers including MLL2, MLL3 and SMARCA4,24 mutations in NOTCH1/2 25 causing 
deregulated Notch signalling, and mutations in TNF receptor-associated factor 2 
(TRAF2) and Baculoviral IAP Repeat Containing 3 (BIRC3) which affect the NFκB 
signalling pathway.26,27 
1.1.2 Cell of origin of mantle cell lymphoma 
MCL cells proliferate in the mantle zone, surrounding germinal centres (GC) within 
lymphoid follicles.28,29 However, the cell of origin of MCL remains a topic of debate. In 
most cases, the MCL cells express an un-mutated (germ line configuration) IGHV gene 
indicating a pre B-cell (antigen-naïve) origin. However IGHV somatic hyper-mutations 
have been reported in 15 - 40% of MCL cases 30-32 which indicate a GC B-cell (antigen-
exposed) origin. In around 10% of these cases, stereotyped heavy complementarity-
determining region 3 (VH CDR3) sequences have been detected which has indicated 
that the development of MCL cells can be driven by antigen selection.16,30 
1.1.3 Immunophenotype of mantle cell lymphoma cells 
MCL cells have a unique immunophenotype which can be determined by the cluster of 
differentiation (CD) proteins they express on their surface. These markers assist in 
identifying their stage in B cell development, and can be useful for differentiating MCL 
from other cell types and from other lymphomas with similar cell morphology. MCL 
cells reflect the phenotype of a mature B-cell with a moderate to strong expression of 
surface immunoglobulins IgM and IgD (mainly lambda).8,33 MCL cells also express the 
pan B-cell antigens including CD19, CD20 and CD22 and the T-cell and chronic 
lymphocytic leukaemia (CLL)-associated antigen CD5.34 However MCL cells do not 
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normally express CD10 (a GC associated antigen), or CD23 (a cell surface molecule for 
B-cell activation and growth).8 The absence of CD23 is particularly useful for identifying 
chronic lymphocytic leukaemia (CLL) cells which strongly express CD23.35,36 
Occasionally, some MCL cells have expression of CD10 and CD23 37 which pinpoints a 
later stage in B-cell development and therefore suggests a different subtype of NHL 
however the cells still display features that are characteristic of MCL. 
1.1.4 Histological subtypes of mantle cell lymphoma  
There are three different histologic patterns of MCL including mantle zone, nodular, 
and diffuse which correspond to different stages in the progression of the disease.38 
The majority of aggressive MCL cases show a diffuse pattern, while indolent MCL cases 
show a growth pattern restricted to the mantle zone, thus it is thought that the 
behavior of indolent cells may correspond to early stages in the development of 
aggressive MCL.16 
Four cytological variants have also been described including classical small-cell, 
blastoid, pleomorphic and marginal zone-like.1,39-41 The classical small-cell variant is the 
most common but the blastoid and pleomorphic variants have a higher Ki67 
proliferation index and are generally more aggressive.8  
1.1.5 Treatment of mantle cell lymphoma  
Conventional treatment for newly diagnosed patients is a combination chemotherapy 
regime which is tailed to the age and co-morbidities of the patient.  For those patients 
not suitable for autologous stem cell transplant then an anthracycline-based 
chemotherapy regime incorporating rituximab, a chimeric monoclonal antibody (mAb) 
which specifically targets the CD20 protein expressed on B-cells (R-CHOP; 
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cyclophosphamide, doxorubicin, vincristine and prednisone) can achieve remissions in 
60-90% of patients.42 However, for most of these patients the remission period is only 
temporary and is followed by relapse (return of disease and symptoms), while other 
patients may be refractory (not responding) to treatment. The median overall survival 
after relapse is between 1 and 2 years.43 More intensive cytarabine based regimes 
followed by an autologous transplant in complete remission offers better long term 
outcomes but is usually only an option for younger MCL patients without comorbidity 
who can tolerate the toxicities associated with these intense chemotherapy 
regimens.44 
Other agents which have been explored in the treatment of patients with MCL include 
bortezomib, lenalidomide and temsirolimus.  Bortezomib is a reversible proteasome 
inhibitor which induces cell cycle arrest and apoptosis in MCL cells.45 In initial clinical 
trials, bortezamib demonstrated overall response rates (ORR) of 32% as a single agent 
in relapsed and refractory MCL, increasing to 71% when given in combination with 
chemotherapy.46 Lenalidomide and temsirolimus, have shown only moderate activity 
as single agents in relapsed and refractory MCL (ORR 35% and 22%, respectively).47,48 
Within the last decade, there has been a fundamental change in the management of 
patients with MCL with the development of Bruton’s tyrosine kinase (BTK) inhibitors 
(BTKi). This will be discussed in more detail in later sections and although these agents 
have improved treatment outcomes in MCL, they are not effective in all patients, and 
those who do respond eventually develop acquired resistance and suffer relapse of the 
disease.  Therefore there is a continued need for drug development for patients with 
MCL. 
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1.2 Mantle cell lymphoma and the tissue microenvironment  
The tissue microenvironment is an important component in the development of many 
forms of cancer49-51 and has been implicated in the pathogenesis and drug resistance 
of several haematological malignancies, including MCL.52-54  
In addition to the intrinsic pathways that lead to the development and progression of 
MCL, there is growing evidence to suggest that interactions between MCL cells and 
accessory cells in the tissue microenvironment lead to disease progression.55,56 While 
the majority of MCL cells can be eliminated by conventional treatments, a minority of 
lymphoma cells reside in protective tissue niches (residual disease), where they receive 
signals from accessory cells that promote lymphoma cell survival, growth and drug-
resistance which lead to relapses.57 
1.2.1 Cellular interactions in the tissues; the role of CD40L 
The cellular components which make up the MCL microenvironment are found within 
the primary lymphoid organs (bone-marrow) and secondary lymphoid tissue (lymph 
nodes, spleen and mucosa-associated lymphoid tissues). Collectively, these include T 
cells, macrophages, follicular dendritic cells (FDCs) and mesenchymal stromal cells 
(MSCs).55 
An important interaction within the MCL microenvironment involves Follicular T helper 
cells (FTH). In normal B-cell maturation, FTH cells are required along with B-cells to 
produce a series of signals in order for the adaptive immune system to elicit a 
response to antigen. 
The first of these signals involves engagement of the FTH cell receptor with various 
antigens. These can either be peptides that are presented on the surface of antigen 
8 
 
presenting cells (APCs) in the context of the major histocompatibility complex II (MHC 
II), or unprocessed innate antigens binding to a cognate B-cell receptor (BCR).58  
The second step involves co-stimulatory signals between activated FTH cells and either 
APCs or B cells. One essential signal is produced by the CD40 Ligand (CD40L) (also 
known as CD154) expressed on activated FTH cells when it engages with the CD40 
receptor expressed on B-cells and APCs.59 
The CD40L is a type II transmembrane protein of the tumour necrosis factor (TNF) 
superfamily.  Although primarily expressed by activated T-cells and B-cells, CD40L can 
also be expressed on dendritic cells, granulocytes, macrophages and platelets.60-62 
CD40L may be cleaved into a soluble form (sCD40L) that has a cytokine-like activity. 
Both forms bind to several receptors, including CD40.60 
Engagement of CD40L to CD40 stimulates the formation of germinal centres (GC) and 
is critical for B cell proliferation, differentiation, antibody class switch recombination 
and affinity maturation. These processes are essential for the generation of memory B 
cells and long-lived plasma cells. 
During B cell differentiation within the GC (Figure 1.1), somatic hyper-mutation takes 
place to allow maturing B-cells to diversify the variable region of their surface 
immunoglobulin; through the addition of mutations in the V(D)J regions of both the 
heavy and light chains. This produces antibodies with high antigen affinity BCRs.63 
GC B-cells expressing BCRs with high affinities for antigen are selectively engaged by 
FTH cells and receive CD40 survival signals through their BCR, whereas GC B-cells 
expressing BCRs with weak affinities for antigen do not receive sufficient CD40 survival 
signals and are deleted via the extrinsic Fas-dependent apoptosis pathway.59 
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The CD40 signal is transduced through the ligand-dependent recruitment of adaptor 
proteins of the TNF receptor-associated factor (TRAF) family. This leads to activation of 
proximal protein kinases and subsequent activation of survival pathways (described in 
section 1.2.3) including the mitogen activated protein kinase (MAPK) pathway, the 
phosphatidylinositol 3-kinase (PI3K) cascade and the nuclear factor kappa-light-chain 
enhancer of activated B cells (NF-κB) pathways. Stimulation of these pathways leads to 
transcription of pro-survival proteins including the B-cell lymphoma-2 (BCL2) proteins 
(described in section 1.2.3) which protects the cell from apoptosis.59,64,65 
The observation from our group and others53,63-67 that ex vivo primary MCL cells 
undergo spontaneous apoptosis in vitro suggests that they depend on these signals 
within the in vivo environment for their survival. 
Established In vitro models have been described in the literature 53,64-67 which exploit 
various interactions within the tissue microenvironment and can be used to facilitate 
survival of primary cells in culture and to explore drug resistance pathways in MCL. 
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Figure 1.1: B cell differentiation and survival through the germinal centre. After encountering 
an antigen, naïve B cells are activated by their CD40L/CD40 interactions in the T cell rich zone 
of the lymph node, and the germinal centre reaction is initiated. B cells proliferate rapidly as 
centroblasts in the dark zone of the lymph node. These cells undergo somatic hypermutation 
(SHM) to diversify the heavy and light chain regions of their surface immunoglobulins. In the 
light zone, proliferation is reduced and some of these centrocytes undergo class switch 
recombination (CSR) of their immunoglobulin isotype. Interactions with follicular dendritic cells 
and T cells select the cells with highest antigen affinity. These cells then differentiate into 
plasma cells or memory B cells. B-cells with a low-affinity BCR undergo apoptosis. (Figure 
adapted from Marr 2016 68). 
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1.2.2 Chemokines, adhesion and migration 
MCL cells have a high propensity for dissemination and homing to different tissue 
compartments. The movement and homing of B lymphocytes is a regulated process 
during which the cells are attracted and retained in the tissues in response to 
chemokine gradients produced by mesenchymal stromal cells (MSCs) such as 
fibroblasts and associated macrophages. This is dependent on the responsiveness of 
chemokine receptors and the expression of various adhesion molecules on the MCL 
cell.52 
MCL cells express high levels of surface adhesion markers, such as the C-X-C motif 
chemokines CXCR4 and CXCR5, and the very late antigen 4 (VLA-4/CD49d), which are 
thought to be important for retaining the cells in their tissue microenvironment, and 
also integrin β1-containing receptors (α4β1 and α5β1) which are major mediators of 
cell adhesion to stroma.65 It is thought that the high expression of these receptors 
facilitates cell adhesion mediated drug resistance (CAM-DR) in MCL which may be 
responsible for characteristic relapses observed in MCL and the reason for the 
incurability of patients following chemotherapy.52,65  
Several studies are focusing on disrupting these homing and adhesion interactions by 
blocking external micro environmental signals.69,70 One study has demonstrated that 
inhibition of VLA-4 and CXCR4 adhesion increases sensitivity to chemotherapy in MCL 
cell lines.70 
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1.2.3 BCR signalling and downstream survival pathways  
The major signalling pathway in B-cell activity is the BCR pathway (Figure 1.2). The BCR 
is linked to downstream pathways which regulate the growth, differentiation and 
survival of normal B cells. BCR signalling pathways are critically involved in the 
progression of mantle cell lymphoma and thus components of the BCR signalling 
pathway are molecular targets for therapeutic approaches.73  
Important proteins required for B-cell signalling and activation are non-receptor 
tyrosine kinases. The BCR is composed of a membrane immunoglobulin (in most cases 
this is IgM) non-covalently bonded to a heterodimer composed of CD79a and CD79b. 
These molecules have cytoplasmic domains that contain Immunoreceptor Tyrosine-
based Activation Motifs (ITAMs) Igα and Igβ.71 When a specific antigen binds to a BCR, 
the tyrosine residues of the ITAMs are phosphorylated by SRC family kinases including 
LCK/YES novel tyrosine kinase (LYN), and spleen tyrosine kinase (SYK).72,73 The 
phosphorylation results in recruitment of many kinases and adaptor proteins, including 
LYN, SYK, PI3K, BTK, the guanine exchange factor VAV proteins, the growth factor 
receptor-bound protein 2 (GRB2) and the B-cell linker (BLNK).74  
Following recruitment of LYN and SYK to the phosphorylated ITAM of the BCR, BLNK is 
recruited to the non-ITAM portion of CD79a and is rapidly phosphorylated by SYK. 
Activated BLNK then recruits BTK for phosphorylation by SYK.75 This enables BTK to 
phosphorylate its direct substrate phospholipase C gamma (γ) 2 (PLCγ2), which 
hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG).
76 This event leads to calcium (Ca+2) 
mobilisation by IP3, and activation of protein kinase C (PKC) by DAG
77,78. The influx of 
calcium directly activates a number of transcription factors, including NF-κB, and 
13 
 
activator protein 1 (AP-1) which regulate important genes required for cell 
proliferation and survival, and nuclear factor of activated T cells (NFAT) which 
regulates cytokine production and other effectors of the immune response74. 
In addition to calcium influx, the β isoform of PKC (PKCβ) can lead to activation of NF-
κB by phosphorylating the caspase recruitment domain-containing protein (CARMA1) 
which activates the CARD11-BCL10-MALT1 (CBM) complex. The CBM activates NFκB 
which translocates to the nucleus to regulate transcription of NFAT and the 
myelocytomatosis viral oncogene homolog (c-MYC).83,84 In normal B cells, MYC 
activates transcriptional programs that favour cell growth and proliferation, and 
suppresses programs that cause cell growth arrest.79 
Activation of PKCβ also leads to activation of the MAPK pathway. The MAPK pathway 
includes the extracellular signal-regulated kinase 1/2 (ERK1/2) which is constitutively 
active in MCL 88,89 and therefore represents an additional target for investigation in this 
thesis. 
The MAPK pathway can also be activated via the PLC-γ2 signal which is transduced to 
the rapidly accelerated fibrosarcoma (RAS) protein through VAV and GRB2, which 
complexes with the son of sevenless (SOS) protein.80 These proteins which are 
recruited by BLNK after BCR ligation activate RAS in the form of RAS-gaunosine 
triphosphate (GTP). RAS-GTP then binds to the serine/threonine kinases B-RAF and C-
RAF. Stimulated RAF kinases phosphorylate and activate mitogen-activated protein 
kinase kinase (MEK1/2), which results in the phosphorylation of ERK1/2. 
Phosphorylated ERK1/2 kinases form dimers, which can then be translocated into the 
nucleus to regulate genes such as c-MYC and the transcriptional activator ETS Like-1 
protein (ELK1).81  The MAPK pathway regulates several other transcription factors 
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including AP-1 and the activating transcription factor 2 (ATF2) through c-Jun N-
terminal kinase (JNK), and the MYC associated factor X (MAX) through p38 MAPK, 
leading to proliferation and survival or apoptosis 74,82. 
There is an increasing body of evidence implicating deregulated BCR signalling in the 
pathogenesis and progression of several lymphomas, including MCL.81 In a phospho-
proteomic analysis of MCL cell lines, the most abundant phosphorylated peptides 
identified were those generated following BCR activation, including SYK, LYN, BTK, and 
PKC. Inhibition of key molecules of these pathways caused apoptosis in MCL cells in 
vitro 81. As mentioned, BTK is an essential protein linked to important BCR survival 
pathways in MCL and has a critical role in the amplification of the BCR signal. Inhibition 
of BTK has produced profound effects in the treatment of MCL patients (discussed in 
detail in section 1.3). 
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Figure 1.2: The key BCR signalling pathways involved in the progression of mantle cell 
lymphoma. BTK is an essential protein linked to important BCR survival pathways in MCL. The 
dashed arrows indicate that several steps may be involved in the activation of each component 
shown (Figure adapted from Roskoski 2016.81 Permission to reproduce this figure was granted 
by Elsevier). 
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As mentioned above, NFkB transcription factors can be activated by several BCR 
signalling components to regulate the growth and survival of B-cells. The NF-κB family 
has five monomers: RelA (p65), RelB, c-Rel, p50/p105 (NF-kB1) and p52/p100 (NF-kB2), 
which homo or hetero dimerise to form up to 15 different NF-κB complexes to regulate 
expression of growth factors, cytokines, chemokines, adhesion molecules, and 
apoptosis inhibitors. 
The two primary pathways for NF-κB activation are the canonical and non-canonical 
pathways (Figure 1.3) and these pathways are frequently deregulated in MCL 83. 
The canonical pathway is triggered by toll-like receptors (TLRs) and pro-inflammatory 
cytokines such as tumour necrosis factor alpha (TNFα) and interleukin-1 (IL-1), which 
initiate inflammatory responses, immune regulation, and cell proliferation. 
The non-canonical pathway is activated by TNF family cytokines, including lymphotoxin 
β (TNFSF3), CD40L and B cell-activating factor (BAFF), which promotes B cell 
maturation and lymphoid organogenesis. 
The common regulatory step in both of these cascades is activation of an inhibitory 
kappa B (IκB) kinase (IKK) complex consisting of catalytic kinase subunits (IKKα and/or 
IKKβ) and the regulatory non-enzymatic scaffold protein NEMO (NF-κB essential 
modulator also known as IKKγ).  
The NF-κB dimers are activated by IKK-mediated phosphorylation of IκB, which triggers 
proteasomal IκB degradation. This enables the active NF-κB transcription factor 
subunits to translocate to the nucleus and induce target gene expression.  
Stimulation of the canonical pathway by TLR leads to the recruitment of adaptors (such 
as TRAF) to the cytoplasmic domain of the receptor. These adaptors in turn recruit the 
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IKK complex, which leads to phosphorylation and degradation of the IκB inhibitor 
resulting in nuclear translocation of NF-κB dimers, predominantly the NF-κB 
heterodimer RelA/p50. 
Activation of canonical NFkB signalling by BCR also leads to nuclear translocation of 
RelA/p50 but occurs via an alternative pathway, involving activation of BTK, PKC and 
the CBM complex which leads to the activation of the IKK complex.  
The non-canonical pathway involves an IKK complex that contains two IKKα subunits, 
but not NEMO. Under non-stimulation, TNF associated factor proteins (TRAF) 2 and 
TRAF3 form a complex with cellular inhibitor of apoptosis 1 and 2 (cIAP 1 and cIAP 2) 
and the NFκB inducing kinase (NIK). Stimulation by TNF family cytokines such as CD40L 
destabilises the complex and releases NIK which phosphorylates and activates the IKKα 
complex leading to phosphorylation of the p52 precursor p100, and the persistent 
activation of the RelB/p52 heterodimer. 
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Figure 1.3: The canonical and non-canonical NF-kB signalling pathways. In the canonical 
pathway, ligand binding to a receptor leads to the recruitment and activation of an IKK 
complex comprising IKK alpha and/or IKK beta catalytic subunits and two molecules of NEMO. 
The IKK complex then phosphorylates IκB leading to proteasomal degradation. NF-κB then 
translocates to the nucleus to activate target genes. Non-canonical NF-kB activation involves 
phosphorylation and processing of the p52 precursor p100 into the mature protein and 
subsequent nuclear translocation of the RelB/p52 heterodimer to the nucleus to activate 
target genes. Chronic active BCR (A) or Toll-like receptor (TLR) (B) signalling activate the 
canonical NF-kB pathway. CD40 signalling (C) activates the non-canonical NF-kB pathway 
(Figure adapted from Colomer & Campo 2014.83 Permission to reproduce this figure was 
granted by Elsevier). 
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Important targets of NF-κB signalling include the BCL2 protein family which are the key 
regulatory proteins governing the intrinsic pathway of mitochondrial apoptosis84. 
The group of pro-apoptotic proteins includes BCL2-associated X protein (BAX), BCL2 
antagonist/killer 1 (BAK), BCL2-associated agonist of cell death (BAD), BCL2-like 11 
(BIM), BCL2 binding component 3 (PUMA) and NOXA which all promote cell death.  
The group of anti-apoptotic proteins to which BCL2 belongs also includes B-cell 
lymphoma-extra large (BCL-XL), the myeloid cell leukemia sequence 1 (MCL-1), BCL2-
like 2 (BCL-W) and the BCL2-related protein A1 (BFL-1), which all promote cell survival. 
As mentioned in section 1.2.1, levels of the BCL2 proteins increase in response to CD40 
stimulation which is important for the survival of mature B cells. CD40 signalling 
stimulates the non-canonical NFκB pathway leading to activation of RelB/p52 which 
induces expression of BCL2, BCL-XL and MCL-1 (Figure 1.4). In the absence of CD40 
stimulation, the cIAP1/2 complex degrades NIK which inhibits further signalling 
through the non-canonical NFkb pathway and promotes B cell apoptosis. 
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Figure 1.4: Survival of B cells in the presence and absence of CD40 signalling through the non 
canonical NFkB pathway. Under non-stimulation, TRAF 2 and TRAF3 form a complex with cIAP 
1 and cIAP 2 and NIK. In the absence of CD40 stimulation, the cIAP1/2 complex degrades NIK 
which inhibits further signalling through the non-canonical NFkb pathway and promotes B cell 
apoptosis. In the presence of CD40 stimulation, the complex is destabilised, permitting the 
release of NIK from the complex and continued signalling through the non-canonical NFκB 
pathway. The non-canonical NF-κB pathway targets activation of the p52/RelB NF-κB complex 
via processing of p100. Nuclear translocation of the p52/RelB dimer activates transcription of 
anti-apoptotic BCL2 family proteins thereby promoting survival (Figure adapted from Elgueta 
et al 2009 59 and Braun et al 2006 85). 
 
 
 
 
21 
 
In normal B cells, the balance of anti- and pro-apoptotic BCL2 proteins protects cells in 
response to cellular stress, but also induces death in damaged cells. Cancer cells can 
manipulate this system by skewing the balance toward anti-apoptotic proteins, 
thereby facilitating prolonged tumour-cell survival.86 
BCL2 proteins are overexpressed in several B cell malignancies including MCL.86-88 In a 
tissue microarray of 62 MCL samples,89 BCL2 expression positively correlated with 
expression of BTK, which as mentioned, is an essential component of the BCR signalling 
complex. BTK (discussed in detail in section 1.3) upregulated BCL2 transcription 
through the canonical NF-κB pathway. In addition, the high BCL2 levels were thought 
to result from a defect in protein degradation due to a deficiency of FBXO10 (the E3 
ubiquitin ligase which targets BCL2 for proteasomal degradation).90 
It has also been indicated that the high BCL2 levels in MCL may be due to mutations in 
the tumour suppressor protein TP53 which lies directly upstream from BCL2 and 
causes resistance to chemotherapy.86 
Several agents which specifically target BCL2 have been explored in B cell 
malignancies, including ABT-199 (Venetoclax). However, resistance to BCL2 inhibitors 
has been observed in CLL and MCL patients, and in CLL has been linked to modulation 
of BCL2 proteins by the tumour microenvironment, particularly in response to CD40 
signalling.88,91,92 Venetoclax is currently being evaluated in combination with BTK 
inhibitors for the treatment of CLL and MCL.93,94 
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1.3 BTK and BTK inhibitors  
1.3.1 BTK 
BTK (MW: 76 KDa) belongs to the TEC family of non-receptor tyrosine kinases and is 
expressed in most haematopoietic cells of both lymphoid and myeloid lineages, with 
the exception of T-cells and plasma cells.95 BTK is constitutively expressed from the 
early stages of B-cell maturation until the stage prior to terminally differentiated 
plasma cells.96  
The BTK gene is situated on the long (q) arm of the X chromosome at the g21.1-22 
locus and encodes a 659 amino acid protein.97 The structure of BTK is characterised by 
five domains, similar to that of other TEC family members (ITK, BMX, TXK and TEC). 
Starting at the N-terminus, these include PH (pleckstrin homology) and BH (TEC 
homology) domains, followed by SH3 (Src homology 3) and SH2 (Src homology 2) 
domains, and end with a tyrosine kinase (TK) domain at the C-terminus 98,99 (Figure 
1.5). Amino acid 481 in the adenosine triphosphate (ATP) binding cleft of the kinase 
domain is a cysteine residue (Cys481) and is crucial for the activity of BTK inhibitors 81 
(described later). 
 
Figure 1.5: BTK protein structure. BTK is a 659 amino acid protein which has five structural 
domains. From the N-terminus: PH (pleckstrin homology), BH (TEC homology), SH3 (Src 
homology 3), SH2 (Src homology 2), TK (tyrosine kinase). The BTK phosphorylation site pY223 is 
located in the SH3 domain and the pY551 site in the TK domain. A crucial cysteine residue 
(Cys481) is located in the TK domain (Figure adapted from Hutchinson and Dyer 2014 98). 
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The BTK gene was identified in 1993, during which time a loss of function mutation 
was discovered and found to be responsible for the production of the defective protein 
which leads to human X-linked agammaglobulinemia (XLA).100,101 This 
immunodeficiency syndrome was originally identified in 1952 by an American Navy 
paediatrician, Colonel Ogden Carr Bruton, who observed a condition in a group of 
young boys characterised by recurrent bacterial infections and caused by an absence 
of mature B lymphocytes and failure of immunoglobulin production.102 Consequently, 
the gene was named after Dr Bruton, in recognition of his initial work. These studies 
demonstrated that BTK was an essential protein tyrosine kinase required for B-cell 
maturation and thus a key protein in BCR signalling events.  
BTK is located downstream of the BCR, predominantly in the cytoplasm (but also in the 
nucleus), and translocates to the plasma membrane via the PH domain for 
phosphorylation and activation. There are two main tyrosine phosphorylation sites 
within BTK. Phosphorylation of tyrosine (Y) 551 within the kinase domain regulates the 
transition between active and inactive states and occurs on localisation to the 
membrane by LYN and SYK kinase.103 A conformational change in the protein then 
enables auto-phosphorylation at Y223 in the SH3 domain98 and subsequent activation 
of PLCy2 which as mentioned, activates pathways for survival, proliferation and 
migration. In addition, BTK stimulates actin polymerization at the cell cortex, leading to 
a reconfiguration of the actin cytoskeleton required for BCR aggregation.80,104  
In addition to its involvement in BCR signalling pathways, BTK is also involved in co- 
stimulatory pathways involving chemokine receptor binding and TLR signalling. BTK is 
activated by chemokine binding to CXCR4 and CXCR5 via interactions with G-protein 
sub-units of the chemokine receptors.98,105 The ligands for these receptors are tissue 
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homing chemokines CXCL12 and CXCL13 (respectively) thus it is believed that BTK has 
a role in B-cell migration and homing. In addition, BTK regulates integrin-mediated 
interaction of tumour cells with the microenvironment and has a role in the secretion 
of chemokine ligands (CCL) CCL3 and CCL4 by MCL cells.106 
1.3.2 First in class BTK inhibitor - Ibrutinib 
Ibrutinib (previously known as PCI-32765) was among a panel of small molecule BTKi 
initially synthesised by Celera Genomics to study BTK function, and was later 
developed by Pharmacyclics.107 The ibrutinib compound demonstrated the most 
favourable activity in animal models of autoimmune disease and arthritis and was 
therefore selected over the alternative compounds for use in further pre-clinical 
studies and subsequent clinical trials.108 
Ibrutinib (trade name: Imbruvica), is an irreversible, small molecule inhibitor of BTK 
with a half maximal inhibitory concentration (IC50) of 0.5nM. The drug is an oral tablet 
administered once daily at an optimal dose of 560 mg in MCL. The irreversibility of the 
drug is attributed to an electrophilic group, which binds covalently to the cystine (Cys) 
481 region within the catalytic ATP binding site of the BTK kinase domain107 which 
prevents its auto-phosphorylation at Y223 and downstream cascade of signals.109 The 
existence of a cysteine residue in the catalytic site is uncommon and therefore 
enhances specificity of ibrutinib to BTK and other TEC kinases.97 Several other BTKi 
have been developed which bind to BTK at the same cysteine residue but with even 
more selectively, one of these is acalabrutinib (discussed later). Figure 1.6 shows the 
binding of acalabrutinib to the ATP binding pocket of BTK.110 
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Figure 1.6: Binding model of acalabrutinib (gold) in the ATP binding pocket of BTK. Figure 
adapted from Barf et al 2017.110 
 
1.3.3 Pre-clinical studies with ibrutinib  
The therapeutic potential of BTK inhibition for treating lymphoma was first 
demonstrated by its effects on malignant cell lines and primary cells in vitro.  
In CLL cell lines, ibrutinib inhibited BCR signalling proteins ERK, PI3K and NF-кB which 
reduced the survival of CLL cells and inhibited CD40, BAFF, TLR and cytokine 
signalling.111 Ibrutinib was also found to inhibit DNA replication, and block pro-survival 
pathways in CLL cells by downregulating CCL3 and CCL4 expression.112 Furthermore, 
ibrutinib disrupted integrin α4β1-mediated adhesion of CLL cells to stromal elements 
such as fibronectin and Vascular cell adhesion protein 1 (VCAM1) and reduced 
migration of primary cells to tissue homing chemokines CXCL12, CXCL13 and CCL19.113  
ATP binding pocket  
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In MCL cell lines, ibrutinib increased apoptosis and reduced levels of anti-apoptotic 
proteins BCL-2, BCL-XL, and MCL-1.114 In addition, knockdown of BTK in MCL cells using 
siRNA (short interfering RNA) was shown to reduce phosphorylated levels of the signal 
transducer and activator of transcription 3 (STAT3) and inhibit the NF-κB pathway, 
which is required for MCL growth and migration.115 
In a study by Honigberg et al,109 ibrutinib selectively blocked BCR signalling and 
induced an objective clinical response of 38% in Canines with naturally occurring B-cell 
NHL. Shortly after this study, ibrutinib entered clinical trials. 
1.3.4 Clinical studies with ibrutinib  
The clinical efficacy of ibrutinib as a single agent was first reported in patients with 
various relapsed and refractory (R/R) B-cell malignancies. Despite the irreversibility of 
the drug, it did not cause any major side effects and demonstrated durable objective 
responses, particularly in CLL and MCL.116 In a subsequent phase Ib/II trial, an overall 
response rate of approximately 71% was achieved in R/R CLL patients on continuous 
treatment with ibrutinib.  
A phase II trial was then initiated in MCL (PCYC-1104), which enrolled 111 patients with 
R/R MCL who had received at least one prior therapy.117 A total of 68% of MCL patients 
had a response to ibrutinib, of which 21% had a complete response (CR) and 47% a 
partial response (PR). Ibrutinib was also found to be highly active in previously treated 
patients with Waldenström’s macroglobulinemia (WM).118 
Due to its significant clinical activity and safety in these B-cell malignancies, ibrutinib 
received a breakthrough designation and accelerated approval by the US Food and 
Drug Administration (FDA) for the treatment of R/R MCL in November 2013, for CLL in 
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July 2014 and for WM in January 2015. Ibrutinib has since been approved in Europe for 
R/R MCL and CLL and for other indications including previously untreated CLL with the 
del(17p13.1) karyotype, and for patients with untreated WM. 
However not all lymphoma subtypes have achieved high response rates following 
ibrutunib treatment. For example, in R/R Follicular lymphoma (FL), 37.5% of patients 
responded to ibrutinib and 12.5% had a complete response.116 In R/R Marginal zone 
lymphoma (MZL), approximately 50% of patients have responded to ibrutinib.119 In R/R 
Diffuse large B-cell lymphoma (DLBCL), complete or partial responses of 37% have 
been achieved in patients with the activated B-cell (ABC) subtype of DLBCL but 
responses of only 5% have been achieved in patients with the germinal centre B-cell 
(GCB) subtype.120  
1.3.5 Therapeutic mode of action of ibrutinib  
Despite the clinical success of ibrutinib, its mechanisms of action are still not entirely 
understood. It is currently unknown why this class of drug has such a profound effect 
in certain B cell lymphoproliferative disorders, particularly in MCL where there is 
dependence on cyclin D1. However, a particular feature of ibrutinib treatment is that a 
peripheral lymphocytosis is observed which is accompanied by a rapid reduction in 
lymph node size and represents the migration of neoplastic cells from tissues to 
blood.117  
A peripheral lymphocytosis is observed in most MCL patients responding to ibrutinib, 
and increases by more than 50% from baseline in 34% of cases. The lymphocytosis 
peaks at a median of 4 weeks and falls to near baseline level after approximately 3 
months.117 This effect is also seen in CLL patients treated with ibrutinib where a 
lymphocytosis is seen in approximately 80% of cases and takes longer to resolve.121 
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These observations have suggested that there is a similar mechanism of action of BTKi 
on adhesion and migration of the neoplastic lymphocytes in patients with CLL and 
MCL.  
Another feature of ibrutinib therapy is the absence of tumour lysis. Tumour lysis 
syndrome is commonly observed following conventional treatment when large 
numbers of tumour cells die rapidly causing metabolic disturbances.122 The absence of 
tumour lysis suggests that apoptosis or inhibition of survival is not a primary 
mechanism of ibrutinib action.  
The findings from pre-clinical studies (section 1.3.3) suggest that ibrutinib may have 
more than one mechanism of action, whereby it acts to inhibit intrinsic B-cell signalling 
pathways resulting in reduced proliferation and survival, and also disrupts the extrinsic 
interactions necessary for homing and retention of malignant cells to the tissues.  
It has also been suggested that the outcome of ibrutinib treatment may result from 
the combined inhibition of BTK and other kinases, acting in synergy. Ibrutinib has a 
broad kinome which includes irreversible inhibition of several other kinases with a 
corresponding cysteine residue in the ATP binding site.123 Analysis of 491 kinase 
sequences revealed 9 additional kinases with a cysteine at position 481. These include 
four other TEC-family kinases (ITK, BMX, TEC, TXK), three epidermal growth factor 
receptor (EGFR) family kinases (EGFR, ErbB2/HER2 and ErbB4/HER4), and two other 
kinases (B lymphoid tyrosine kinase (BLK) and Janus Kinase 3 (JAK3)). In addition, 
ibrutinib binds strongly to SRC family kinases.109,110,121  
It is thought that this broad specificity could be the cause of off-target side effects 
observed in MCL such as bleeding, arthralgia, atrial fibrillation and diarrhoea.124 For 
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example, diarrhoea is also seen in patients treated with EGFR inhibitors 125 and 
therefore might be caused by off target inhibition of EGFR by ibrutinib. 
1.3.6 Second generation BTK inhibitors  
Due to the broad specificity of ibrutinib for BTK and its multiple modes of action, 
several second generation BTKi have been developed which have enhanced selectivity 
for BTK. These include acalabrutinib (ACP-196), tirabrutinib (GS/ONO-4059) and 
zanubrutinib (BGB-3111) which are currently being evaluated for the treatment of 
several B-cell malignancies. Table 1.1 summarises the data of completed trials in MCL, 
showing the response rates achieved in MCL patients following single agent treatment 
with several second generation BTKi compared with response rates achieved by 
ibrutinib as a single agent and in combination with rituximab. 
The furthest second generation BTKi in development is acalabrutinib (trade name 
CALQUENCE®) (formally known as ACP-196). Acalabrutinib is an irreversible BTKi which 
like ibrutinib, forms a covalent bond with cysteine 481 in the BTK kinase domain. In 
comparison to ibrutinib, it has higher selectivity for BTK as determined in a 
competition binding assay on a panel of 456 human kinases.110 The improved 
selectivity is thought to be due to the reduced intrinsic reactivity of acalabrutinib’s 
propiolamide electrophile compared to ibrutinib’s acrylamide electrophile which 
causes fewer off-target interactions with other kinases such as ITK, EGFR, ERBB2/4, 
JAK3, LYN, and SRC.110,126 
In the competition binding assay, acalabrutinib inhibited BTK at a higher concentration 
than ibrutinib (IC50 of 5.1 and 1.5nmol/L, respectively), however the IC50 against 
other kinases was much greater.110 The figure below (Figure 1.7) shows the chemical 
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structures and kinome scan images for acalabrutinib and ibrutinib and compares their 
binding affinities to all kinases which contain a cysteine residue at position 481 in BTK.  
The first pre-clinical study of acalabrutinib in canine models of NHL demonstrated 
enhanced in vivo potency compared to ibrutinib.127  
In a phase II study (ACE-LY-004), acalabrutinib was given to 124 patients with R/R MCL 
who had received 1 to 5 prior lines of therapy. The drug achieved an ORR of 82% and 
CR of 40%. At a median follow-up of 12 months, 72% of patients remained in 
response.128 As a result of this trial, acalabrutinib was granted accelerated approval by 
the FDA in October 2017 for the treatment of MCL patients whose disease has 
progressed after receiving at least one prior therapy. 
Since acalabrutinib has a shorter half-life, it is taken twice a day at a dosage of 100 mg 
in MCL. It is believed that this dosing improves BTK inactivation since BTK synthesis in 
malignant lymphocytes may be faster than the 24 hour dosing interval of ibrutinib 128 
 
 
 
 
 
 
 
 
31 
 
Therapeutic regimen  Patient 
population 
Phase Efficacy  Reference 
Ibrutinib (PCI-32765) R/R MCL Phase II  ORR (68%), CR (21%) Wang et al 
117
 
Ibrutinib (PCI-32765) R/R MCL Phase III ORR (72%), CR (19%) Dreyling et al 
129
  
Ibrutinib (PCI-32765) + 
Rituximab  
R/R MCL Phase II  ORR (88%), CR (44%), PR (44%) Wang et al 
130
 
Acalabrutinib (ACP-196) R/R MCL Phase II  ORR (81%), CR (40%), PR (41%) Wang et al 
128
 
Tirabrutinib (GS/ONO-4059) R/R MCL Phase I ORR (92%) Walter et al 
124
 
Zanubrutinib (BGB-3111) R/R MCL Phase Ib ORR (88%) Tam et al 
131
 
 
Table 1.1: Results of completed clinical trials evaluating the efficacy of several BTK inhibitors 
as single agents in MCL. R/R Relapsed or refractory, MCL Mantle cell lymphoma, ORR overall 
response rate, CR complete response, PR partial response.132 
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 IC50 (nM) 
Kinase Acalabrutinib Ibrutinib 
BTK 5.1 1.5 
BMX 46  0.8 
ITK >1000 4.9 
TEC 93  7.0 
TXK 368  2.0 
EGFR >1000 5.3 
ERBB2 ~1000 6.4 
ERBB4 16 3.4 
JAK3 >1000 32 
BLK >1000 0.1 
 
Figure 1.7: Chemical structures and kinase inhibition of acalabrutinib and ibrutinib. 
Recombinant enzymes were used to profile the in vitro activity of acalabrutinib compared with 
ibrutinib. Each BTK inhibitor was profiled at 1mM in a competition binding assay on a panel of 
456 human kinases (using KINOMEscan at DiscoverX, Fremont, CA). The size of the circles 
represents intervals of the percentage of remaining activity versus the untreated control. The 
table shows the IC50s for the kinases that contain a cysteine residue aligning with cysteine 481 
in BTK. IC50 denotes half-maximal inhibitory concentration (Figure adapted from Barf et al 
2017110 and Herman et al 2017133). 
Ibrutinib  Acalabrutinib  
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In addition to using BTKi as single agents for treating MCL, various combinations are 
also being explored incorporating BTKi and other targeted therapies into standard 
chemo immunotherapy regimens. 
Currently, there are 20 ongoing clinical trials evaluating the efficacy of BTKi in MCL 
(Table 1.2). These include either single agent BTKi, or BTKi in combination with other 
agents (including monoclonal antibodies and/or chemotherapy) in previously treated 
as well as untreated MCL.  
Some combinations have already been shown to be beneficial for improving treatment 
outcomes. For example, the response rate of ibrutinib as a single agent in the phase II 
trial was 68%, however in combination with rituximab, the ORR increased to 88%. 
When both agents were combined with bendamustine the ORR in 12 MCL patients was 
94% and 76% had a complete remission. However results from these trials are on-
going and will help to determine optimal treatment combinations for patients with 
MCL. 
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 Therapeutic regimen Patient population Phase Identifier 
1 Novel BTK inhibitor (BGB-3111) R/R MCL Phase II NCT03206970 
2 Novel BTK inhibitor (M7583) R/R MCL Phase II NCT02825836 
3 Novel BTK inhibitor (CT-1530) R/R NHL (including MCL) Phase II NCT02981745 
4 Novel BTK inhibitor (AC0010) R/R NHL (including MCL) Phase I NCT03060850 
5 Novel BTK inhibitor (CC-292) + 
Lenolidamide 
R/R NHL (mixed cohort) Phase Ib NCT01766583 
6 Acalabrutinib/ Bendamustine/ 
Rituximab 
Previously untreated MCL Phase III NCT02972840 
7 Ibrutinib (long-term) B cell lymphoma (including 
MCL) 
Phase II  NCT01109069 
8 Ibrutinib after induction therapy Previously untreated MCL  Phase II NCT02242097 
9 Ibrutinib and Obinutuzumab R/R MCL Phase II NCT02736617 
10 Ibrutinib and Carfilzomib R/R MCL Phase I/II NCT02269085 
11 Ibrutinib and Palbociclib R/R MCL Phase I NCT02159755 
12 Ibrutinib and Lenolidamide R/R NHL (including MCL) Phase I NCT01955499 
13 Ibrutinib and Pembrolizumab  R/R NHL (including MCL) Phase I NCT02950220 
14 Ibrutinib and Selinexor   Aggressive NHL (including 
MCL) 
Phase I NCT02303392 
15 Ibrutinib and Pevonedistat  R/R NHL (including MCL) Phase I NCT03479268 
16 Ibrutinib and Cirmtuzumab Cirmtuzumab treated MCL  Phase II NCT03088878 
17 Ibrutinib/ Bendamustine/ 
Rituximab 
Relapsed MCL or Indolent 
NHL 
Phase I NCT01479842 
18 Ibrutinib/ Bendamustine/ 
Rituximab 
Newly  diagnosed  MCL  Phase III NCT01776840 
19 Ibrutinib and Lenalidomide / 
Rituximab 
R/R MCL Phase I NCT02446236 
20 Ibrutinib, Avelumab, 
Utomilumab, Rituximab 
and Combination Chemotherapy 
R/R MCL Phase I NCT03440567 
 
Table 1.2: On-going clinical trials evaluating BTK inhibitors (as single agents and in 
combination therapy) in MCL. BTK Bruton’s tyrosine kinase, R/R Relapsed or refractory, MCL 
Mantle cell lymphoma, NHL Non-Hodgkins Lymphoma.134 
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1.3.7 Primary and acquired resistance to BTK inhibitors  
Despite the success of BTKi, approximately 30% of MCL patients display primary 
resistance to these agents and patients who initially respond eventually develop 
acquired BTKi resistance and aggressive relapse of the disease. About 25% of patients 
discontinue ibrutinib therapy after 20 months due to progression.135 The 1 year 
survival rate for those who experience disease progression after ibrutinib treatment is 
only 22%.103 Current available therapies for patients who have relapsed on BTKi 
treatment are often not effective which therefore indicates the need to discover 
biomarkers of BTKi resistance so that agents which target specific resistance 
mechanisms can be developed to overcome them.  
Nearly 700 unique mutations have been detected in the BTK gene which cause XLA136 
although none of these leads to its constitutive activity in MCL. However, several 
mutations have been identified in patients who have relapsed following BTKi therapy. 
These mutations can either affect BTK directly, or it’s downstream signalling 
components including PLCγ2. The first mutation identified was a point mutation 
causing a protein substitution (cysteine to serine) at the ibrutinib binding site (C481S) 
resulting in ineffective BTK inhibition due to loss of covalent binding.137 The C481S 
mutation has been observed following BTKi therapy with both ibrutinib and 
acalabrutinib,121,137-141 and results in chronic activation of downstream BTK and 
mammalian target of rapamycin (mTOR) / Protein kinase B (AKT) pathways. 
In R/R CLL patients with this mutation, the activity of BTK was restored even in the 
presence of ibrutinib, demonstrating reactivation of BCR signalling which enabled 
proliferation to proceed.137 
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The BTK C481S mutation has been characterised by many studies as the most common 
mechanism of ibrutinib resistance. In a study by Sharma et al 135 the C481S mutation 
showed 25-fold less sensitivity to ibrutinib than the wild type.  
In another study, Chiron et al 138 identified C481S in 2 out 5 MCL patients who initially 
responded to ibrutinib but then progressed. The C481S mutation resulted in increased 
BTK and AKT activation which was driven by the cell cycle regulator CDK4. The 
mutation was only present in patients who had prolonged exposure to ibrutinib, and 
was not present in 6/6 patients with primary resistance, nor in patients who only 
partially responded to ibrutinib.  
Other BTK mutations have been found in ibrutinib refractory cases of CLL including 
C481F/Y/R, T474I/S, and L528W.135 These mutations all occur in the kinase domain of 
BTK and either directly attenuate (T474I/S) or hinder (L528W) ibrutinib binding. 
There has also been one report of a mutation T316A located in the SH2 domain in a 
R/R CLL patient.135 This mutation did not directly interfere with ibrutinib binding but 
prevented inhibition of CLL proliferation compared to the wild type cells. 
Mutations in molecules other than BTK have been identified. A gain-of-function 
substitution (R665W) has been reported in PLCγ2 which produces a constitutively 
active enzyme, which no longer needs to be phosphorylated by BTK.137 This mutation is 
thought to involve PI3K-AKT activation which overrides the inhibitory mechanism of 
BTK. 
Thus far, BTK mutations have only been detected in patients exposed to ibrutinib. 
However it has been suggested that the mutations may be present in tiny clones prior 
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to therapy which undergo subsequent clonal selection and expansion with continued 
use of ibrutinib.142,143  
Whole exome/transcriptome profiling of serial biopsies from the start of ibrutinib 
treatment until drug resistance in a patient with MCL, showed the evolution of the BTK 
C481S mutation.138  
Chronic exposure to ibrutinib has been shown to result in kinome reprogramming and 
activation of the PI3K-AKT-mTOR pathway in MCL cells, causing acquired ibrutinib 
resistance.144 However, some ibrutinib relapsed MCL and CLL patients do not have 
mutations in BTK or PLCy2 135,138 which suggests that other mechanisms for ibrutinib 
resistance exist. 
Primary resistance to ibrutinib in MCL is thought to involve PI3K-AKT activation since 
inhibition of ERK1/2 and AKT correlates with cellular response to BTK inhibition in 
vitro.145 
In other in vitro experiments, proliferation of ibrutinib resistant MCL cell lines was 
found to be mediated through the alternative NF-ĸB pathway, via TRAF2, TRAF3 and 
BIRC3 mutations.26,27 
In addition, as with conventional treatment, it is thought that interactions between 
MCL cells and accessory cells in the MCL microenvironment may be involved in 
resistance to BTKi. Amplified activation of the CXCR4-CXCL12 pathways have been 
detected in an MCL patient with ibrutinib resistance.26 
These studies demonstrate the need to identify biomarkers which can predict 
response to treatment so that patients with primary BTKi resistance do not receive 
unnecessary exposure to a drug which has no effect, and so that patients who do 
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respond to BTKi can be offered alternative therapies before these BTK mutations fully 
evolve and result in relapse.  
This thesis will particularly focus on the transcription factor Interferon Regulatory 
Factor 4 (IRF4) to determine whether this could represent a biomarker of BTK 
sensitivity or resistance in MCL. 
1.4 Interferon regulatory factor 4 (IRF4) 
IRF4 is implicated in the pathogenesis of several B-cell malignancies. Overexpression of 
IRF4 is seen in cases of ABC DLBCL and multiple myeloma (MM), both of which respond 
well to treatment which suppresses levels of IRF4. The role of IRF4 in the pathogenesis 
of MCL or in response to treatment (particularly with BTKi) is currently unknown and 
therefore represents an important area of investigation. 
IRF4 (MW: 50 KDa) (also known as MUM1, LSIRF, Pip, NFEM5 and ICSAT) is one of nine 
members (in humans and mice) of the interferon regulatory factor (IRF) family of 
transcription factors and has critical functions in various cell types of the immune 
system including B cells, macrophages and DCs.146  
Most IRF members are induced by type I and II interferons and cytokines in response 
to viral infections, however IRF4 is unique in that its expression is regulated by 
pathways of lymphocyte activation including BCR, LPS and CD40 signalling in response 
to various stimuli.147 These stimuli all activate the Rel/NF-kB pathway, which leads to 
activation of the IRF4 promoter.148,149 
1.4.1 Structure and function of IRF4 in normal B cells  
IRF4 is a 450 amino acid protein which has an N-terminal DNA binding domain (DBD) 
and a C-terminal interferon activation domain (IAD) (separated by a flexible linker) 
39 
 
(Figure 1.8) through which it can form homo or hetero-dimers with other members of 
the IRF family and with other proteins to activate transcription of its target genes.150 At 
the C terminal, there is an auto regulatory (AR) domain comprising an auto inhibitory 
region which interacts with the DBD to maintain the protein in an inactive state.151 The 
DBD is highly homologous to other IRF members due to the presence of five 
tryptophan sequences repeated at 10-18 amino acid intervals.150 Here, homo-or 
hetero-dimers formed between IRF4 and other IRF family members (predominantly 
IRF8) bind DNA with low affinity at Interferon-Stimulated Response Elements (ISREs 5’-
GAAANNGAAA-3’).150,152  
In addition to its interaction with other IRFs, IRF4 can also form heterodimers with 
members of the E-twenty-six (ETS) family, or the activator protein-1 (AP-1) family of 
transcription factors.153-156 
In B-cells, the principal co-binding partners for IRF4 are the ETS family members PU.1 
and SPI-B, which are critical for B-cell development and maturation. Hetero-dimers 
formed between IRF4 and PU.1 bind at ETS Interferon Composite Elements (EICEs: 5′-
GGAANNGAAA-3′)157 in the IAD. ETS proteins contain a sequence rich in proline, 
glutamic acid, serine, and threonine (PEST). Interaction of the IAD with the PEST region 
of an ETS protein relieves the auto-inhibitory effect and allows IRF4 to bind its target 
sequence with much greater affinity. 
Heterodimers formed by IRF4 and AP-1 family members such as the Basic leucine 
zipper transcription factor, ATF-like (BATF), regulate genes containing AP-1-IRF 
Composite Elements (AICEs: 5’-GAAATGAGTCA-3’ or 5’-GAAANNNNTGAGTCA-3’) 154-156 
which are important for regulating cellular functions in DCs and T-cells particularly in 
response to CD40 signalling. 
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Figure 1.8: IRF4 protein structure. IRF4 is a 450 amino acid protein which has an N-terminal 
DNA binding domain (DBD) and a C-terminal interferon activation domain (IAD), separated by a 
flexible linker. An auto regulatory (AR) domain comprising an auto inhibitory region is located 
at the C terminal  and maintains the protein in an inactive state. The DBD of IRF4 binds to 
other IRFs with low affinity. Interaction of the IAD with an ETS protein through its PEST 
domain, triggers the DBD to relieve the autoinhibition, allowing IRF4 to bind to its target with 
high affinity (Figure adapted from Marr 2016 68). 
 
IRF4 controls important events during B-cell development and maturation by 
transducing signals from various receptors to either activate or repress gene 
expression.  
During the early stages of B-cell development in the bone marrow, IRF4 interacts with 
its close family member IRF8 to coordinate the transition from the large pre B-cell to 
small pre B-cells.150 These events are mediated by several transcription factors 
including the paired box 5 (PAX5), a B-cell lineage specific activator.158 IRF4 and IRF8 
are direct targets of PAX5 and function with PU.1 to regulate PAX5 expression by 
binding to an enhancer region in the PAX5 locus.150  
At the pre-B cell stage, IRF4/8 and PU.1 regulate the rearrangement and expression of 
the immunoglobulin light chain by binding to the 3′ κ enhancer and λ enhancer 
regions, where EICE motifs were first identified.151,159,160  
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Downstream to pre-B cell receptor signalling, IRF4 and IRF8 induce the expression of 
the transcription factors ikaros and aiolos which function as negative regulators of BCR 
signalling and cell cycle progression.150 Ikaros and aiolos repress the expression of the 
surrogate light chain (SLC), an essential component of the pre-B cell receptor 
complex,161 and also inhibit large pre-B cell expansion by directly binding and 
repressing MYC.162 
IRF4 has been shown to regulate the expression of CXCR4 in pre-B cells by shifting pre-
B cells towards CXCL12 expressing stromal cells and away from IL-7 secreting stromal 
cells.163,164 IL-7 signalling inhibits pre-B cell differentiation by directly repressing light 
chain rearrangements. 
In mature B-cells, IRF4 is involved in the initiation and termination of the GC reaction, 
and cooperates with IFR8 to control plasma cell differentiation and class-switch 
recombination (CSR).165-168 At low levels, IRF4 binds cooperatively with ETS and AP-1 
family members at EICE/AICE motifs and induces expression of BCL6, OCT-Binding 
Factor 1 (OBF1) and Activation-induced cytidine deaminase (AID) which are required in 
order to initiate the GC reaction. BCL6 is a master regulator for GC reaction, while AID 
is critical for somatic hyper-mutation to generate high avidity BCRs, and CSR. Mice 
lacking IRF4 specifically in B-cells failed to form GCs due to insufficient induction of 
BCL6, OBF1 and AID.166 
Within the centrocytes of GCs, high levels of IRF4 are induced by antigen binding to 
high avidity BCRs. This causes a shift in the binding of IRF4 from EICE/AICE motifs, to 
binding low affinity ISRE motifs. IRF4 binding to ISRE induces the B lymphocyte-induced 
maturation protein-1 (BLIMP-1) and represses BCL6 which is required to end the GC 
reaction and to initiate plasma cell differentiation.166 
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IRF4 also has a role in the positioning of mature B lymphocytes within lymphoid 
microenvironments by its regulation of NOTCH2.169 
1.4.2 IRF4 in B cell malignancies  
Deregulation of the processes controlled by IRF4 has been linked to the pathogenesis 
of several types of B cell malignancies which correspond to specific developmental 
stages.146,147,170,171 This has highlighted that IRF4 can function both as an oncogene as 
well as a tumour-suppressor in different lymphoma subtypes (Figure 1.9).  
IRF4 has oncogenic roles in several GC and post-GC lymphomas, including Hodgkin 
lymphoma (thought to be derived from GC cells), the ABC subtype of DLBCL (thought 
to be derived from post GC cells), and multiple myeloma (MM) (a malignancy derived 
from plasma cells). On the other hand, IRF4 acts as a tumour suppressor in B cell acute 
lymphoblastic leukaemia (B-ALL) (derived from immature B cells) and in CLL (derived 
from quiescent mature B cells).150 
 
 
 
 
 
 
 
 
 
Figure 1.9: IRF4 in B cell malignancies. Red arrows point towards malignancies where IRF4 
functions as an oncogene, blue arrows point towards malignancies where IRF4 functions as a 
tumour suppressor.    
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IRF4 overexpression is seen in cases of ABC DLBCL.172 In DLBCL cell lines, IRF4 functions 
with ETS family member SPI-B to repress type I interferon responses.173 Specifically, 
IRF4 and SPI-B co-bind to EICE motifs to suppress IRF7 causing subsequent inhibition of 
interferon β production and interferon response mediated cell death.150,173  
The role of IRF4 in MM is unusual in that it directs plasma cell differentiation while it 
also functions as a survival factor for MM cells, a concept described as non-oncogene 
addiction.147,171 Studies have identified MYC as a direct target of IRF4 in MM. 
Upregulation of IRF4 and MYC contributes to cell proliferation and aggressiveness but 
it is thought that MYC deregulation is the critical factor in the pathogenesis of MM, 
and IRF4 functions in part as a survival factor by directly regulating MYC expression.171  
In CLL, higher IRF4 expression has been associated with better prognosis.170 Single 
nucleotide polymorphisms (SNPs) have been identified in the 3′ untranslated region 
(UTR) of the IRF4 locus174 and are associated with increased susceptibility for 
developing CLL. The risk alleles harbouring the SNPs are linked to downregulation of 
IRF4 and are associated with poor prognosis.174-176  
In NHL as a whole, IRF4 is associated with several genes including BATF, LIM domain-
containing protein 1 (LIMD1), CASP8 and FADD-like apoptosis regulator (CFLAR), 
serine/threonine-protein kinase pim-2 (PIM2), and CCND2 which are involved in B-cell 
development, oncogenesis, cell cycle regulation, and cell death157 However the 
molecular targets regulated by IRF4 specifically in MCL and in response to BTKi are 
unknown and require investigation. 
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1.4.3 Expression of IRF4 in mantle cell lymphoma 
Little is known about the involvement of IRF4 in MCL.  In a gene expression profiling 
study, IRF4 was shown to be over expressed in MCL along with several other 
lymphoma subtypes157 although this was only representative of 8 MCL cases. 
The majority of MCL tumour biopsies are usually negative for IRF4 expression, however 
IRF4 was expressed in 35% of MCL tumour biopsies (45/ 127 cases) with a 
characteristic GC or post-GC phenotype.149 As mentioned in section 1.1.2, MCL cells 
are derived mainly from antigen naïve pre GC B-cells, however up to 40% of MCL cases 
carry somatic mutations of the IGVH genes, indicative of a GC or post GC phenotype 
therefore IRF4 expression is likely to vary depending on the phenotypic subtype.  
In a small number of cases, it has been demonstrated that MCL cell clones can undergo 
plasma cell differentiation.177,178 A partial plasmacytic phenotype has been identified 
displaying stronger CD38 and IRF4 expression, identifying a biologically distinct subset 
of MCL.179  
IRF4 is expressed to varying degrees in several MCL cell lines including REC-1, HBL2, 
JEKO-1 and MINO179 and it has been demonstrated that REC-1 cells depend on IRF4 
expression for survival.179 IRF4 is also expressed in G519 and JVM2 cells180 however it 
should be noted that these cell lines have been transformed into lymphoblastoid cell 
lines by Epstein Barr Virus (EBV). IRF4 expression can be regulated through modulation 
of NF-κB signalling by viral proteins such as EBV.181 
1.4.4 IRF4 in response to treatment 
The immunomodulatory agent lenolidamide has demonstrated clinical responses in 
lymphomas which are characterised by IRF4 overexpression, including MM and DLBCL. 
45 
 
In the ABC subtype of DLBCL, IRF4 and SPI-B transcription factors prevent interferon 
beta (IFNβ) production by repressing IRF7 and amplify pro-survival NF-κB signalling by 
transactivating CARD11.173 Lenalidomide kills ABC DLBCL cells by downregulating IRF4 
and SPI-B, thereby increasing production of IFNβ and reducing the pro-survival effects 
of NF-κB signalling.  Lenalidomide has also demonstrated clinical activity in R/R MCL as 
a single agent117,182 which suggests involvement of IRF4 in aggressive relapse of MCL.   
IRF4 has been proposed as a potential marker of bortezomib (BZM) resistance in 
MCL.179 MCL cells from patients with poorer clinical responses to BZM showed high 
expression of IRF4 and MYC. Gene knockdown of IRF4 repressed expression of MYC in 
vivo, and was toxic for the subset of MCL cells with plasmacytic differentiation.180 
1.4.5 IRF4 in response to BTK inhibitors  
A small number of studies have demonstrated downregulation of IRF4 in response to 
ibrutinib in vitro. Ibrutinib induced downregulation of IRF4 has been demonstrated in 
DLBCL and MCL in vitro 106,173,183 and has also been shown previously by our group in ex 
vivo primary CLL cells (unpublished data). 
In MCL, Sun et al 183 showed that IRF4 was downregulated by ibrutinib in sensitive MCL 
cell lines and was rescued by a PKC agonist through reactivation of the NFkB pathway.  
IRF4 has also been shown to be downregulated in MCL cell lines in response to a 
combination of the BTKi spebrutinib (CC-292) and lenolidamide.106 In this study, the 
REC-1 cell line demonstrated enhanced sensitivity to both ibrutinib and CC-292 by 
inducing apoptosis, although only marginal apoptosis was induced by CC-292 (10-15%) 
after 72 hours treatment. Phosphorylated BTK Y223 was reduced in all cell lines (REC-1, 
MINO, UPN-1, MAVER-1 and Z138) regardless of their sensitivity to ibrutinib. However, 
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CC-292 downregulated the expression of the surrogate marker for NF-κB activation 
pIkB, only in MCL cell lines sensitive to CC-292. It has been described previously that 
lenolidamide (which directly targets NF-kB) downregulates IRF4 in sensitive cell lines 
180 and this study demonstrated that co-treatment with CC-292 significantly enhanced 
this effect in REC-1 cells. These results are of particular note given the results we will 
describe in this thesis. 
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1.5 Summary of introduction and aims of thesis 
General Background to approach  
MCL is often an aggressive lymphoma that has very poor outcome for patients. BTK 
inhibitors have shown a significant clinical activity in patients with particular subtypes 
of NHL; importantly this includes patients with MCL.  Research has shown that 
modifying the intracellular-signalling downstream of the BCR through inhibition of BTK 
alters the interaction between the neoplastic cells and their environment, with that 
there is an associated controlled regression of the MCL.117 This allows patients with 
MCL to achieve a clinical remission.  However, despite the promise of these agents in 
this difficult-to-treat disease, one third of MCL patients have primary resistance to 
BTKi, and most patients who initially respond eventually acquire secondary resistance 
with aggressive relapse of the disease.  
Hypothesis  
This clinical promise offered by BTKi provides an impetus for this project, it was 
hypothesised that study of relevant protein expression could identify processes that 
underlie sensitivity or resistance to BTKi in MCL, and that findings could be exploited to 
suggest new avenues for therapy as well as highlighting predictive biomarkers for 
treatment response that could be used to rationally direct therapy.   
Selection of IRF4 as a candidate molecule and Aims of thesis  
At the start of this PhD little was known about the mechanism(s) of action of BTK 
inhibitors in MCL, and importantly the mechanisms of BTKi resistance were unclear. 
However, preliminary work within this research group had suggested a protective role 
for the cellular microenvironment, and a potential role for IRF4 in mediating protection 
from the effects of BTKi. This provided the basis for the approach.  
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The Aims were: 
1. To identify, characterise and develop cell line models of MCL that reproduced 
the relevant features of disease behaviour including responsiveness or 
resistance to two BTKi drugs used clinically to treat MCL. 
2. To use these models to explore key elements of the biological response of MCL 
cells to BTKi with particular emphasis on the chemo-protective effects of the 
cellular microenvironment and on the potential role of IRF4. 
3. To expand on these findings to look at possible mechanisms of those chemo-
protective changes that were identified. 
4. To confirm findings using primary MCL cells.   
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2 Chapter 2- Materials and Methods 
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2.1 Reagents and buffers 
2.1.1 Buffers for cell culture  
Culture media  
RPMI 1640 growth media with GlutaMAXTM, supplemented with 10% Fetal 
Bovine Serum (FBS) and 1% penicillin/ streptomycin (Gibco, Fisher Scientific). 
Freezing media 
90% FBS containing 10% dimethylsulphoxide (DMSO). 
General wash buffer 
1X phosphate buffered saline (PBS) (Fisher Scientific). 
1 X Trypsin-EDTA 
1X Trypsin- EDTA, diluted in 1X PBS from 10X liquid (0.5% Trypsin, 5.3mM EDTA 
4Na) (Gibco, Fisher Scientific #10779413). 
RIPA lysis buffer  
20mM Tris, 150mM NaCl, 1mM EDTA, 1% Triton-X-100, with protease and 
phosphatase inhibitors (10µl/mL) (Sigma Aldrich #P8340/#P5726). 
Low stringency lysis buffer:  
1M Tris base pH8 (0.2mL), 3M NaCl, 10% Triton-X-100, MilliQ H2O. Protease 
inhibitor (Sigma Aldrich #P8340) was added before use.  
 
2.1.2 Buffers for flow cytometry  
1X Annexin-V binding buffer 
Diluted from 10X Annexin-V binding buffer (BD Biosciences). 
Fixation buffer 
Paraformaldehyde (PFA) diluted to 4% in 1X PBS 
Permeablisation buffer 
Triton X- 100 detergent diluted to 0.1% or 0.2% in 1X PBS  
Staining buffer   
0.5% Bovine serum albumin (BSA) diluted in 1X PBS containing 0.1% Triton-X-
100. 
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2.1.3 Buffers for 1D SDS-PAGE, western blotting and immunohybridisation  
10% (w/v) SDS 
 
For 100mL: 10g SDS dissolved in 90mL deionised water (dH2O). 
 
10% (w/v) Ammonium pursulphate (APS) 
 
For 1mL: 100mg APS dissolved in 900µl dH2O. For 10mL: 1g APS dissolved in 
9mL dH2O. 
 
1.5 M Tris-HCl, pH 8.8 (MW 121.14) 
 
18.17g Tris base dissolved in 70mL dH2O, and brought up to 100mL with dH2O. 
 
0.5 M Tris-HCl, pH 6.8 (MW 121.14) 
 
6g Tris base dissolved in 60mL dH2O, and brought up to 100mL with dH2O. 
 
10X Tris buffer   
 
30.2g of 24mM Tris-HCL, 144g of 191mM Glycine, dissolved and brought up to 
1000mL with dH2O. 
 
10X Tris buffered saline (TBS) 
 
24.2g of Trizma base, 80.06g of Sodium chloride (NaCl) dissolved in 800mL of 
dH2O. 
Resolving gel (10% acrylamide) 
 
1.5M Tris (pH 8.8), 10% (w/v) SDS, 10% APS, dH2O, 30% acrylamide (National 
diagnostics ProtoGel EC-890, Fisher Scientific # 12381469), 10µl N,N,N’,N’-
tetramethylethylenediamine (TEMED) (Sigma Aldrich). 
Stacking gel (4% acrylamide) 
 
0.5M Tris (pH 6.8), 10% (w/v) SDS, 10% APS, dH2O, 30% acrylamide, 6.7µl 
TEMED. 
2X Laemmli sample buffer (SDS reducing) 
 
0.5M Tris-HCL (pH 6.8), Glycerol, 10% (w/v) SDS, 0.5% (w/v) Bromophenol blue, 
dH2O + β-mercaptoethanol (BME) at 5% of the sample volume added just 
before use.  
 
1X Running buffer  
 
 24mM Tris, 191mM Glycine, 10% SDS.        
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1X Transfer buffer   
 
24mM Tris, 191mM Glycine, 20% MeOH 
 
Wash buffers 
1 X TBS diluted from 10X TBS 
1X TBST: 1 X TBS with 0.1% Tween-20. 
Blocking buffer and antibody dilution buffer 
5% BSA diluted in 1X TBST. 
Immunoprecipitation (IP) buffer  
1X PBST (1X PBS with 0.1% Tween-20) 
 
2.1.4 Buffers for agarose gel electrophoresis 
1X Tris Borate EDTA (TBE) 
Diluted from 10X TBE (89mM Tris, 89mM boric acid, 2mM EDTA) (Thermo 
Fisher Scientific #B52).    
DNA loading dye buffer  
6X DNA loading dye buffer (10mM Tris-HCL (pH 7.6), 0.03% bromophenol blue, 0.03% 
xylene, 60% glycerol 60mM EDTA, (Thermo Fisher Scientific #R0611). 
 
2.1.5 Buffers/reagents for chromatin immunoprecipitation 
1X enzymatic lysis buffer A  
(50µl of 4X Buffer A (CST #7006) + 750ul dH2O)) + 0.5µl 1M Dithiothreitol (DTT) 
and 5µl of 200X protease inhibitor cocktail (PIC), per IP preparation. 
1X enzymatic lysis buffer B  
(275µl of 4X Buffer B (CST #7007) + 825ul dH2O)) + 0.55µl 1M DTT, per IP 
preparation. 
1X ChIP buffer  
(10µl of 10X ChIP Buffer (CST #7008) + 90µl dH2O)) + 0.5µl 200X PIC, per IP 
preparation. 
Low salt wash  
(300μl of 10X ChIP Buffer + 2.7mL dH2O) 
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High salt wash  
(100μl of 10X ChIP Buffer + 900µl dH2O) + 70μl 5M NaCl (CST #7010) 
 
1X ChIP elution buffer 
(75µl 2X ChIP Elution Buffer (CST #7009) + 75µl dH2O, per IP preparation. 
 
Other reagents for ChIP 
 37% Formaldehyde (Fisher Scientific) 
 10X Glycine solution (CST #7005) 
 Micrococcal nuclease (CST #10011) 
 0.5M EDTA (CST #7011) 
 5M NaCl (CST #7010 
 RNAse A (10 mg/mL) (CST #7013) 
 Proteinase K (20mg/mL) (CST #10012) 
 ChIP-Grade Protein G magnetic beads (CST #9006) 
 Human RPL30 Exon 3 Primers 1 (CST #7014) 
 1M DTT (192.8mg DTT (CST #7016) + 1.12mL dH2O)  
(All provided in the SimpleChIP® enzymatic chromatin IP kit, CST #9003) except for 
formaldehyde. 
 
2.1.6 Buffers for DNA purification  
DNA binding buffer  
Containing chaotropic salts: guanadinium hydrochloride (Gu-HCl)/ sodium 
iodide (NaI). 
DNA wash buffer  
10mM Tris-HCl pH 7.5, 80% Ethanol (EtOH) 
DNA elution buffer  
10mM Tris pH 8-9 
(All provided in the SimpleChIP® DNA Purification kit (CST #14209). 
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2.1.7 Buffers for RNA extraction 
Buffer RLT 
Denaturing buffer containing guanidine-thiocyanate. 10µl of β-ME was added 
per 1mL of buffer RLT. 
Buffer RW1 
Stringent wash buffer containing guanidine salt and EtOH.  
Buffer RPE  
Mild wash buffer supplied as concentrate and diluted in 4 volumes of EtOH 
(96–100%). 
(All provided in the RNeasy Mini kit (Qiagen # 74104). 
 
2.2 Cells and general culture 
2.2.1 Cells and characterisation  
Blood samples from MCL patients were obtained by the clinical research team at 
Derriford hospital (University Hospitals Plymouth NHS trust, UK). MCL cases were 
confirmed by the presence of the t(11; 14) translocation by fluorescence in situ 
hybridisation and /or detection of cyclin D1  expression (by molecular , 
immunohistochemistry) and for the characteristic immunophenotypic cell surface 
expression by flow cytometry.  
All blood samples were obtained following informed consent (Integrated Research 
Application System project ID number: 145245), and under existing regulatory 
approval granted by the NHS Health Research Authority National Research Ethics 
Service Committee East of England – Cambridge East. 
Human MCL cell lines Granta 519 (G519), JEKO-1 and JVM2 were purchased from 
Deutsche Sammlung von Mikroorganismen and Zellkulturen (DSMZ, Braunschweig, 
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Germany). The REC-1 cell line was a kind gift from Professor Martin Dyer (University of 
Leicester, UK). The authenticity of the selected MCL cell lines is summarised in Table 
2.1.184,185  
The NIH3T3 murine bone marrow fibroblast cell lines, one transfected with CD40-
Ligand (T-CD40L), and the other, non-transfected (NT-CD40L) were also provided by 
Professor Martin Dyer.  
Table 2.1: Authentication summary of MCL cell lines used in this study.184,185  
 
2.2.2 Peripheral blood mononuclear cell preparation  
Whole blood samples were processed in a sterile laminar flow hood within 16 hours 
from the time of collection. Peripheral blood mononuclear cells (PBMCs) were 
separated by density-gradient centrifugation using LymphoprepTM (AXIS SHIELD 
#1114545) or Ficoll-Paque PLUS (Fisher Scientific #11768538) following manufacturer’s 
instructions. Four to five 5mL EDTA tubes of whole blood was collected from each 
patient and was very slowly added on top of an equal volume of lymphoprep/Ficoll in a 
50mL falcon tube held at a 45 degree angle. In order to isolate the PBMCs, the tube 
containing the blood and lymphoprep/Ficoll was centrifuged at 2000rcf for 30 minutes 
Cell line Source Diagnosis t(11;14) CCND1/ 
cyclin D1 
EBV 
transformed  
REC-1 Peripheral 
blood/lymph 
node 
B-NHL, diffuse large cell 
progressing to transformed 
mantle cell, blastoid 
variant 
     
G519 Peripheral 
blood 
B-NHL (leukemic 
transformation of mantle 
cell lymphoma, stage IV) 
      
JEKO-1 Peripheral 
blood 
Mantle cell lymphoma 
 
     
JVM2 Peripheral 
blood 
B-prolymphocytic 
leukaemia (B-PLL) 
      
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at room temperature, with zero brake speed. The PBMCs were extracted from the 
interface between lymphoprep/Ficoll and plasma using a pasteur pipette and added to 
a fresh 50mL falcon tube. The cells were washed with 1X PBS and the supernatant was 
discarded. The pellet of cells was re-suspended in 10mL of culture media and a cell 
count was performed (section 2.2.7).  
2.2.3 Cellular cryopreservation  
Cell lines and primary lymphocytes were re-suspended in 1mL freezing media (section 
1.1). Cell lines were divided into aliquots containing 5 X 106 cells, and the primary 
lymphocytes were divided into aliquots containing 2 x 107 cells (low lymphocyte count) 
or 1 x 108 cells (high lymphocyte count) and added to 2mL cryopure tubes (Sarstedt). 
Cells were frozen gradually (1 degree per minute) to -80°C in a cryopreservation 
container filled with isopropyl alcohol (C3H8O). Cells were stored in liquid nitrogen (-
180°C) for future use. Cell pellets were prepared at 5 x 107 for protein assays and were 
frozen dry at -80°C. 
Cryopreserved PBMCs were thawed from liquid nitrogen in a water bath set to 37°C, 
and transferred to a 50mL falcon tube (Sarstedt). To remove the 10% DMSO, a volume 
of 9mL of warmed culture media was slowly added to the 1mL of cells to avoid 
temperature shock. The cells were centrifuged at 1500rcf for 5 minutes at room 
temperature and the supernatant containing DMSO was discarded. The cell pellet was 
re-suspended in 1mL of fresh culture media and topped up to the required volume. 
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2.2.4 Culture of suspension cell lines  
Suspension cell lines were grown in culture media in 25cm2 or 75cm2 vented flat-
bottom culture flasks (Sarstedt) and maintained in a humidified incubator at 37°C with 
5% CO2. All cell lines were passaged two to three times per week depending on their 
doubling time, to maintain optimal cell density. After every 28 culture passages, the 
cells were discarded and fresh aliquots of cells were obtained from liquid nitrogen. 
Suspension cell lines were tested for mycoplasma contamination by indirect staining 
with the fluorescent dye; 4’,6-diamidino-2-phenylindole (DAPI) which binds to DNA186 
and can be visualised by fluorescence microscopy. The figure below (Figure 2.1) shows 
DAPI fluorescence from the nuclei of two MCL cell lines, REC-1 (at passage 25) and 
G519 (at passage 28) with the detailed method described in the figure legend. 
Mycoplasma DNA (visualised as small white dots or flecks of fluorescence) was not 
detected within the cells or in the surrounding medium of either cell line. 
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Figure 2.1: Immunofluorescent analysis of REC-1 and G519 cell nuclei by DAPI staining. REC-1 
and G519 cells were seeded onto 5mm coverslips within a standard 24 well plate (Sarstedt) in 
culture media and left to settle overnight at 37°C. The media was carefully removed leaving 
the remaining cells attached to the coverslip surface. Cells were fixed in 200µl of 4% 
paraformaldehyde for 10 minutes, washed twice in 200µl of 1X PBS for 5 minutes and 
permeablised using 200µl of 0.1% Triton X-100 for 5 minutes. Cells were washed twice in 1X 
PBS for 5 minutes and blocked in 200µl of 1% BSA blocking buffer for 30 minutes at room 
temperature. The coverslips were removed from the 24 well plate and left to air dry overnight 
at room temperature. Cells were stained with 20µl of VectorSheild Hard Set Antifade Mounting 
Medium (containing DAPI) (Vector laboratories #H-1500), and mounted on to standard glass 
slides and left to cure for 4 hours.  A NIKON fluorescent microscope with NIS-Elements imaging 
software was used to visualise DAPI fluorescence. Left-REC-1 cell nuclei, right-G519 cell nuclei. 
Top-20X magnification, bottom- 100X magnification. 
 
 
 
 
 
 
REC-1 G519 
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2.2.5 Culture of T-CD40L and NT-CD40L murine bone marrow fibroblasts  
The murine bone marrow fibroblasts were previously transfected with a human CD40L 
sequence and were supplied to our group along with the non-transfected control 
fibroblasts by Professor Martin Dyer (University of Leicester, UK). The CD40L 
transfected cells (T-CD40L) and the non-transfected cells (NT-CD40L) were grown in 
culture media in sterile 75cm2 vented flat-bottom flasks with a special coating to 
support cell surface adhesion (Sarstedt). Once 70-80% confluent, the cells were 
washed in 1 X PBS and detached from surface of the culture flask using 1 x Trypsin- 
EDTA (section 1.1), then passaged 1 in 5 into fresh culture medium for ongoing culture. 
Surface expression of CD40L was determined by detection of a phycoerythrin (PE) dye, 
conjugated to a mouse-anti-human CD40-ligand monoclonal antibody (BD #555700) 
and assessed using both fluorescence microscopy (Figure 2.2) and flow cytometry 
(Figure 2.3).  
For assessment of CD40L by fluorescent microscopy, the T-CD40L and NT-CD40L 
fibroblasts were cultured on 5mm coverslips within standard 24 well plates in culture 
media for 48 hours until 70% confluent.  The media was discarded leaving the 
remaining cells attached to the coverslip surface. Each coverslip was stained with 50µL 
of anti-human CD40L-PE and incubated in the dark for 20 minutes. The coverslips were 
washed with 1X PBS and the cells were fixed with 200µL of 4% PFA for 10 minutes.  The 
coverslips were washed with 1X PBS for 5 minutes, then removed from the 24 well 
plate and left to air dry overnight in the dark at room temperature. Cells on each 
coverslip were stained with 20µL of VectorSheild Hard Set Antifade Mounting Medium 
(containing DAPI), then mounted on to standard glass slides and left to cure for 4 
hours.  
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The slides were then visualised using a NIKON fluorescent microscope with NIS-
Elements imaging software. The figure below (Figure 2.2) shows the images obtained 
following fluorescence microscopy indicating the presence of CD40L on the surface of 
the T-CD40L fibroblasts but not on the surface of the NT-CD40L fibroblasts. 
 
 
 
 
 
 
 
Figure 2.2: Characterisation of CD40L expression by fluorescence microscopy. Top images – 
NT-CD40L fibroblasts; bottom images – T-CD40L fibroblasts.  Left images - cells stained with 
DAPI alone (blue); middle images - cells stained with PE-anti-CD40-ligand mAb alone (red); 
right images – merged images of cells stained with DAPI (blue) and PE-anti-CD40-ligand mAb 
(red), 60X magnification. 
 
 
 
 
 
 
 
 
 
T-CD40L 
DAPI PE-CD40L DAPI + PE-CD40L 
  
NT-CD40L 
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For assessment of CD40L by flow cytometry, the detached T-CD40L and NT-CD40L 
fibroblasts were added to individual FACS tubes and stained with 20µl of anti-human 
CD40L- PE along with a corresponding IgG-PE isotype control and incubated in the dark 
for 20 minutes (extracellular antibody conjugation method, section 2.3.1). 
 
 
 
 
 
 
 
 
 
Figure 2.3: Characterisation of CD40L expression by flow cytometry. A gate was placed 
around the fibroblast population (P1) of the T-CD40L cells and the NT-CD40L cells. Expression 
of CD40L-PE was constricted to P1. Top row: forward and side scatter plots of fibroblast cells 
gated on P1. bottom row: peak plots showing the percentage of CD40L expression. Left: the PE 
isotype control (IgG1-PE), middle: the non-transfected fibroblasts and right: the CD40L 
transfected fibroblasts. 
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2.2.6 Culture of primary MCL cells  
The murine fibroblasts (T-CD40L and NT-CD40L) were seeded into standard flat-
bottomed 6 well plates (for protein assays) or 12 or 24 well plates (Sarstedt) (for 
functional assays) at a concentration of 5 x 105/mL, and returned to the incubator until 
70% confluent.  
To slow the proliferation rate of the fibroblasts, the well plates were irradiated 
through external beam radiation delivered through a linear accelerator (LINAC) by 
clinical physicists at Derriford Hospital Radiotherapy Department (University Hospitals 
Plymouth NHS Trust, UK). In brief, the cells were irradiated in the well plate using a 
6MV photon beam at the machine isocentre. The sample was at a depth of 5cm in a 
solid water phantom and the field size used was 20cm2. The dose of radiation 
delivered to the cells was 15Gy (Gray) in a single fraction. 
Once the irradiated fibroblasts had settled and adhered to the surface of the wells, the 
media was removed and the two monolayers of fibroblasts were washed in 1X PBS. 
Primary MCL cells were seeded at 4 x 106/mL (REC-1 cells at 5 x 105/mL) on to each 
fibroblast monolayer and returned to the incubator. The figure below (Figure 2.4) 
shows phase-contrast images of the murine fibroblast monolayers and the primary 
MCL cells after 48 hours in co-culture.   
 
 
 
 
63 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Phase-contrast images of murine fibroblast monolayers and co-culture with 
primary MCL cells.  Top: fibroblast monolayers, Left: NT-CD40L, and Right: T-CD40L. Bottom: 
Primary MCL cells (seeded at 4 X 106/mL) on top of the fibroblast layers after 48h in co-culture. 
 
2.2.7 Assessment of cell number  
A cell count was performed by counting the number of viable cells on a neuabauer 
haemocytometer using a trypan blue assay. On occasions, the trypan blue stained cells 
were counted with a TC20TM automated cell counter (Bio-rad). 
2.2.8 B-cell receptor activation  
The B-cell receptor (BCR) was stimulated by crosslinking IgM. Activating the BCR by 
stimulating IgM rather than IgG was preferred since most mature B-cell malignancies 
derived from antigen dependant BCR signalling express a functional IgM type BCR 
which promotes NFkB activation and cell proliferation.187,188 Cells were stimulated with 
                  NT-CD40L                                             T-CD40L  
Fibroblast 
monolayers   
Primary 
MCL cells 
seeded on 
top of the 
fibroblasts   
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Goat Fab’ 2 anti-human IgM antibody (0.5mg/mL) (Bio-Rad AbD Serotec, STAR146), 
diluted to 3µg/mL and signalling responses assessed after a time-dependent period as 
described in the results chapters. 
2.2.9 In vitro drug treatments  
The two BTK inhibitors used in this study were ibrutinib (Ibr) and acalabrutinib (Acal). 
Ibr was purchased from Selleckchem (Houston, Texas, USA), and Acal was supplied as a 
gift by Acerta Pharma (San Francisco, USA) prior to FDA approval. A ten millimolar 
stock solution of each drug was prepared in DMSO and stored at -20°C or -80°C for 
short and long term use (respectively). Ten millimolar stocks were diluted in DMSO to 
various working concentrations within the range of 10mM-1nM. Drugs were added to 
cell cultures using a 1 in 1000 dilution. 
2.2.10 Acquired BTK inhibitor resistant cell lines  
Cells from a cell line demonstrating sensitivity to BTKi (REC-1) were cultured at a 
density of 2 x 105 in 12mL of culture media (+10% FBS) in 25cm2 flasks. The cells were 
treated with increasing concentrations of Ibr at the following doses: 1nM, 3nM, 10nM, 
30nM, 100nM, 300nM, 1µM, 3µM.  
At the lower doses (<100nM), cells were passaged every 2-3 days and 3 times at each 
dose. At higher doses (>100nM), the density of REC-1 cells was increased to 5 x 105 in 
12mL and cells were passaged every 3-4 days, and 6 times at each dose, until the cells 
were proliferating at the same rate as untreated parent REC-1 cells cultured under the 
same conditions. The sensitised cells were then treated continuously for 8 weeks at 
1µM and 3µM, above the in vivo dose for Ibr (400nM),116,145 and grown for use in 
subsequent experiments.  
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Before each passage, the cells were centrifuged at 1500rcf and the supernatant was 
discarded. To wash the cells and remove the drug from the previous culture, the pellet 
was re-suspended in 10mL of serum free media, re-centrifuged at 1500rcf and the 
supernatant was discarded. The washed pellet of cells was then re-suspended in 12mL 
fresh culture media (+10% FBS) and split 1 in 2 into two fresh culture flasks. The cells 
were then treated directly with a 1 in 1000 dilution of Ibr and incubated at 37°C with 
5% CO2 until the next passage.  
At a later stage in the study, REC-1 cells were also sensitised to Acal in the same way to 
generate a cell line model of acquired Acal resistance. The continuous dosage did not 
exceed 1µM for Acal and therefore cells were sensitised to just below the in vivo dose 
for Acal which is 2µM (personal communication from Acerta Pharma). 
2.3 Flow cytometric assays  
Each antibody was conjugated to a specific fluorochrome which emits different 
wavelengths of fluorescence when activated and can be quantified by flow cytometry. 
2.3.1 Extra cellular antibody conjugation method 
This method was required for the detection of cellular antigens on the surface of cells. 
The below method was required for the detection of CD40L expression and for 
defining the primary MCL cell population.   
Fluorochrome-conjugated antibody (recommended amount per test described in 
relevant results chapters) was added to a volume of 100-200µl of cell suspension 
media. Tubes were incubated in the dark for 20 minutes at room temperature unless 
indicated otherwise.  Cells were diluted in 300µl of staining buffer, and analysed by 
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flow cytometry. Fluorescence was measured against an isotype control of the same IgG 
subclass and fluorochrome. 
2.3.2 Intracellular antibody conjugation method  
An intracellular antibody conjugation method was required for the detection of the 
nuclear antigen Ki67 (for assessment of proliferation) and for the detection of 
intracellular BTK (for assessment of BTK activity). 
Each assay had different culture requirements before fixation and are therefore 
described separately. 
For the proliferation assay, cells were cultured in 12 or 24 well plates in cell culture 
media at a concentration of 5 x 106/mL. A volume of 200µl was removed, pelleted by 
centrifugation at 13000rpm for 5 minutes, and then fixed in 200µl of 4% PFA for 10 
minutes at room temperature. 
For the BTK assay, cells were cultured in 1.5mL Eppendorf tubes and fixed in 
suspension. Cell lines were cultured at 1 x 106/mL in 1mL of serum free culture media 
and fixed with 200µl of PFA to a final concentration of 4% for 10 minutes at room 
temperature. 
For primary MCL cells, 200µl of cells (at 5 x 106/mL) in culture media (+ 10% FBS) were 
pre-labelled with anti-CD5 and anti-CD19 on ice for 20 minutes prior to fixation (as 
described above).  
Following fixation, cells were washed in 1 x PBS and permeablised with 0.2% Triton X- 
100 on ice for 10 minutes. Cells were re-suspended in 100µl of staining buffer and 
stained with fluorescein conjugated monoclonal antibodies directed against Ki67 or 
BTK (and an IgG isotype control) and incubated in the dark for 20-25 minutes. Cells 
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were diluted in 300µl of staining buffer, transferred to a FACS tube and analysed by 
flow cytometry. 
2.3.3 Apoptosis staining method  
For the apoptosis assay, cell lines were cultured at 1 x 106/mL in standard 12 well or 24 
well plates.  A volume of 100µl of cell suspension was collected into FACS tubes and 
stained with 5µl annexin V-FITC (BD #556419), gently vortexed and incubated in the 
dark for 20 minutes. Cells were analysed in 400µl of 1X annexin-V binding buffer 
(section 2.1).  
Primary MCL cells were cultured at 4 x 106/ml and 200µl of cells were pre-labelled with 
MCL surface markers on ice for 20 minutes before the addition of annexin-V- FITC. 
2.3.4 Analysis of flow cytometry data  
Samples were analysed on a BD AccuriTM C6 flow cytometer (BD Biosciences). Data 
were collected and plotted onto a 2D forward and side scatter plot. Analysis was 
performed on a minimum of 20,000 events per experimental condition using BD 
AccuriTM CFlow Plus software (BD Biosciences).  Cells were vortexed immediately prior 
to analysis to promote a single cell population.   
Gating was used to isolate the lymphocyte population based on forward and side 
scatter which allowed for exclusion of debris and cell clumps. In addition, assessment 
of the pulse area (FSC-A) vs the pulse height (FSC-H) was used to exclude doublets. 
The appropriate gating was then applied to a histogram which was used to determine 
the proportion of activated fluorescence of the specified cell population against an 
unstained or isotype control. The analysis applied to define the MCL population and to 
determine apoptosis, proliferation and phosphorylation of BTK in cell lines and primary 
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MCL cells is described in detail in the Appendix. In brief, apoptosis was determined by 
analysing the percentage of annexin V-FITC positive cells against viable cells. Cell 
proliferation was determined by analysing the percentage of KI67-FITC positive cells 
against an isotype control of the same IgG subclass. BTK phosphorylation was assessed 
by obtaining the median fluorescence intensity values of the BTK positive cells.   
The percentages and the median fluorescence intensity values were exported to 
Microsoft ExcelTM and GraphPad PrismTM (version 5) for statistical analysis. The 
proportion of cells expressing pBTK-Y223 was determined by calculation of the median 
fluorescence intensity ratio (MFIR) = median fluorescence intensity of pBTK-Y223 
antibody divided by median fluorescence intensity of isotype control. 
2.4 Biochemical assays 
2.4.1 Cell lysis 
Whole cell protein extracts were prepared by lysing ~1 x 107 cells in 100µl of RIPA 
buffer (section 2.1). The cells were incubated on ice for 30 minutes and vortexed every 
10 minutes. The lysed cells were pelleted by centrifugation at 13500rpm and the 
supernatant containing the protein was transferred to a fresh tube. The extracted 
protein was then quantified and stored at -20°C. 
2.4.2 Protein quantification 
Protein concentrations were estimated using the BCA (Bicinchoninic acid) Protein 
Assay Reagent kit (Thermo Fisher UK) according to the manufacturer’s instructions. 
One Bovine Albumin Standard Ampule (Thermo Scientific Pierce #11811345), was 
diluted into 9 different dilutions in 1X PBS to make a set of protein standards. Ten 
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microliters of each BSA standard was added in triplicate to a 96 well plate (Fisher 
Scientific) to construct a standard calibration curve.  
Protein lysates were diluted 1 in 5 in 1 X PBS, to bring them to within the detection 
range of the kit (0.2‐2mg/mL). Ten microliters of each diluted sample was added in 
duplicate to the 96 well plate. An adequate volume of working reagent (BCA reagent A 
and BCA reagent B, mixed at a ratio of 50:1) was prepared and 190µl was added to 
each sample including the BSA standards. The plate was then incubated at 37°C for 30 
minutes. The mean absorbance values of the samples were measured at 562nm using 
a microplate reader and protein concentrations were corrected against the standard 
curve. A multiplication factor of 5 was applied to the resulting sample values to 
account for the 1 in 5 sample dilutions. 
2.4.3 Gel preparation, sample loading and 1D electrophoretic separation 
A fresh 10% resolving gel mixture was prepared (section 2.1) and poured into a 1.5mm 
chamber between two glass plates up to three quarters of the length of the inner plate 
and left to polymerise for 45 minutes. A fresh 4% stacking gel mixture was prepared 
and was added on top of the resolving gel to the top of the inner glass plate. A 10 or 15 
well comb was added and the gel was left to polymerise for 45 minutes.    
 The glass plates containing the gels were placed in a Mini – PROTEAN Tetra cell system 
(Biorad; 165-8004) filled with 1X running buffer (section 2.1) and placed inside a gel 
tank.  
Protein was added to 1.5mL Eppendorf tubes and diluted in dH2O to achieve equal 
protein concentrations between all samples. Protein was denatured by adding an 
70 
 
equal volume of 2 X Laemmli sample buffer containing 5% β-mercaptoethanol to the 
protein, and heating the samples at 95°C on a heat block for 5 minutes. 
Samples were loaded into individual wells of the stacking gel along with 5µl of protein 
standard (Biorad) used as a marker to identify proteins based on their molecular 
weight. Samples were electrophoresed at 70 volts (V) using a Bio-Rad power pack, for 
35 minutes or until protein had lined up at the bottom of the stacking gel. The voltage 
was then increased to 140V and proteins were separated based on mass through the 
resolving gel for 1 hour.   
2.4.4 Co-immunoprecipitation (Co-IP) 
REC-1 cells were seeded at 10 x 107/mL and lysed in 1mL of low stringency lysis buffer 
(100µl lysis buffer/ 1 x 107 cells) (section 2.1). 
The cells were sheared using a needle and syringe to gently break the nuclear 
membrane. The protein concentration was estimated using the BCA assay (section 
2.4.2).  For each immunoprecipitation, 600µg of protein was diluted in 200µl of 1X 
PBST.  
Prior to immunoprecipitation, a pre clearing step was performed to eliminate any non-
specific binding to the beads. The diluted protein lysate was incubated with 50µl of 
protein G magnetic dynabeads (Novex) in a 1.5mL Eppendorf tube and agitated on a 
daisy wheel for 30 minutes at 4°C. The magnetic beads were pulled out of solution 
using a magnetic separator (Cell signalling technology #7017) and the pre-cleared 
lysate was transferred to a fresh 1.5mL Eppendorf tube.  
Immunoprecipitations (IP) were performed indirectly by adding antibodies specific to 
the protein(s) of interest to the diluted REC-1 protein lysate at concentrations 
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indicated on the data sheet,  and incubating with agitation over night at 4°C. A volume 
of 50µl of the protein G beads was added to each IP sample and incubated with 
agitation for 2 hours at 4°C.  
The samples were placed on a magnetic separator and the magnetic beads bound to 
the protein of interest were attracted to the side of the tube. The post IP fraction 
(remaining solution) was removed and saved for SDS-PAGE analysis to ensure the 
immunoprecipitation had worked. The beads were washed 5 times in low stringency 
buffer and eluted in 30µl of 2 X Laemmli buffer (section 2.1).  
The protein complex was separated from the beads, by adding 5% β-ME to each 
sample and heating the samples at 95°C for 5 minutes. The beads were pelleted by 
centrifugation at 14000rpm and the supernatant (containing the protein of interest) 
was collected and subjected to ID electrophorectic separation.  
2.4.5 Preparation of Mass spectrometry samples  
Protein immunoprecipitations were performed as previously described (section 2.4.4) 
and eluted in 30µl of fresh 2 X laemmli buffer. A fresh 10% resolving gel and 4% 
stacking gel was prepared. To prevent as much contamination as possible, all 
equipment including falcon tubes, Eppendorf tubes, glass plates and a ruler was 
soaked in methanol and left to air dry. The reagents used to make the gels including 
the MilliQ dH20, 30% acrylamide, tris buffer and SDS were drawn into a 20mL sterile 
plastic syringe (Becton Dickinson LOT: 7500C13LF) and filtered into a sterile falcon tube 
through a sterile Milllex GP filter unit 0.22µM (Merck Millipore #SLGP033RB). The 
polymerising agents (10% APS and TEMED) were subsequently added, and the gel 
mixture was poured into the chamber between the glass plates. A volume of 5% BME 
was added to each IP sample and the samples were heated at 95°C for 5 minutes.    
72 
 
A volume of 30µl of each IP sample was added to a 10 well gel as shown in the gel 
template below (Figure 2.5). Each IP sample was surrounded by empty wells 
(containing only 2 x Laemmli buffer) to prevent protein contamination from the ladder 
when cutting. 
The gel was left unstained to prevent any staining interference with the mass 
spectrometry. Therefore, after the running of the IP samples, the gel was flipped over 
and kept on the bottom 1.5mm spacer plate. The wells from the stacking gel were 
used as a guide to identify each lane. As shown in Figure 2.5. The IP lanes were cut 
vertically and then a sterile ruler was used to measure and cut out 8 individual pieces 
horizontally using a clean sterile surgical steel blade scalpel (Swann-Morton Sheffield 
England, REF 0503, Lot: 6901412) for each individual cut. The gel pieces were added to 
corresponding labelled tubes. Since the gel was flipped over, the IP samples were 
located in the opposite direction from the direction the samples were originally 
loaded. Each gel piece was covered in 1mL of MilliQ H2O and frozen at -80°C. 
Samples were sent to Manchester University on dry ice and analysed by research staff 
using SWATH MS (sequential window acquisition of all theoretical fragment ion spectra 
mass spectrometry). Analysis of the SWATH MS data is explained in more detail in 
Chapter 5. 
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Figure 2.5: Image of gel after separation of IRF4 IP samples. The image shows the 
approximate position of the cuts and the numbered gel pieces that were sent off for mass 
spectrometry analysis (samples were cut in the opposite direction from the way they were 
loaded). Samples 4 and 5 (possibly 6) contain the IRF4 IP at around 50KDa. 
 
2.4.6 Western blotting  
Proteins were transferred from the gel onto polyvinylidene difluoride (PVDF) 
membranes (Biorad #1620177). The PVDF membrane was prepared by immersing in 
100% Methanol for 20 seconds. The membranes were then rinsed in dH2O and left to 
soak in pre-chilled 1X transfer buffer for at least 20 minutes along with the fiber pads 
and filter paper. The membrane and gel were sandwiched between two pieces of filter 
paper and two fiber pads, all held together inside a mini gel holder cassette. The 
cassette was placed inside a Mini Trans-blot central core unit fixed inside the blotting 
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tank. An ice cold blue cooling unit was placed inside the tank in front of the central 
core unit and the tank was filled with 1X Transfer buffer. Proteins were transferred at 
100V using a Bio-Rad power pack for 1.5 hours. 
2.4.6.1 Immunohybridisation  
The membranes were rinsed briefly in 1X TBS and then incubated in blocking buffer 
(section 2.1) for 1 hour at room temperature.  The membranes were then incubated 
with primary antibodies diluted in blocking buffer overnight at 4°C. The membrane was 
washed for 10 minutes, 3 times in 1X TBST, to remove some of the background from 
the primary antibody and then incubated with a secondary antibody conjugated to-
HRP for one hour at room temperature. Again, the membranes were washed for 10 
minutes, 3 times in 1X TBST, to remove some of the secondary antibody background.   
2.4.6.2 Detection and analysis  
Membranes were enhanced for chemiluminescent visualization following incubation 
with ECL or ECL Prime western blotting substrate (GE Healthcare) for 1 or 5 minutes 
(respectively). The membranes were placed in a hyper cassette and exposed to XR film 
(Fisher Scientific) in a dark room and developed with a Compact X4 Xograph Imaging 
system (Xograph Healthcare Ltd). 
The protein bands detected on the western blot films were quantified using an Image J 
processing tool. The data was exported to Microsoft Excel where the recorded pixel 
densities for all data (bands, controls and their backgrounds) were inverted using the 
following formula; 255 – X, where X is the value recorded by ImageJ. The inverted 
background value was deducted from the corresponding inverted band value to obtain 
a net value. The final relative quantification values were determined by the ratio of net 
75 
 
band to net loading control. The ratios were represented as bar graphs and protein 
expression levels were statistically analysed using Graph pad Prism 5 software. 
2.5 Molecular assays  
2.5.1 Messenger RNA expression 
RNA was extracted from MCL cell lines using the RNeasy Mini Kit (QIAGEN, Hilden, 
Germany) following manufacturer’s instructions. Briefly, 5 x 106 cells were added to 
1.5mL Eppendorf tubes and centrifuged at 13500 rpm for 5 minutes at 4°C. The cell 
pellet was lysed in 350µl of denaturing buffer (Buffer RLT), centrifuged for 3 minutes at 
13500 rpm and the supernatant was carefully transferred to a clean 1.5mL Eppendorf 
tube. A volume of 350µl of 70% ethanol was added to the lysate to facilitate the 
selective binding of the RNA to the silica membrane of the RNeasy spin column. A 
volume of 700µl of the sample containing ethanol was loaded into a spin column 
placed inside a 2mL collection tube and centrifuged for 15 seconds at 10000 rpm. The 
flow through in the collection tube was discarded.  
A volume of 700µl of stringent salt buffer (Buffer RW1) was added to the spin column 
to remove any biomolecules that were non-specifically bound to the silica membrane. 
The spin column was centrifuged at 10000 rpm and the flow through was discarded. To 
remove the salt, a volume of 500µl of a mild wash buffer (Buffer RPE) was added to the 
spin column and centrifuged at 10000 rpm for 15 seconds and the flow through was 
discarded. This was repeated a second time with a 2 minute centrifugation. The spin 
columns were placed inside a clean collection tube and centrifuged at 13000 rpm for 
an extra 1 minute to dry the membrane. The spin columns were then placed inside a 
clean 1.5mL collection tube. 
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To elute the RNA, 30µl of RNase free water was added to the spin column and 
centrifuged for 1 minute at 10000rpm. The spin column was discarded leaving the 
purified RNA in the 1.5mL collection tube.    
The RNA was quantified using a NanoDrop 2000 spectrophotometer (Thermo 
Scientific). The purity of each RNA sample was determined from the ratio of 
absorbance at 260nm and 280nm. RNA was considered pure at ratio of ~2. Samples 
were stored at -80°C. 
2.5.2 Reverse transcription (RNA- cDNA) 
RNA was converted to complementary DNA (cDNA) using the Tetro cDNA synthesis kit 
(Bioline #BIO-65042) following manufacturer’s instructions. A priming premix was 
prepared on ice in RNAse free tubes (Fisher Scientific) containing 1µl of oligo dT, 1µl of  
dNTP mix (10mM), 4µl of reverse transcription buffer, 1µl of Ribosafe RNAse inhibitor 
and 1µl of Tetro reverse transcriptase enzyme per sample.  The quantity of RNA to add 
to the reaction (no more than 12µl or 2µg) was standardised to obtain equal 
concentrations for each sample. Diethyl pyrocarbonate (DEPC) treated water was 
added to the samples to bring the total reaction volume up to 20µl. Samples 
containing no reverse transcriptase (NRT) were also prepared to control for each test 
sample reaction. The samples were heated at 45°C for 30 minutes in a GSTORM 
thermal cycler (Applied Biosystems). The reaction was terminated by denaturing the 
enzyme at 85°C for 5 minutes. The samples were then chilled on ice and stored at -
20°C.   
 
77 
 
2.5.3 Polymerase chain reaction (PCR) 
Regions on IRF4 and PU.1 were amplified from cDNA by PCR and analysed against the 
housekeeping gene HPRT. The primers for IRF4 and HPRT were designed previously by 
the haematology group, the PU.1 primers were taken from Mankai et al 189. All primers 
were designed to span exon junctions thereby preventing amplification of genomic 
DNA. Each primer pair was evaluated for target specificity using NCBI primer blast 
https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi. The oligonucleotide 
sequences are shown in Table 2.2. All primers were purchased from Sigma Aldrich. 
Stock solutions of 10µM were prepared in nuclease free water (Fisher Scientific, 
BP2484-100) and stored at -20°C.  
Conventional PCR was used to optimise the primer annealing temperatures (Ta) prior 
to experimentation by running a temperature gradient (56-62°C). Primers were diluted 
to a final concentration of 200nM (each) in a PCR mix containing 10X Dream Taq buffer 
and 2X Dream Taq DNA polymerase (Thermo Fisher Scientific #EP0701), dNTP mix 
(Thermo Fisher Scientific #R0191), and nuclease free water (Fisher Scientific, BP2484-
100), and 2µl of each cDNA sample was added for a total reaction volume of 23µl. IRF4 
was amplified using a GSTORM thermal cycler (Applied Biosystems), following the cycle 
sequence outlined in Table 2.3. The PCR products were analysed by agarose gel 
electrophoresis (section 2.5.5). 
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Table 2.2: Oligonucleotide sequences used for amplifying IRF4, PU.1 and HPRT from cDNA. 
The IRF4 and HPRT primers were designed previously by the haematology group and the PU.1 
(Spi-1) primers were taken from Mankai et al189. 
 
 
 
Table 2.3: PCR cycle sequence for optimisation of primer annealing. 
 
 
Gene  Primer sequence 5’ - 3’) Size (bp) Amplicon 
size (bp) 
IRF4 Forward ACCCGCAGATGTCCATGAG 19 
 
 
90 
 
 
IRF4 Reverse GTGGCATCATGTAGTTGTGAACCT 24 
 
PU.1 Forward GTGCCCTATGACACGGATCT 20 
 
 
279 
 
 
PU.1 Reverse GTAGAGGACCTGGTGGCC 18 
 
HPRT Forward  CCTGGCGTCGTGATTAGTGAT 21 
 
 
131 
 
 
HPRT Reverse  AGACGTTCAGTCCTGTCCATAA 22 
 
Step Temperature Time No of cycles 
Heated lid 112°C   
Automatic hot start 95°C 10 minutes 1 
Start cycle amplification    
Denaturation  95°C 30 seconds  
40 Annealing  Ta gradient 56, 58, 60, 62°C  30 seconds 
Extension 72°C 60 seconds 
End cycle amplification    
Hold 4°C Infinite  
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2.5.4 Real time quantitative PCR (qPCR) 
Expression levels of IRF4 and PU.1 mRNA were compared against HPRT during the 
exponential growth phase of PCR. Primers were diluted to a final concentration of 
200nM in a PCR mix containing 2X SYBR Green Master I and PCR grade water (ROCHE). 
The PCR mix was added to each test well in a clear optical 96 well plate (ROCHE), and 
1-5µl (25-100ng) of each cDNA sample was added in triplicate in a total reaction 
volume of 15-20µl. The cDNA was amplified using the LightCycler 480 instrument 
(ROCHE) following the cycle sequence outlined in Table 2.4. A melting curve was 
included to determine the specificity of the primers for the PCR product and to ensure 
absence of non-specific amplification. The Cp values (also known as cycle threshold or 
Ct values) were obtained from the LightCycler 480 instrument and transported to 
Microsoft Excel. Relative quantification of IRF4 and PU.1 expression levels was 
normalised against HPRT and determined using the delta delta Ct method. 
 
Step Temperature Time No of cycles 
    
Pre incubation  95°C 10 minutes 1 
Denaturation  95°C 10 seconds  
45 Annealing  60°C  20 seconds 
Extension 72°C 10 seconds 
Melting curve 95°C 5 seconds 1 
 65°C 60 seconds 
Cooling  40°C 10 seconds 1 
 
Table 2.4: Cycle sequence for qPCR amplification of cDNA regions. 
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2.5.5 Agarose gel electrophoresis  
A 1 or 2% agarose gel was prepared in a glass flask by adding 1 or 2 grams of agarose 
powder (Fisher Scientific, UK) to 100mL of 1X TBE buffer (section 2.1). After gentle 
swirling, the mixture was heated for approximately 2 minutes until the agarose was 
completely dissolved in solution. In order to visualise the DNA, 5µl of GelRed TM 
(10,000X in water) nucleic acid gel stain (Cambridge Bioscience #BT41003) was added 
to the mixture. The gel mixture was then poured into a gel tray. A 15 or 20 well comb 
was added and the gel was left to set for at least 30 minutes before loading the 
samples.  
In order to track the PCR products during electrophoresis the samples were mixed with 
a 1 in 6 dilution of 6XDNA loading dye buffer (section 2.1) and then loaded into the 
wells of the agarose gel, alongside a Gene ruler 1Kb plus DNA ladder (Thermo Fisher, 
UK #10600301) or a 100bp DNA ladder (Norgen, Germany). The samples were 
electrophoresed through the gel using a Biorad power pack at a constant voltage of 
130V for 45 minutes or until the samples had almost migrated the length of the gel. 
Following electrophoresis, DNA in each sample was visualised using a UVP GelDoc-It® 
Imager (UVP, Cambridge, UK) aided by the Launch Vision Works LS programme. 
2.5.6 Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitations were prepared from several cell lines using the 
SimpleChIP® Enzymatic Chromatin IP Kit (Magnetic Beads) (Cell signalling technology 
#9003), following manufacturer’s instructions. 
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Preparation of chromatin for ChIP  
A cell count was performed for each cell line using a TC20TM automated cell counter 
(Bio-rad) and cells from each cell line were cultured at 5 x 106 in 20mL of fresh culture 
media in 15cm sterile culture dishes (Thermo Scientific #130183).           
Cross-linking chromatin  
To cross-link proteins to DNA, cells were fixed in 540µl of 37% formaldehyde to 
achieve a final concentration of 1% in each 20mL of cell suspension and left to 
incubate for 10 minutes at room temperature.  
To quench the formaldehyde and prevent non-specific cross linking, a volume of 2mL 
of 10X glycine solution was added to each cell suspension and left at room 
temperature for 5 minutes. 
Each cell suspension was then transferred to a 50mL falcon tube and centrifuged at 
1,500rpm for 5 minutes at 4°C. The supernatant was discarded and the remaining 
pellets were washed twice in 20mL of ice cold 1 X PBS and centrifuged at 1,500rpm for 
5 minutes after each wash.  
Nuclei preparation  
Each pellet was re-suspended in 1mL of ice cold 1X enzymatic lysis buffer A (section 
2.1), and incubated on ice for 10 minutes, and mixed by inversion every 3 minutes. The 
suspension was centrifuged at 3,000rpm for 5 minutes at 4°C and the supernatant 
discarded. Each pellet was then re-suspended in 1mL of ice cold 1X enzymatic lysis 
buffer B (section 2.1), the centrifugation was repeated and supernatant was very 
carefully discarded. Each pellet was then re-suspended in 100µl of 1X enzymatic lysis 
buffer B, transferred to a 1.5mL Eppendorf tube and placed on ice.  
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Chromatin digestion and fragmentation 
To digest DNA to an optimal length for successful ChIP experiments (approximately 
150-900bp), a volume of 0.5 - 0.8µl of micrococcal nuclease (#10011) was added to 
each chromatin preparation, incubated for 20 minutes at 37°C, and mixed frequently 
by inversion. The digest was stopped after 20 minutes by adding 10μl of 0.5M EDTA 
(#7011) and placing the tube on ice. The nuclei was pelleted at 13500rpm for 1 minute 
at 4°C, the supernatant was discarded and the pellet was re-suspended in 100µl 1X 
ChIP buffer (section 2.1). 
The chromatin from each sample was sonicated in 100µl 1X ChIP buffer (section 2.1) 
using a Standard Bioruptor ® (Diagenode, Belgium). Nuclei were observed under a light 
microscope before and after sonication and were determined to be completely lysed 
(no whole cells visualised) after 10 sonication rounds of 30 seconds ON and 30 seconds 
OFF.  After sonication, the lysates were clarified by centrifugation at 10,000rpm for 10 
minutes at 4°C. Approximately 100µl of the supernatant containing the cross-linked 
chromatin was then transferred to a clean tube. 
Confirmation of chromatin fragment length prior to ChIP 
One 50µl aliquot of each sonicated chromatin sample was electrophoresed on agarose 
gel to check the chromatin digestion and fragmentation. A 1% agarose gel was 
prepared (as described in section 2.5.5). To prepare the samples, cross-linked protein- 
DNA interactions were reversed (see reversal of cross links) to free up the DNA 
fragments for electrophoresis. The DNA was purified using spin columns (as described 
later). Following DNA purification, a 10µl sample was removed, mixed with 6X DNA 
loading dye buffer and run on agarose gel alongside a 100bp DNA ladder (Norgen, 
Germany) as previously described.   
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Determination of DNA concentration in chromatin preparation  
DNA concentration and quality was determined using a NanoDrop 2000 
spectrophotometer (Thermo Scientific). The optical density was assessed at 260 nm to 
280 nm and the DNA quality threshold for the A260/A280 ratio was 1.8- 2.0. 
Preparation of the digested chromatin samples for ChIP, and preparation of the input 
sample.  
For each IP sample, the digested cross-linked chromatin was diluted to 1-10µg in 100-
500µl of 1X ChIP buffer. Ten microliters of each diluted solution was removed to a 
separate Eppendorf tube for the 2% input sample and frozen at -20°C. 
Indirect binding of chromatin with ChIP antibody 
A ChIP validated antibody specific for the protein of interest was added directly to the 
digested cross-linked chromatin preparation at the concentration specified on the data 
sheet. A histone (H3) antibody (used as a positive control) and a species matched 
normal IgG antibody (used as a negative control) were added to separate chromatin 
preparations at the concentrations specified in the protocol for establishment of the 
ChIP procedure. Samples were incubated over night at 4°C with rotation on a daisy 
wheel. 
Binding of Protein G magnetic beads to the antibody/chromatin complex 
A volume of 30µl of ChIP-grade protein G magnetic beads #9006 was added to each IP 
sample and incubated for 2 hours at 4°C with rotation on a daisy wheel. Each tube was 
then placed in a magnetic separation rack (cell signalling technology #7017) for 30 
seconds to attract the protein G beads bound to the antibody-antigen complex, to the 
side of the tube. The supernatant (which should not contain the relative chromatin 
fragments of interest) was discarded. Each bead pellet was washed 3 times in 1mL of 
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low salt wash (section 2.1), then washed once in 1mL of high salt wash (section 2.1) at 
4°C for 5 minutes with rotation. After each wash the tubes were placed in the 
magnetic separation rack and the supernatant was discarded.  
Elution of chromatin from antibody- protein G magnetic beads  
A volume of 150µl of 1X ChIP elution buffer (section 2.1) was added to each IP sample 
and to the 2% input samples. All samples were heated at 65°C for 30 minutes and 
gently agitated at 1200rpm in a thermomixer (ThermoFisher) to release the chromatin 
fragments bound to the antibody from the beads. The tubes were placed in the 
magnetic separation rack to attract the unbound beads and the supernatant 
containing the immunoprecipitated chromatin was transferred to fresh tubes.  
Reversal of cross links 
Cross-links within the antibody chromatin complexes were reversed by adding 6µl of 
5M NaCl and 2µl of proteinase K (#10012) to all tubes including the 2% input samples 
and incubating for 2 hours at 65°C. Proteinase K destroys the antibody-protein 
complexes, allowing them to be removed from solution, leaving only the DNA 
fragments. 
DNA Purification using spin columns  
A volume of 750ul of DNA binding buffer (#10007) was added to each DNA sample and 
vortexed briefly. Each sample was transferred (450µl at a time) to a spin column placed 
in a collection tube and centrifuged at 14,000rpm for 30 seconds. The flow through 
was discarded and the spin column was placed back in the collection tube. A volume of 
750µl of DNA wash buffer (#10008) was added to the spin column and centrifuged at 
14,000rpm for 30 seconds. The flow through was discarded and the spin column was 
placed back in the collection tube. The spin columns were centrifuged a second time at 
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14,000rpm for 30 seconds. The collection tube containing the flow through was 
discarded and the spin columns were placed into fresh 1.5mL Eppendorf tubes. A 
volume of 50µl of DNA elution buffer (#10009) was added to each spin column and 
centrifuged at 14,000rpm for 30 seconds to elute the DNA. The spin columns were 
discarded and the eluate containing the purified DNA was stored at -20°C.   
Confirmation of ChIP procedure by conventional PCR  
To determine the success of the ChIP, the purified DNA obtained from each sample 
(the IP and the input DNA samples) was amplified by conventional PCR for detection of 
the ribosomal protein L30 (RPL30) gene locus.  
A PCR reaction-mix was prepared (Table 2.5), the volume of each reagent was 
multiplied for the required number of samples (to include the positive control (Histone 
H3), negative control (normal rabbit IgG) and a NTC)). The mix was vortexed and 18µl 
was added to individual PCR tubes. A volume of 2µl of each DNA sample was added to 
the individual PCR mixes. The DNA was amplified on a Verity thermal cycler (Applied 
Biosystems) following the PCR cycle sequence in Table 2.6. For analysis of the RPL30 
amplicons, 10µl of PCR product from each sample was run on a 2% agarose gel (section 
2.5.5). 
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Table 2.5: The PCR reaction mixture for amplification of the RPL30 locus from ChIP samples 
 
Step Temperature Time Cycles 
    
Initial denaturation 95 5 minutes 1 
Denaturation  95 30 seconds  
40 Annealing  62 30 seconds 
Extension 72 30 seconds 
 72 5 minutes 1 
 
Table 2.6: The PCR cycle sequence for amplification of the RPL30 locus from ChIP samples.  
 
Confirmation of DNA concentration and fragment length using Bio-analyser    
Following PCR confirmation of the ChIP samples, pre-sequencing assessments were 
carried out by Dr Michele Kiernan (Plymouth University) using high sensitivity DNA kits. 
First, the DNA samples were quantified using the Qubit® dsDNA High Sensitivity assay 
kit (Life Technologies) and a Qubit fluorometer. 
Reagent  Volume for 1 PCR Reaction (18 μl)  
 
Nuclease-free H2O  13.1 µl  
 
10X PCR Buffer  2.0 µl  
 
4mM dNTP Mix  0.4 µl  
 
5μM RPL30 Primers  2.0 µl  
 
Taq DNA Polymerase  0.5 µl  
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Next, the size of the DNA fragments from each sample was assessed on the Agilent 
2100 Bio-analyser system (Agilent Technologies, Cheshire, UK)  using the High 
Sensitivity DNA Analysis Kit (Agilent Technologies #50674626,).  
In brief, a gel-dye mix was prepared and loaded into a well-marked ‘G’ (in a black 
circle) on a High Sensitivity DNA chip fixed to a chip priming station. A plunger was 
lowered and held in position for 1 minute before slowly pulling the plunger back to the 
1mL position. More gel mix was loaded into the remaining ‘G’ wells to complete 
loading of the gel-dye mix.  
Next, the marker, ladder and samples were loaded into allocated wells. The chip was 
vortexed for 1 minute at 2400rpm and loaded onto the bio-analyser instrument within 
5 minutes. Results were acquired using 2100 Expert Software (version B.02.08, Agilent 
Technologies).   
Prior to the assessment of individual samples, the gel and electropherogram of the 
DNA Ladder was evaluated to ensure that the required peaks were visible, all peaks 
were adequately defined, the baseline was flat and there was correct identification of 
both markers. 
2.5.7 Next generation sequencing (NGS) 
All sequencing procedures (including library preparation, sequencing and initial 
analysis) were performed by Dr Michele Kiernan (Plymouth University).  
Purified DNA from the ChIP sample was sequenced using an Ion personal genome 
machine (Ion PGM) (Ion Torrent). The ChIP sequencing data was imported on to a 
bioinformatics system and analysed using CLC Workbench software (version 11.1). 
Peaks were aligned to the human genome using the reference HG38.  
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3 Chapter 3- Characterising MCL cell line models of BTKi 
sensitivity and resistance 
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3.1 Introduction 
Inhibitors of BTKi have shown a significant clinical effect in the treatment of MCL, 
however one third of MCL patients have primary resistance to BTKi and a proportion of 
responding patients develop secondary resistance and aggressive relapse. Current 
therapies are less effective in relapsed cases, indicating the need to investigate the 
mechanisms underlying the cellular sensitivity of MCL to BTKi, and to discover 
biomarkers of BTKi resistance so that alternative treatments targeting specific 
resistance mechanisms can be used.  
Due to the complications associated with the culturing of primary MCL cells, the 
characterisation of MCL cell line models which have defined sensitivity or resistance to 
BTKi was of particular importance. 
This chapter describes the characterisation of MCL cell line models of BTKi sensitivity 
and resistance and subsequent development of a cell line model with acquired BTKi 
resistance. Our aim was to define these cell line models to allow identification of 
specific functional and signal responses to BTKi which may ultimately identify 
biomarkers which predict response to treatment with BTKi in MCL.  
Sensitivity to BTKi was assessed through functional assays of apoptosis and 
proliferation, linking these to responses of key BCR signalling proteins – pBTK and 
pERK1/2 and assessing the role of IRF4 as a potential biomarker of BTKi sensitivity. 
3.2 Methods employed 
The methods employed in this chapter involve the general culture of four validated 
MCL cell lines (REC-1, G519, JEKO-1 and JVM2) (Methods section 2.2.4). These cell lines 
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were assessed by flow cytometry for apoptosis (annexin V-FITC) and proliferation (Ki-
67-FITC) in response to varying concentrations of Ibr or Acal (Methods section 2.2.9).  
The cell line displaying BTKi sensitivity (REC-1) was additionally continuously treated 
with BTKi (Ibr / Acal) to generate an in vitro model of acquired BTKi resistance 
(Methods section 2.2.10).  
Assessment of responses by key signalling proteins of the BCR pathway following BTKi 
treatment were determined  through biochemical assays (Methods section 2.4) of 1D-
SDS PAGE (section 2.4.3) , western blotting (section 2.4.6) and immunohybridisation 
(section 2.4.6.1) using cell lysates or by flow cytometry following IgM stimulation 
(Methods section 2.2.8 and 2.3.2) .  
A table of antibodies/probes used in this chapter is shown below (Table 3.1).  
All data (flow cytometry and western blotting) were analysed using Microsoft Excel™ 
and GraphPad Prism™ Version 5 software. The statistical tests employed are described 
in the figure legend of each experiment. 
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Table 3.1: Antibodies/probes used in chapter 3. FC = flow cytometry, WB= western blotting, 
BD = BD Biosciences, CST= Cell signalling technology. 
 
 
 
 
 
 
Antibody/probe Species  Application Ref Source Conc 
Annexin-V-FITC  FC 556419 BD 5ul/test 
Ki67 (IgG1k) -FITC Mouse anti human FC 556026 BD 10ul/test 
BTK pY223 (IgG1k) -PE Mouse anti human FC 562753 BD 5ul/test 
BTK pY551 (IgG1k)-PE Mouse anti human FC 558129 BD 10ul/test 
BTK (IgG2a)-PE Mouse anti human FC 558527 BD 20ul/test 
IgG1k isotype-FITC  Mouse anti human FC 556026 BD 10ul/test 
IgG1k isotype-PE Mouse anti human FC 559320 BD 10ul/test 
IgG1k isotype-APC Mouse anti human FC 555751 BD 10ul/test 
IgG2ak isotype-PE Mouse anti human FC 555574 BD 20ul/test 
IRF4 primary antibody Rabbit anti human WB #4964 CST 1/1000 
pERK1/2 primary antibody Rabbit anti human WB #9101 CST 1/2000 
ERK1/2  primary antibody Rabbit anti human WB #9102 CST 1/2000 
GAPDH  primary antibody Rabbit anti human WB #2118 CST 1/5000 
Secondary antibody-HRP Goat anti rabbit WB #P0448 Dako 1/2000 
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3.3 REC-1 cells demonstrate increased apoptosis in response to Ibr but 
not Acal.  
Of the four mantle cell lymphoma cell lines assessed, REC-1 cells showed sensitivity 
to Ibr with increased apoptosis in a dose and time dependent manner. This effect on 
apoptosis was found to be less apparent following treatment with the more selective 
BTKi Acal.   
3.3.1 Assessment of apoptosis in MCL cell lines in response to Ibr  
Cell lines were tested for their apoptotic response to increasing concentrations of Ibr 
or Acal at regular time points over 72 hours. In REC-1 cells, apoptosis was induced by 
Ibr in a dose and time dependent manner indicating sensitivity to BTKi (Figure 3.1). 
This was confirmed by linear regression analysis (Figure 3.2) which showed a positive 
correlation between Ibr concentration and the percentage of apoptosis which was 
most significant after 72 hours (R2=0.71). However, more than 60% of the REC-1 cells 
remained viable after 72 hours even at the highest dose used (10µM). 
Unlike REC-1, the G519 cells showed no induction of apoptosis above baseline level at 
any concentration of Ibr, suggesting resistance to BTKi (Figure 3.1). In the JEKO-1 cells, 
apoptosis was increased by 7% after 24 hours, although only at a very high 
concentration (10µM) and there was no further increase over the 72 hours. In the 
JVM2 cells, there was a slight increase in apoptosis after 24 hours at 1µM, although 
this was not much higher than the baseline cell death over the 72 hours. Significant 
apoptosis was observed in this cell line at the highest dose (10µM), however this was 
not seen at lower doses suggesting this might be an off-target drug effect. 
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Figure 3.1: Cell death response to Ibr in MCL cell lines. Cells were seeded at 5 x 105/mL, 
treated with DMSO (vehicle) or increasing concentrations of Ibr (FC: 10nM, 100nM, 1µM and 
10µM). Cell death was determined by flow cytometry with annexin V-FITC staining at each 
concentration after 24, 48 and 72 hours incubation (N=3). 
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Figure 3.2: Regression analysis of Ibr concentration and apoptosis in REC-1 cells. The graph 
shows log (Gaussian) non-linear correlation curves showing a positive correlation  between 
concentration of Ibr and apoptosis of REC-1 cells at each time point with the greatest 
correlation at 72 hours ( R2 =0.71) N=3. 
 
3.3.2 Assessment of apoptosis in MCL cell lines in response to Acal 
In response to the more selective BTKi (Acal), apoptosis was only minimally increased 
in REC-1 cells compared to the control cells and only at doses >100nM. Apoptosis was 
only increased by Acal by 6% after 72 hours at high dosage (10µM) (Figure 3.3A), 
indicating that Acal induces less apoptosis when compared to Ibr at the equivalent 
doses. In G519 cells there was no induction of apoptosis above baseline level at any 
concentration of Acal (Figure 3.3B), which is equivalent to the lack of apoptosis seen 
with Ibr. In response to a higher dose range of Acal (1-100µM), apoptosis of REC-1 cells 
did not significantly increase until the dose reached 100µM (Figure 3.3C), and with 
approximately 55% of the cells still viable after 48 hours, even this extreme dose was 
insufficient to cause complete cytotoxicity. Apoptosis of the resistant G519 cells was 
also increased at this dose, suggesting off target effects due to the very high 
concentration of Acal (or DMSO). 
 
95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Cell death response to Acal in MCL cell lines. Cells were seeded at 5 x 105/mL, 
treated with DMSO (vehicle) or increasing concentrations of Acal. Cell death was determined 
by flow cytometry with annexin V-FITC staining at each concentration after 24, 48 and 72 
hours incubation. A) REC-1, and B) G519 over a 72 hour time course with Acal (FC: 10nM, 
100nM, 1µM, 10µM). C) G519 and REC-1 cells after 48 hours Acal treatment using a higher 
dose range (FC: 1µM, 3µM 10µM, 30µM, 100µM). 
 
 
 
 
 
 
A) B) 
C) 
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3.4 REC-1 cells demonstrate reduced proliferation in response to both 
Ibr and Acal 
The proliferation of REC-1 cells is markedly sensitive to both Ibr and Acal with 
reduction in proliferation seen early (24 hours) and at very low concentrations (nM).  
This contrasts to the other MCL cell lines, particularly G519 cells and represents a 
laboratory assessment to determine BTKi sensitivity. 
3.4.1 Assessment of proliferation in MCL cell lines in response to Ibr  
The cell lines were tested for changes to proliferation in response to increasing 
concentrations of Ibr. In REC-1 cells, proliferation was reduced by Ibr equally at all 
doses tested (10nM, 100nM, 1µM, 10µM) as early as 24 hours after treatment (Figure 
3.4A). This reduction was time dependant; with proliferation reduced to approximately 
30% of control levels after 72 hours of treatment, but not dose dependant suggesting 
the proliferation of REC-1 cells may be reduced at lower doses of Ibr. 
In response to a lower dose range of Ibr, the reduction of REC-1 cell proliferation was 
shown to occur at doses as low as 1nM after only 24 hours treatment (Figure 3.4D). In 
contrast, the G519 cells did not show any reduction of proliferation over baseline 
levels over the 72 hours treatment with Ibr at the highest dose (10µM) (Figure 3.4B) 
which correlates with the survival of G519 cells in response to Ibr. 
The JEKO-1 and JVM2 cells were also analysed for the percentage of Ki67 positive cells 
after 48 hours treatment. Like G519, the JEKO-1 cells did not indicate any reduction in 
proliferation above baseline at any dose but the JVM2 cells showed a considerable 
reduction in proliferation at the highest dose (10µM) (Figure 3.4C), which  correlates 
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with the increased death of these cells only at 10µM and indicating likely off target 
drug effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Proliferation response to Ibr in MCL cell lines. Cells were seeded at 5 x 105/mL, 
treated with DMSO (vehicle) or increasing concentrations of Ibr as indicated. 1 x 106 cells at 
each concentration were taken at various time points, and stained with a Ki67-FITC antibody 
for analysis by flow cytometry. Cell proliferation was determined by analysing the percentage 
of KI67-FITC positive cells against an isotype control using an IgG1-FITC antibody (N=2). A) 
Proliferation of REC-1 and B) G519 in response to Ibr over a 72 hour time course. C) 
Proliferation of JEKO-1 and JVM2 cells after 48 hours Ibr treatment. D) Proliferation of REC-1 
cells in response to a low dose range of Ibr (10pM, 100pM, 1nM, 10nM). 
 
 
 
A) B) 
C) D) 
98 
 
3.4.2 Assessment of proliferation in MCL cell lines in response to Acal 
In response to Acal, the G519 cells showed no reduction of proliferation (<10µM after 
72 hours) (Figure 3.5), therefore providing more evidence that these cells are resistant 
to BTKi. The REC-1 cells showed a 32% reduction in proliferation after 72 hours of Acal 
treatment at a dose of 100nM (Figure 3.5), 100 fold higher than that seen with Ibr, 
demonstrating sensitivity to Acal, despite the lack of correlative apoptosis of the cells 
in response to Acal. 
 
Figure 3.5: Proliferation response to Acal in MCL cell lines. Cells were seeded at 5 x 105/mL, 
treated with DMSO (vehicle) or increasing concentrations of Acal as indicated. 1 x 106 cells at 
each concentration were taken at various time points, and stained with a Ki67-FITC antibody 
for analysis by flow cytometry. Cell proliferation was determined by analysing the percentage 
of Ki67-FITC positive cells against an isotype control using an IgG1-FITC antibody. Proliferation 
of G519 and REC-1 cells after 72 hours Acal treatment. 
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3.4.3 Comparison of proliferation in REC-1 cells in response to Ibr or Acal 
In a separate experiment, the proliferation of REC-1 cells was compared following 
treatment with either Ibr or Acal at a single effective dose (100nM). Proliferation was 
reduced equally in response to Ibr and Acal (100nM) from 24 to 72 hours (Figure 3.6). 
In vitro assays assessing proliferation were found to be a more sensitive indicator of 
BTKi effect than assays of apoptosis. Proliferation was therefore used as a measure of 
BTKi sensitivity for subsequent experiments. 
 
Figure 3.6: Proliferation response to Ibr versus Acal in REC-1 cells. Proliferation of REC-1 cells 
in response to Ibr or Acal treatment (100nM). 
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3.5 All MCL cell lines show increased levels of phosphorylated BTK 
(Y223) following BCR activation and down-regulation with Ibr  
The activity of BTK can be assessed through flow cytometric assessment of the 
intracellular phosphorylation of BTK at tyrosine 233 (Y223).  All 4 MCL cell lines 
irrespective of their sensitivity to treatment with BTKi showed a functional BCR with 
an increase in phosphorylated BTK (Y233) following anti-IgM stimulation and 
inhibition of this response by Ibr.  
Having established that REC-1 cells were sensitive to BTKi treatment it was important 
to assess BTK activity between the different cell lines.  Previous experiments from the 
group showed that assessment of BTK phosphorylation was difficult with western 
blotting and antibody hybridisation. We therefore assessed BTK phosphorylation by 
flow cytometry (Methods section 2.3.2) using an antibody to BTK, and the Y223 and 
Y551 phosphorylation sites of BTK (Table 3.1).   
3.5.1 Baseline assessment of BTK activity in REC-1 cells following Ibr 
treatment  
The sensitive cell line REC-1 was first analysed for total levels of BTK and BTK 
phosphorylation at Y551 and Y223 at baseline, and after 1 hour treatment with Ibr 
(10µM). REC-1 cells showed low levels of total BTK and phosphorylated BTK at Y551, 
however phosphorylation at Y223 was readily detected in unstimulated REC-1 cells and 
phosphorylation was reduced by Ibr (10µM) after 1 hour (Figure 3.7).  Upon B cell 
receptor (BCR) stimulation, Y223 is auto-phosphorylated which subsequently activates 
the enzymatic activity of BTK. With these results, we therefore used phosphorylation 
of BTK at Y223 as a surrogate marker of BTK activity. 
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Figure 3.7: Comparison of BTK phosphorylation and total BTK levels in unstimulated REC-1 
cells before and after 1 hour of Ibr treatment. REC-1 cells were treated with 10µM Ibr for 1 
hour and analysed for phosphorylated BTK and total BTK levels by flow cytometry. Bars 
represent the median fluorescence intensity ratios (PE marker/PE isotype control), units are 
arbitrary.    
 
 
3.5.2 Assessment of Ibr treatment on basal levels of Y223 BTK 
phosphorylation in all MCL cell lines   
All MCL cell lines (REC-1, G519, JEKO-1, JVM2) were subsequently analysed for levels of 
BTK phosphorylation at Y223 at baseline and after 1 hour treatment with Ibr (100nM, 
10µM). Ibr inhibited the activity of BTK in a dose dependent manner in all cell lines 
(Table 3.2, Figure 3.8) emphasising that sensitivity to BTKi treatment was through 
modulation of pathways downstream of the BCR and BTK molecule. 
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Ibr REC-1 G519 JEKO-1 JVM2 
Control 16.03268 5.309242 7.676796 16.12012 
100nM 9.558824 3.386256 4.588398 10.48649 
10µM 5.348039 2.446682 3.44337 3.45045 
 
Table 3.2: Median fluorescence intensity ratios (MFIR) for BTK phosphorylation at Y223 in 
unstimulated MCL cell lines in response to Ibr. Each MCL cell line was treated with Ibr (100nM 
and 10µM) for 1 hour. The table data represents the raw MFIR values for pBTK Y223 obtained 
for each unstimulated cell line before and after 1 hour incubation with Ibr (100nM and 10µM).  
Ratios calculated by marker / isotype control. MFIR expressed in arbitrary units. 
 
 
Figure 3.8: Reduction of pBTK Y223 following 1 hour Ibr treatment in unstimulated MCL cell 
lines. Lines represent the median fluorescence intensity ratios (expressed in arbitrary units) for 
pBTK Y223 (Table 3.2) illustrating the effect of IgM stimulation on BTK phosphorylation in each 
cell line at each time point, and the reduction of pBTK Y223 after 1 hour Ibr treatment. 
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3.5.3 Assessment of Ibr treatment on Y223 BTK phosphorylation following 
BCR activation  
Most BCR in MCL are IgM and can be stimulated via cross-linking with an anti-IgM 
antibody. MCL cell lines were stimulated with anti-IgM for a varying length of time to 
determine the optimal response to BTK phosphorylation.  In all MCL cell lines, pBTK-
Y223 rapidly developed following BCR activation and returned to near basal levels after 
60 minutes (Figure 3.9). REC-1 cells showed the greatest increase after 1 minute IgM 
stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Levels of pBTK Y223 in MCL cell lines following IgM stimulation. A) Graphical 
representations of pBTK Y223 median fluorescence intensity ratios (MFIR) in all MCL cell lines 
stimulated with IgM at various time intervals over 1 hour. B) Flow cytometry peak plots 
showing baseline levels of pBTK Y223 (blue) against an IgG1 isotype control (black) and the 
increase in pBTK Y223 following IgM stimulation for 1 minute (red). All cell lines responded to 
IgM stimulation at varying degrees but REC-1 showed the greatest increase after 1 minute.  
 
A) 
B) 
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Phosphorylation levels at Y223 of BTK were then determined before and after Ibr 
treatment in response to BCR stimulation for 1, 15 and 60 minutes. The addition of Ibr 
reduced phosphorylation of BTK-Y223 in all IgM stimulated cells in a dose dependent 
manner, as indicated by the reductions in MFI ratio with increasing dosage (Table 3.3, 
Figure 3.10), emphasising as in Figure 3.8 that all cells behave similarly whether they 
are sensitive or resistant to BTKi, suggesting that other signalling events further 
downstream from BTK may define sensitivity or resistance to BTKi in MCL.  
 REC-1 G519 JEKO-1 JVM2 
Unstimulated 
Control 16.03268 5.309242 7.676796 16.12012 
100nM Ibr 9.558824 3.386256 4.588398 10.48649 
10µM Ibr 5.348039 2.446682 3.44337 3.45045 
IgM: 1 minute 
Control 136.3905 9.640995 34.36602 21.86411 
100nM Ibr 130.1757 8.055687 24.65953 14.69745 
10µM Ibr  39.52451 2.470379 3.296961 4.310811 
IgM: 15 minutes 
Control  123.634 9.356635 11.3826 20.96547 
100nM Ibr 105.9273 4.753555 19.96478 14.82432 
10µM Ibr 62.98448 2.058057 7.259669 4.283784 
IgM: 60 Minutes 
Control  52.58824 5.103081 12.33564 20.7455 
100nM Ibr  41.91503 4.712085 8.13674 14.80931 
10µM Ibr  29.85621 1.906398 4.05663 5.261261 
 
Table 3.3: Median fluorescence intensity (MFI) ratios for pBTK Y223 following Ibr treatment 
in IgM stimulated MCL cell lines. The table data represents the raw MFI Ratio values for pBTK 
Y223 obtained for each IgM stimulated cell line before and after 1 hour incubation with Ibr 
(100nM and 10µM). MFI ratios were calculated by PE marker / PE isotype control. MFI ratios 
are expressed in arbitrary units. 
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Figure 3.10: Reduction of pBTK Y223 following 1 hour Ibr treatment in four MCL cell lines 
stimulated with IgM over time. Lines represent the median fluorescence intensity ratios 
(expressed in arbitrary units) for pBTK Y223 (Table 3.3) illustrating the effect of IgM stimulation 
on BTK phosphorylation in each cell line at each time point, and the reduction of pBTK Y223 
after 1 hour Ibr treatment. 
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3.6 All MCL cell lines showed downregulation of phosphorylated ERK 
(pERK) in response to Ibr, however pERK induced by BCR activation 
was only partially downregulated.  
The extracellular signal regulated kinase (ERK), is located directly downstream from 
BTK. All 4 MCL cell lines whether showing sensitivity to treatment with BTKi showed 
inhibition of baseline levels of phosphorylated ERK (pERK) with Ibr. Following BCR 
activation with anti-IgM, levels of pERK were increased but only partly reduced by 
Ibr in both REC-1 and G519 cells. 
3.6.1 Assessment of ERK activity in REC-1 cells following treatment with Ibr  
The sensitive REC-1 cells were first treated with three concentrations of Ibr (10nM, 
1µM, 10µM) for 4 hours, and levels of ERK1/2 phosphorylation were assessed in 
protein lysates through immunohybridisation (Methods section 2.4.6.1). Total levels of 
ERK 1/2 were abundant at each concentration. However, ERK1/2 phosphorylation 
(pERK) was downregulated by Ibr at all concentrations compared to the control cells 
(Figure 3.11), suggesting phosphorylation of ERK1/2  results from BTK activity in 
unstimulated REC-1 cells and that the BTK/ERK signalling pathway is involved in BTKi 
treatment response in sensitive MCL cells. 
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Figure 3.11: Immunoblot analysis of phosphorylated ERK (pERK) levels in REC-1 cells pre and 
post Ibr treatment for 4 hours. REC-1 cells were seeded at 5 x 106/mL and treated with a 
DMSO vehicle or Ibr at a range of doses (10nM, 1µM and 10µM). The cells were lysed after 4 
hours incubation with Ibr. 10% SDS gel. 25µg protein. pERK (Cell Signalling technology #9101) 1 
in 2000 dilution, ERK1/2 (Cell signalling technology #9102) 1 in 2000 dilution, GAPDH (Cell 
Signalling technology #2118) 1 in 5000 dilution in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-
HRP (Dako, P0448) 1 in 2000 dilution (pERK, ERK1/2) 1 in 5000 dilution (GAPDH) in 5% 
BSA/TBST, 1 hr, RT. ECL (Pierce, Life Technologies). 
 
3.6.2 Assessment of Ibr action on levels of phosphorylated ERK in all MCL cell 
lines  
To determine whether the downregulation of ERK phosphorylation was observed in all 
cell lines in response to BTKi and whether it was a transient or a continuous effect 
sustained over time, all four cell lines including REC-1 were treated with a single 
concentration of Ibr (10µM), and ERK1/2 phosphorylation was assessed at regular time 
points (as indicated) over 48 hours (Figure 3.12). Levels of total ERK1/2 in all 4 MCL cell 
lines remained fairly constant in all unstimulated cells over 48 hours.  However 
inhibition of ERK1/2 activity (measured as pERK) by Ibr, was observed in all MCL cell 
lines, both sensitive and resistant, therefore levels of pERK do not define sensitivity to 
BTKi, however it does suggest that BTKi have an effect on the MAP kinase pathway in 
these cell lines.  
For the REC-1 and G519 cells, pERK levels were normalised to ERK1/2. A paired t-test 
was used to compare pERK levels in control cells versus Ibr treated cells at 
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corresponding time points (Figure 3.13).   In REC-1 cells, pERK was reduced at as early 
as 1 hour following treatment and this reduction was statistically significant for up to 8 
hours compared to the untreated REC-1 cells at corresponding time points (p=0.0444). 
However pERK levels started to increase again after 24 to 48 hours suggesting 
reactivation of the ERK pathway through alternative, redundant pathways. Levels of 
pERK were also reduced after 1 hour in G519 cells following Ibr treatment and this 
reduction was statistically significant for the entire 48 hours (p=<0.0001).   
For JEKO-1 and JVM2 cells, pERK levels were normalised against GAPDH.  The levels of 
pERK were significantly reduced after 1 hour of Ibr treatment and the reduction was 
sustained for 48 hours in both JEKO-1 cells (p=0.0003) and JVM2 cells (p=0.0138). 
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Figure 3.12: Immunoblot analysis of p-ERK and ERK1/2 in MCL cell lines pre and post Ibr 
treatment. REC-1, G519, JEKO-1 and JVM2 cells were seeded at 5 x 106/mL, treated with a 
DMSO vehicle or Ibr (FC: 10µM). Lysates were taken at time zero (T0), and after 1, 4, 8, 24 and 
48 hours. 10% SDS gel. 15µg protein. p-ERK (Cell Signalling technology #9101) 1 in 2000 
dilution, ERK1/2 (Cell signalling technology #9102) 1 in 2000 dilution, GAPDH (Cell Signalling 
technology #2118) 1 in 5000 dilution in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-HRP (Dako, 
P0448) 1 in 2000 dilution (pERK, ERK 1/2) 1 in 5000 dilution (GAPDH) in 5% BSA/TBST, 1 hr, RT. 
ECL (Pierce, Life Technologies). One of two blots is shown for each cell line representing results 
of 2 independent experiments. 
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Figure 3.13: Densitometry analysis of the levels of pERK in MCL cell lines before and after 
treatment with Ibr (10µM). Levels of pERK were assessed by densitometry using Image J. P 
values were obtained by comparing the levels of pERK in untreated cells vs treated cells at 
each time point using paired t-test. Levels of pERK in REC-1 and G519 cells were normalised to 
ERK1/2. pERK was downregulated by Ibr in REC-1 cells for up to 8 hours (p= 0.0444) and for up 
to 48 hours in G519 cells (p=<0.0001). Levels of pERK in JEKO-1 and JVM2 were normalised to 
GAPDH. pERK was downregulated by Ibr for up to 48 hours in JEKO-1 cells (p=0.0003) and 
JVM2 (P= 0.0138). 
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3.6.3 Assessment of Ibr treatment on levels of phosphorylated ERK following 
BCR activation  
To determine whether pERK expression changed following activation of the BCR, cells 
of one sensitive cell line (REC-1) and one resistant (G519) were treated with Ibr (10µM) 
and stimulated with anti-IgM for 15 minutes or 4 hours. Protein lysates were prepared 
from the cells after 8 hours and 24 hours incubation with Ibr.  
Following cross-linkage of the BCR with anti-IgM after 15 minutes or sustained over 4 
hours, ERK1/2 activation, as indicated by pERK, was induced in both sensitive REC-1 
and resistant G519 cells, as already shown for BTK (pY223). Ibr had no effect on 
phosphorylated ERK levels following 8 hours of Ibr treatment.  In REC-1 cells, levels of 
pERK appeared to be reduced by Ibr after 24 hours compared to the levels in G519 
cells which were sustained (Figure 3.14), therefore upon BCR activation, pERK is only 
partially reduced by Ibr in both cell lines suggesting that ERK is additionally activated 
through alternative pathways to BTK and is not defining for sensitivity to BTKi. These 
results therefore suggest that pERK is not the best candidate for use as a biomarker to 
determine BTKi sensitivity. 
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Figure 3.14: Immunoblot analysis of pERK and ERK1/2 in REC-1 and G519 cells (+/- IgM 
stimulation) pre and post Ibr treatment. REC-1 and G519 cells were seeded at 5 x 106/mL, 
treated with a DMSO vehicle or Ibr (FC: 10µM) and stimulated with anti-IgM (3µg/mL) for 15 
minutes or 4 hours. The cells were lysed after 8 hours and 24 hours incubation with Ibr. 10% 
SDS gel. 15µg protein. p-ERK (Cell Signalling technology #9101) 1 in 2000 dilution, ERK1/2 (Cell 
signalling technology #9102) 1 in 2000 dilution, GAPDH (Cell Signalling technology #2118) 1 in 
5000 dilution in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-HRP (Dako, P0448) 1 in 2000 
dilution (pERK, ERK1/2) 1 in 5000 dilution (GAPDH) in 5% BSA/TBST, 1 hr, RT. ECL (Pierce, Life 
Technologies). 
 
 
 
 
 
G519 cells 
 
REC-1 cells 
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3.7 IRF4 protein expression is downregulated following treatment with 
BTKi in REC-1 cells  
IRF4 is downregulated following BTKi treatment (Ibr or Acal) only in sensitive REC-1 
cells and not in resistant cell lines.  IRF4 was downregulated early (8 hours) and at 
low concentration (nM).  The expression level of IRF4 was not increased following 
BCR activation with anti-IgM and shows a differential response between sensitive 
and resistant cells with REC-1 cells showing a persistent down-regulation of IRF4 
after 24 hours of Ibr treatment even following BCR activation with anti-IgM.  
Preliminary results from this group identified IRF4 as a protein of interest following 
BTKi treatment in patients with CLL.  This is maybe not surprising as IRF4 
overexpression is seen in various subtypes of NHL including DLBCL and MM and 
downregulation of IRF4 in response to a combination of treatment with Ibr and 
lenolidamide has been shown in the ABC subtype of DLBCL.173 However the role of 
IRF4 in response to BTKi treatment in MCL is currently unknown and was therefore 
investigated. 
3.7.1 Assessment of levels of IRF4 in MCL cell lines following treatment with 
BTKi  
All MCL cell lines were tested for baseline expression of IRF4 (by western blotting and 
immunohybridisation) and subsequent changes in expression following Ibr treatment 
(10µM). In all non-stimulated cells, IRF4 was consistently expressed in all four cell lines 
over a 48 hour time course (Figure 3.15). Treatment with Ibr had no effect on IRF4 
expression in the resistant cell lines (G519, JEKO-1 and JVM2), however IRF4 was 
significantly downregulated by Ibr in sensitive REC-1 cells (p= 0.0078), commencing at 
around 4 hours and almost abolished by 48 hours, as determined by a paired t test of 
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the densitometry data (Figure 3.16). This precedes the Ibr-induced reduction in 
proliferation observed at 24 hours and the increased apoptosis observed at 24 to 48 
hours. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Immunoblot analysis of IRF4 in MCL cell lines pre and post Ibr treatment. The red 
arrow indicates downregulation of IRF4 expression after 48 hours Ibr treatment only in REC-1 
cells. 10% SDS gel. 25.0µg protein. IRF4 (Cell Signalling technology #4964) 1 in 1000 dilution, 
GAPDH (Cell Signalling technology #2118) 1 in 5000 dilution in 5% BSA/TBST, o/n at 4°C.  Goat 
anti-rabbit-HRP (Dako, P0448) 1 in 2000 dilution (IRF4) 1 in 5000 dilution (GAPDH) in 5% 
BSA/TBST, 1 hr, RT. ECL (Pierce, Life Technologies) (GAPDH) ECL prime (IRF4). 
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Figure 3.16: Levels of IRF4 in MCL cell lines before and after treatment with Ibr. Levels of IRF4 
were assessed by densitometry using Image J and normalised to GAPDH. A paired t test was 
used to determine the significance of IRF4 downregulation in cells treated with Ibr (10µM) 
compared to the untreated cells. Error bars represent standard error of the mean of 2 
independent experiments for each cell line. 
 
 
 
 
 
 
 
 
 
 
117 
 
To identify the particular dose of BTKi required to downregulate IRF4, and determine 
whether this dose would be therapeutically achievable in vivo, REC-1 cells were 
cultured as described above and treated with Ibr or Acal at a range of concentrations 
(10nM, 100nM, 1µM 10µM).  Protein lysates were prepared from cells after 48 hours 
in culture.  
IRF4 was shown to be downregulated by Ibr at a dose of 10nM while the dose required 
for Acal was 10 fold higher at 100nM (Figure 3.17). However, both doses were below 
the reported maximum achievable in vivo dosage for each drug (400nM for Ibr,116,145 
and 2µM for Acal (personal communication from Acerta Pharma). 
 
 
 
 
 
 
Figure 3.17: Immunoblot analysis of IRF4 in REC-1 cells pre, and 48 hours post BTKi treatment 
with Ibr and Acal. 10% SDS gel. 30.0µg protein. IRF4 (Cell Signalling technology #4964) 1 in 
2000 dilution, GAPDH (Cell Signalling technology #2118) 1 in 5000 dilution in 5% BSA/TBST, o/n 
at 4°C. Goat anti-rabbit-HRP (Dako, P0448) 1 in 2000 dilution (IRF4) 1 in 5000 (GAPDH) in 5% 
BSA/TBST, 1 hr, RT. ECL (Pierce, Life Technologies). 
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3.7.2 Assessment of IRF4 expression in response to BCR activation and 
treatment with Ibr 
To determine the expression of IRF4 following BCR activation with anti-IgM and BTKi 
treatment, both REC-1 cells and G519 cells were stimulated with anti-IgM for 15 
minutes or 4 hours. Proteins were extracted after 8 hours and 24 hours incubation 
with Ibr (10µM).  
Short-term or sustained BCR stimulation did not alter baseline levels of IRF4 in either 
REC-1 or G519 cells. However, IRF4 was clearly down-regulated in REC-1 cells following 
24 hours of Ibr treatment, even in the presence of BCR activation (Figure 3.18).This 
change possibly occurred as early as 8 hours after Ibr treatment. Importantly in 
resistant G519 cells there was no downregulation of IRF4 seen in response to Ibr. 
 
 
 
 
 
 
 
 
 
Figure 3.18: Immunoblot analysis of IRF4 in REC-1 and G519 cells treated with Ibr following 
acute and chronic BCR activation. 10% SDS gel. 20.0µg protein. IRF4 (Cell Signalling technology 
#4964) 1 in 2000 dilution, GAPDH (Cell Signalling technology #2118) 1 in 5000 dilution in 5% 
BSA/TBST, o/n at 4°C.  Goat anti-rabbit-HRP (Dako, P0448) 1 in 2000 dilution (IRF4), 1 in 5000 
dilution (GAPDH) in 5% BSA/TBST, 1 hr, RT. ECL (GAPDH), ECL prime (IRF4) (Pierce, Life 
Technologies).   
 
 
Ibr 10µM 
Anti-IgM 
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3.8 IRF4 downregulation is not seen in cells which have acquired 
resistance to BTKi. These cells show stable levels of phosphorylated 
BTK following treatment with BTKi. 
An in vitro model of acquired Ibr or Acal resistance was created using the REC-1 cell 
line. In contrast to the parent REC-1 cells, the resistant REC-1 cells demonstrated 
resistance to the actions of BTKi on survival and proliferation, with a possible 
increased baseline proliferation. Phosphorylated BTK (Y223) was not downregulated 
following BTKi treatment and levels of IRF4 were maintained. 
3.8.1 Determination of BTKi resistance in REC-1 cells. 
REC-1 cells were passaged in the presence of Ibr until stable resistance to Ibr was 
established, and then continuously treated at concentrations exceeding that of the 
maximum in vivo dose (>400nM). At a later stage in the study, REC-1 cells were also 
sensitised to Acal in the same way to generate a cell line model of Acal resistance (For 
full details on developing the resistant cell lines see Methods section 2.2.10).  
The resistance status of the cells was determined by assessing the proliferation 
response to Ibr compared to the sensitive REC-1 cells. The REC-1 cells sensitised to 
1µM of Ibr (REC-1/R (Ibr 1µM)) and to 3µM of Ibr (REC-1/R (Ibr 3µM)) were re- treated 
with 1µM and 3µM Ibr (respectively) along with the parent REC-1 control cells (REC-
1/P) at the same dosage. A total volume of 1 x 106 cells was harvested from each 
sample at regular time points over 72 hours for analysis of proliferation by flow 
cytometry (Methods section 2.3.2). 
Compared to the treated parental REC-1 cells, Ibr did not reduce proliferation of the 
Ibr sensitised REC-1 cells (at either dose). In fact, the sensitised cells were more 
proliferative than the parent untreated REC-1 control cells. A paired student t test 
120 
 
revealed that proliferation was significantly reduced in the ‘parent’ REC-1 cells treated 
with 1µM and 3µM doses of Ibr compared to the sensitised REC-1 cells treated with 
the corresponding doses at all time points (p= 0.0094) (Figure 3.19). 
 
 
Figure 3.19: Proliferation response to Ibr in parent vs Ibr resistant REC-1 cell lines.  Resistant 
REC-1 cells (one sensitised to 1µM and the other to 3µM Ibr) were washed in media to remove 
the drug after 72 hours of previous culture with Ibr. A volume of 12mL containing 3 x 105/mL 
cells at each concentration were added to clean culture flasks. An equal volume and density of 
parent REC-1 cells was added to 3 separate flasks. One flask of parent REC-1 cells was treated 
with DMSO (vehicle control) and cells in each other flask were treated with either 1µM or 3µM 
of Ibr. Approximately 1 x 106 cells from each flask were taken at the indicated time points over 
72 hours, then fixed in PFA and permeablised in triton X-100, and stained with a Ki67-FITC 
antibody for analysis by flow cytometry. Cell proliferation was determined by analysing the 
percentage of Ki67-FITC positive cells against an isotype control using an IgG1-FITC antibody. 
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3.8.2 Assessment of IRF4 expression in BTKi resistant REC-1 cells  
After resistance to both Ibr and Acal had been established in REC-1 cells (by showing 
no BTKi induced reduction of proliferation), an experiment was devised to identify 
changes in IRF4 expression compared to sensitive parent REC-1 cells in response to 
both BTK inhibitors to  determine whether differences in IRF4 expression could be seen 
in cells of acquired BTKi resistance. 
The REC-1 cells sensitised to 1µM of Ibr (REC-1/R (Ibr 1µM), 3µM of Ibr (REC-1/R (Ibr 
3µM) and 1µM of Acal (REC-1/R (Acal 1µM) were re- treated with corresponding doses 
of Ibr or Acal along with the parent REC-1 control cells (REC-1/P) at the same dosage. 
Cells were removed from each sample after 72 hours incubation for analysis of 
apoptosis, proliferation and BTK Y223 phosphorylation by flow cytometry, and protein 
lysates were prepared for analysis of IRF4 expression by western blotting and 
immunohybridisation.  
The parent REC-1 cells treated with Ibr (1µM and 3µM) showed downregulated IRF4 
compared to the parent REC-1 control cells (as shown previously), while the acquired 
resistant REC-1 cells continuously treated with 1µM Ibr showed no downregulation of 
IRF4 in response to Ibr (Figure 3.20). These results match the findings for IRF4 
expression in innate resistant cells (G519, JVM2 and JEKO-1 cells) in response to Ibr, 
providing more evidence that IRF4 could be a potential biomarker of BTKi sensitivity in 
MCL. 
In the Ibr resistant REC-1 cells continuously treated with 3µM Ibr, IRF4 protein was not 
as expressed as the parent REC-1 control cells but was clearly more expressed than the 
parent REC-1 cells treated at this dose, indicating that a dose of 3µM was still having 
some effect on IRF4 downregulation.  A likely explanation for this however looking at 
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the apoptosis/ proliferation responses is that the cells are yet to become totally 
resistant to 3µM at the time of this experiment. In the Acal resistant REC-1 cells 
continuously treated with 1µM Acal, again IRF4 protein was not as expressed as in the 
parent REC-1 control cells but was clearly more expressed compared to the parent 
REC-1 cells treated at the same dose of Acal. Again however at the time of the 
experiment the Acal resistant cell line was still in the process of being sensitised to 
1µM suggesting that resistance at this dosage may not have been fully established. 
The table below (Table 3.4) compares the survival and proliferation between parental 
cells treated with BTKi and corresponding acquired resistant cells.  Overall survival and 
proliferation is maintained in acquired resistant cells compared to parental treated 
cells and is statistically significant (Figure 3.21) compared to parental treated cells.  As 
highlighted above, survival and proliferation in the acquired Ibr resistance cells at 3µM 
was slightly reduced, suggesting these cells were not entirely resistant to Ibr at this 
dose.   
 
 
 
 
 
 
 
 
 
 
 
123 
 
 
 
 
 
 
 
 
 
Figure 3.20: Immunoblot analysis of IRF4 expression in parent vs resistant REC-1 cells treated 
with BTKi. Parent (P) and resistant (R) REC-1 cells were treated with corresponding doses of Ibr 
or Acal (as indicated). Cells were lysed after 72 hours incubation and analysed for IRF4 
expression by western blotting. 10% SDS gel. 20.0µg protein. IRF4 (Cell Signalling technology 
#4964) 1 in 2000 dilution, GAPDH (Cell Signalling technology #2118) 1 in 5000 dilution in 5% 
BSA/TBST, o/n at 4°C.  Goat anti-rabbit-HRP (Dako, P0448) 1 in 2000 dilution (IRF4), 1 in 5000 
dilution (GAPDH) in 5% BSA/TBST, 1 hr, RT. ECL (GAPDH), ECL prime (IRF4) (Pierce, Life 
Technologies).   
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 Apoptosis (%) Proliferation (%) 
P control 12.34 89.28 
P + Ibr 1µM 19.22 37.84 
P + Ibr 3µM 28.44 44.58 
P+ Acal 1µM 16.68 47.56 
R (Ibr 1µM) + Ibr 1µM 6.78 83.53 
R (Ibr 3µM) + Ibr 3µM 16.21 79.82 
R (Acal 1µM) + Acal 1µM 8.84 85.15 
 
Table 3.4: Percentage of apoptosis and proliferation in parent vs resistant REC-1 cells treated 
with BTKi, corresponding to IRF4 expression (Figure 3.20). Parent (P) and resistant (R) REC-1 
cells were treated with corresponding doses of Ibr or Acal (as indicated). Cells were removed 
after 72 hours incubation and analysed for apoptosis (Annexin V-FITC) and proliferation (Ki67-
FITC) by flow cytometry. 
 
 
 
 
 
 
 
 
 
Figure 3.21: Paired t test comparing the percentage of apoptosis and the percentage of 
proliferation in parent vs resistant REC-1 cells treated with BTKi. 
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3.8.3 Assessment of BTK activity in REC-1 cells with acquired BTKi resistance  
As previously shown, Ibr reduces basal levels of BTK phosphorylation (pBTK-Y223) in all 
MCL cell lines including REC-1 (Table 3.2). However, in the acquired resistant Ibr and 
Acal REC-1 cells, no reduction in pBTK Y223 is seen, as demonstrated by the increased 
median fluorescence intensity ratios for pBTK Y223 compared with the parent REC-1 
control cells (Figure 3.22).  It is possible that the resistant cell lines have developed a 
BTK mutation causing ineffective binding of BTKi to the BTK catalytic site and therefore 
BTK phosphorylation is no longer reduced in response to BTKi. 
 
 
 
 
 
 
 
 
 
Figure 3.22: Median fluorescence intensity ratios (MFIR) for pBTK Y223 following BTKi 
treatment in parent REC-1 control cells vs resistant REC-1 cells. Parent (P) REC-1 control cells 
treated with DMSO and Resistant (R) REC-1 cells treated with corresponding doses of Ibr 
(1µM/3µM) or Acal (1µM) were removed after 72 hours incubation, and stimulated for 1 
minute with anti-IgM. Cells were fixed and permeablised, stained with anti-human pBTK Y223-
PE and analysed by flow cytometry. MFIR= pBTK Y223-PE/ IgG1-PE isotype control. Units are 
arbitrary. 
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3.9 Discussion 
Of the four MCL cell lines tested, the REC-1 cell line proved to be an excellent model to 
assess responses to the microenvironment, BCR stimulation and BTKi sensitivity. This 
was shown by the induction of apoptosis in response to Ibr and reduced proliferation 
in response to Ibr and Acal. The effects on proliferation and apoptosis in REC-1 cells 
were also achieved at Ibr doses between 1nM and 10nM, which is below the reported 
maximal achievable dose in vivo (400nM).116,145 The large proportion of REC-1 cells 
which remained viable after 72 hours Ibr treatment indicated that cell death is not the 
main mechanism of action in these cells.  
In addition to this cell line model of Ibr sensitivity, this study has also identified models 
of Ibr resistance. The G519 cell line was the most consistently resistant cell type 
showing no changes in proliferation or apoptosis from baseline over 72 hours even at 
the highest dose of drug. The JVM2 cells showed a considerable reduction of 
proliferation at 10µM together with increased cell death. The JEKO-1 cells showed no 
reduction in proliferation, but like JVM2, had a cell death response at the highest dose 
(10µM). It can be suggested that since these high concentrations greatly exceed the 
activity range of Ibr for BTK, the effect on cell death in particular, may represent off-
target activity in these cells, through non-specific binding to other kinases, particularly 
within the TEC family. Additionally, in REC-1 cells, despite Acal being more selective for 
BTK, the drug did not induce the same level of apoptosis compared with Ibr, and there 
was an absence of off-target effects in response to high doses of Acal providing further 
evidence that the apoptotic effect of Ibr is more likely a result of multiple kinase 
inhibition rather than a direct mechanism of BTKi action. The lack of apoptosis in 
response to Acal suggests that BTK inhibition may not directly induce cell death and 
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thus represents a secondary effect of BTKi. The identical reduction of REC-1 cell 
proliferation in response to both Ibr and Acal suggests that BTKi directly targets 
proliferation and therefore the Ki67 assay is a better measure to determine sensitivity. 
Excluding the results at the highest dose (10µM), the JVM2 and the JEKO-1 cells were 
characterised as Ibr resistant. This is contrary to other studies which have 
characterised JVM2 cells as sensitive to Ibr,190 although that study used a 5µM 
concentration which again, may cause off-target effects and is not therapeutically 
achievable in vivo. Like JVM2, the JEKO-1 cell line has been shown to be sensitive to 
Ibr114,145 and this was achieved at therapeutic doses. Since the JEKO-1 cells used for this 
study were frozen down at low passage (Passage 4), development of mutations 
through continued culturing is unlikely. We have noted that the JEKO-1 cells shown by 
others to be  sensitive to Ibr,114,145 were purchased from the American type culture 
collection whereas in this study the JEKO-1 cells were purchased from the German 
collection (DSMZ), indicating possible variation between the two JEKO-1 lines.  
In all cell lines there was evidence of basal BTK activation, represented by Y223 
phosphorylation that was universally inhibited by Ibr. This BTK activity was shown to 
induce ERK1/2 activation (pERK) which was reduced following Ibr treatment in all MCL 
cell lines, suggesting that ERK1/2 activation is dependent on BTK signalling. Activation 
of the BCR increased Y223-BTK and ERK1/2 phosphorylation in both sensitive and 
resistant cells, but although levels of pY223-BTK were reduced upon Ibr treatment, the 
levels of pERK were only partially reduced. This is consistent with other studies 190 and 
suggests that this subsequent activation of ERK1/2 depends only partly on BTK signals 
and suggests an additional route for ERK1/2 activation following BCR stimulation, 
possibly through activation of MAPK and PI3K pathways. 
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Expression of IRF4 (present in all cell lines), was completely inhibited following Ibr 
treatment in the REC-1 cells, but not in the resistant cell lines. This change in IRF4 
expression was shown to be an early and specific indicator of biological (proliferation 
and apoptosis) responses to Ibr. This IRF4 down-regulation occurred even in the 
presence of BCR stimulation in Ibr-sensitive cells (REC-1). Results from these 
experiments suggest that IRF4 has potential use as a biomarker in monitoring BTKi 
treatment in MCL by identifying patients who may or may not respond to BTKi and also 
those who are acquiring resistance to these agents. 
To understand the resistance to BTKi agents observed clinically, an in vitro model of 
acquired Ibr resistance was created in the REC-1 cell line. Long-term Ibr treatment 
(1μM) led to the establishment of a REC-1 cell line with acquired resistance (REC-1/R 
(Ibr 1µM)), while the passage-matched parent REC-1 cells used as the vehicle control 
line (REC-1/P) remained sensitive to Ibr as assessed by cell proliferation. 
In the presence of both Ibr and Acal, BTK activation was maintained in the REC-1 
resistant cell lines, which correlates with the continued proliferation of the cells.  
Although sequencing for BTK mutations was not carried out in this study, it is possible 
that the resistant cell lines had developed a BTK mutation causing ineffective binding 
of each inhibitor to the BTK C481 residue and therefore BTK phosphorylation is no 
longer reduced in response to Ibr. This would explain the expression of IRF4 in the REC-
1/R (Ibr 1µM) cells which was not downregulated with Ibr and matches IRF4 expression 
seen in the untreated parent REC-1 cells.  
This is different from the innate resistant cells (G519, JEKO-1 and JVM2), here, IRF4 is 
not downregulated by BTKi, although the BTK pY223 response was reduced. This 
suggests the drug was still able to bind to BTK preventing phosphorylation at Y223, 
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suggesting other downstream mechanisms are involved in primary resistance (tissue 
microenvironment).  
These results demonstrate that IRF4 is downregulated in sensitive MCL cell lines but 
not downregulated in the same cells with acquired BTKi resistance or in innate 
resistant cell lines. These findings suggest that IRF4 is a potential biomarker of 
treatment response to BTKi. To validate these findings, IRF4 protein levels were 
assessed in ex vivo primary MCL cells taken from MCL patients currently on clinical 
treatment with BTK inhibitors (discussed in CHAPTER 4) and in models representing the 
tissue microenvironment. 
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4 Chapter 4- Assessing the response of MCL cells to BTK 
inhibitors within the microenvironment  
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4.1 Introduction 
Within the bone marrow and lymph nodes, mature B-lymphocytes receive essential 
signals for growth and survival by interacting with specific accessory cells. There is 
evidence that these signals are essential for the survival of MCL cells in vitro.53,65,117,191 
BTKi are thought to have a role in disrupting the interactions which retain the cells in 
their protective tissue niches; however, processes such as the engagement of CD40L or 
BCR within the tissues may induce the activation of cellular processes including NFkB, 
MAPK and PI3K pathways which may be involved in forming resistance pathways, and 
may allow the malignant cells to bypass the effects of BTK inhibition. It was 
hypothesised that development of an in vitro system which reproduces the in vivo 
tissue microenvironment could be used to explore BTKi resistance pathways in MCL. 
This chapter describes the assessment of cell lines and primary MCL cells when co-
cultured on a stromal monolayer of murine fibroblasts, focussing on changes to BTKi 
induced apoptosis, proliferation, and protein expression of pERK1/2 and IRF4 in 
response to Ibr and Acal. The aim was to determine whether factors from the tissue 
microenvironment protect MCL cells from the effects of BTK inhibition in vitro. 
Subsequently, paired clinical samples taken before commencement and during BTKi 
therapy were assessed to confirm the relevance of the cell line findings concerning 
expression levels of IRF4, and to determine whether IRF4 could be used to predict 
response to BTKi treatment. 
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4.2 Methods employed  
The methods employed in this section involve the culture of sensitive and resistant 
REC-1 cells (Methods section 2.2.4 and 2.2.10), the isolation of ex vivo primary MCL 
cells (Methods section 2.2.2), and their co-culture onto two separate monolayers of 
murine fibroblast cell lines, one expressing CD40L (T-CD40L), and the other not 
expressing CD40L (NT-CD40L) (Methods section 2.2.6).   
The fibroblast cells were characterised for expression of CD40L (CD154) by 
immunofluorescence and flow cytometry (Methods section 2.2.5). Cells were assessed 
by flow cytometry for apoptosis (annexin V-FITC), and / or proliferation (Ki67-FITC) 
with and without fibroblast support and in response to varying concentrations of Ibr or 
Acal (Methods section 2.2.9 and 2.3). Primary MCL cells were distinguished by their 
forward and side-scatter characteristics and by their co-expression of CD5 and CD19. 
Assessment of signalling proteins following BTKi treatment (in vitro and clinical) were 
determined  through biochemical assays (Methods section 2.4) of 1D-SDS PAGE 
(Methods section 2.4.3), western blotting (Methods section 2.4.6) and 
immunohybridisation (Methods section 2.4.6.1) on cell lysates  or by flow cytometry 
following IgM stimulation (Methods section 2.3.2 and 2.2.8).  
A table of antibodies/probes used in this chapter is shown below (Table 4.1).  
All data (flow cytometry and western blotting) were analysed using Microsoft Excel™ 
and GraphPad Prism™ Version 5 software. The statistical tests employed are described 
in the figure legend of each experiment. 
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Antibody/probe Species  Application Ref Source Conc 
Annexin-V-FITC  FC 556419 BD 5µl/test 
Ki67 (IgG1k) -FITC Mouse anti human FC 556026 BD 10µl/test 
BTK pY223 (IgG1k) -PE Mouse anti human FC 562753 BD 5µl/test 
CD19 (IgG1k) -FITC Mouse anti human FC 555412 BD 10µl/test 
CD19 (IgG1k) -APC Mouse anti human FC 555415 BD 10µl/test 
CD5 (IgG1k) -PE Mouse anti human FC 555353 BD 10µl/test 
CD5 (IgG1k) -APC Mouse anti human FC 555355 BD 10µl/test 
CD154 (IgG1k) -PE Mouse anti human FC 555697 BD 20µl/test 
IgG1k isotype-FITC  Mouse anti human FC 556026 BD 10µl/test 
IgG1k isotype-PE Mouse anti human FC 559320 BD 10µl/test 
IgG1k isotype-APC Mouse anti human FC 555751 BD 10µl/test 
IRF4 primary antibody Rabbit anti human WB #4964 CST 1/1000 
pERK1/2 primary antibody Rabbit anti human WB #9101 CST 1/2000 
ERK1/2  primary antibody Rabbit anti human WB #9102 CST 1/2000 
GAPDH  primary antibody Rabbit anti human WB #2118 CST 1/5000 
Secondary antibody-HRP Goat anti rabbit WB #P0448 Dako 1/2000 
 
Table 4.1: Antibodies and stains used in Chapter 4. For flow cytometry the list includes 
antibodies with corresponding isotype controls used for assessment of apoptosis, proliferation 
and BTK phosphorylation and for labelling primary MCL cells. For western blotting the list 
includes antibodies used for immunohybridisation in cell lines and primary MCL cells. FITC - 
fluorescein isothiocyanate; PE - phycoerythrin; APC –allophycocyanin. FC- Flow cytometry, WB- 
western blotting, BD- BD Biosciences, CST- Cell signalling technology. 
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4.3 REC-1 cells show a dependence on CD40L following treatment with 
BTKi. This dependence is lost when cells acquire resistance to BTKi. 
REC-1 cells cultured in vitro demonstrated protected survival and proliferation from 
CD40L-stromal support following treatment with BTKi. In addition, stimulation with 
CD40L altered signalling, preventing down-regulation of pERK and IRF4 in response 
to BTKi treatment. These responses were also seen in the resistant REC-1 cells but 
were independent of stromal support. 
4.3.1 Assessment of apoptosis and proliferation within a CD40L co-culture 
system in response to BTKi. 
REC-1 cells were seeded into wells in culture media alone or in co-culture with 
fibroblast cells, either NT-CD40L or T-CD40L. Cells were treated with Ibr at a range of 
doses (as indicated) and assessed for rates of apoptosis and proliferation after 48 
hours as previously described.  
REC-1 cells co-cultured with the NT-CD40L cells demonstrated the same Ibr-induced 
proliferation effect and cell death response as the REC-1 cells cultured alone 
suggesting that stromal cell support in the absence of CD40L does not affect the 
response to BTK inhibition. In contrast (and rather surprisingly a for a cell line), stromal 
cell support with the T-CD40L cells prevented the reduction in proliferation and 
attenuated cell death (Figure 4.1), indicating that REC-1 cells were protected from the 
effects of BTK inhibition by stroma induced CD40-CD40L interactions. This was also 
shown in response to a dose range of Ibr treatment (10nM-10µM) (Figure 4.2).  
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Non-linear regression analysis (Figure 4.2) indicated that the rate of death for REC-1 
cells following Ibr treatment was approximately 3-fold greater across the dose range 
when cells were cultured in media alone compared with those cultured with CD40L. 
 
 
 
 
 
 
 
 
 
Figure 4.1: Survival and proliferation of REC-1 cells treated with Ibr in response to stromal 
cell stimulation (+/- CD40L). Murine fibroblast cells (NT-CD40L and T-CD40L) were seeded at 5 
x 105/mL, irradiated and incubated o/n. REC-1 cells were seeded at 5 x 106/mL on to the 
fibroblast monolayers, and treated with Ibr (FC: 100nM and 10µM). Approximately 1 x 106 cells 
were removed at 48 hours and analysed using flow cytometry. For the apoptosis assay, cells 
were stained with annexin V-FITC. For the proliferation assay, cells were fixed, permeablised 
and stained with Ki67-FITC and IgG1-FITC. A) Assessment of apoptosis (%) before and after Ibr 
treatment, B) Assessment of proliferation (%) before and after Ibr treatment. 
  
 
 
 
 
 
 
 
 
A) B) 
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Figure 4.2: Survival of REC-1 cells treated with Ibr in the presence of stromal cell stimulation 
(T-CD40L). Murine fibroblast cells (T-CD40L) were seeded at 5 x 105/mL, and incubated o/n. 
REC-1 cells were seeded at 5 x 106/mL on to the fibroblast monolayer, then treated with Ibr 
(FC: 10nM, 100nM, 1µM and 10µM). Cells were taken after 48 hours, stained with annexin V-
FITC and analysed by flow cytometry (N=1). Left: Ibr induced apoptosis (%) at each 
concentration; Right: Graph of the correlation between apoptosis and Ibr concentration 
analysed by non-linear regression. The curves of best fit: T-CD40L R2=0.9845, media alone R2= 
0.9780. The equation of the curves of best fit: T-CD40L y= 1.24x, Media alone y= 3.2x 
representing an approximate increase in death of 3-fold in the absence of CD40L. 
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4.3.2 Assessment of ERK1/2 phosphorylation and IRF4 expression in response 
to BTKi within a co-culture system.  
To determine the effects of BTKi treatment on ERK1/2 phosphorylation in the presence 
or absence of CD40L stimulation, REC-1 cells were seeded onto a fibroblast monolayer 
expressing CD40L (T-CD40L) and compared with REC-1 cells cultured in media alone. 
REC-1 cells under both conditions were treated with Ibr at a range of doses (10nM, 
100nM, 1µM, 10µM) and incubated for up to 48 hours. Protein was extracted after 24 
hours and 48 hours treatment (Methods section 2.4.1). 
The presence of CD40L did not significantly effect baseline expression of pERK. 
However, CD40L did oppose the down-regulation of pERK induced by Ibr treatment in 
cells cultured in media alone (Figure 4.3). 
 
 
 
 
 
 
Figure 4.3: Immunoblot analysis of pERK and ERK1/2 in REC-1 cells (cultured in media alone 
and with T-CD40L fibroblasts) pre, and 24 hours post Ibr treatment. Fibroblast cells (T-CD40L) 
were seeded at 5 x 105/mL and incubated o/n. REC-1 cells were seeded at 2 x 106 /mL, on to 
the fibroblast monolayer and treated with a DMSO vehicle, followed by increasing 
concentrations of Ibr (10nM, 100nM, 1µM, 10µM). Protein was extracted after 24 hours 
incubation. 10% SDS gel. 20.0µg protein. pERK (Cell Signalling technology #9101) 1 in 2000 
dilution, ERK1/2 (Cell signalling technology #9102) 1 in 2000 dilution, GAPDH (Cell Signalling 
technology #2118) 1 in 5000 dilution in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-HRP (Dako, 
P0448) 1 in 2000 dilution (pERK, ERK1/2), 1 in 5000 dilution (GAPDH), in 5% BSA/TBST, 1 hr, RT. 
ECL (Pierce). 
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The assessment of IRF4 expression of REC-1 cells showed that in the presence of 
stromal cells that expressed CD40L the baseline expression of IRF4 was increased; and 
(compared to cells cultured in media alone) these conditions opposed the IRF4 
downregulation seen with Ibr over a range of doses at 24 hours and 48 hours (Figure 
4.4). These data suggest that signalling following BTKi treatment is modulated in cells 
cultured on a CD40L-stromal layer preventing down regulation of IRF4 expression. 
 
 
 
 
 
 
 
 
Figure 4.4: Immunoblot analysis of IRF4 in REC-1 cells (cultured in media alone and with T-
CD40L fibroblasts) pre, and 24-48 hours post Ibr treatment. Murine fibroblast cells (T-CD40L) 
were seeded at 5 x 105/mL and incubated o/n. REC-1 cells were seeded at 2 x 106 /mL, on to 
the fibroblast monolayer and treated with a DMSO vehicle, followed by increasing 
concentrations of Ibr (10nM, 100nM, 1µM, 10µM). Protein was extracted after 24 and 48 
hours incubation.  Upper panel IRF4 expression after 24 hours; Lower panel IRF4 expression 
after 48 hours. 10% SDS gel. 20.0µg protein. IRF4 (Cell Signalling technology #4964) 1 in 2000 
dilution, GAPDH (Cell Signalling technology #2118) 1 in 5000 dilution in 5% BSA/TBST, o/n at 
4°C.  Goat anti-rabbit-HRP (Dako, P0448) 1 in 2000 dilution (IRF4), 1 in 5000 dilution (GAPDH) 
in 5% BSA/TBST, 1 hr, RT. ECL (GAPDH), ECL prime (IRF4) (Pierce, Life Technologies). 
 
 
 
  
 
 
Media alone              T-CD40L 
 
24 hours 
48 hours 
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To confirm CD40L was responsible for these IRF4 results as opposed to stromal cell 
interactions alone, REC-1 cells were seeded onto both fibroblast monolayers, T-CD40L 
and NT-CD40L. In addition, the response to both Ibr and the more specific BTKi Acal 
was assessed. Protein was extracted after 48 hours as described previously and 
assessed for IRF4 expression. 
As shown in Figure 4.5, IRF4 was downregulated by both Ibr and Acal when cultured 
with the NT-CD40L stromal cells correlating  with the reduced survival and 
proliferation data of  REC-1 cells cultured  in the absence of CD40L (Figure 4.1). 
However in REC-1 cells cultured with T-CD40L stromal cells, as demonstrated above, 
IRF4 expression was upregulated in the control cells with no/ or limited  
downregulation of IRF4 seen with Ibr and Acal treatment respectively and correlates 
with the previously shown data of enhanced survival and proliferation in the presence 
of CD40L (Figure 4.1).   
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Figure 4.5: IRF4 expression in REC-1 cells co-cultured with stromal cells NT-CD40L and T-
CD40L following 48 hours treatment with BTKi. REC-1 cells were seeded at 5 x 106/mL in 
culture media alone and onto two fibroblast monolayers NT-CD40L and T-CD40L. Cells were 
treated with a DMSO vehicle control, Ibr (100nM) and Acal (1µM). Protein was extracted after 
48 hours incubation. A) Immunoblot analysis of IRF4 expression B) Densitometry analysis of 
IRF4 levels relative to GAPDH (units are arbitrary). 10% SDS gel. 25.0µg protein, IRF4 (Cell 
Signalling technology #4964) 1 in 2000 dilution, GAPDH (Cell Signalling technology #2118) 1 in 
5000 dilution in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-HRP (Dako, P0448) 1 in 2000 
dilution (IRF4), 1 in 5000 dilution (GAPDH) in 5% BSA/TBST, 1 hr, RT. ECL (GAPDH), ECL prime 
(IRF4) (Pierce, Life Technologies). 
 
 
 
 
 
 
 
A) 
B) 
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4.3.3 Functional and biochemical response of acquired BTKi resistant REC-1 
cells when cultured on a CD40L co-culture system. 
As determined in chapter 3, acquired BTKi resistant REC-1 cells show no reduction in 
survival, proliferation or levels of IRF4 expression in the presence of BTK inhibitors. To 
determine whether stromal interaction would modulate this response, the acquired 
BTKi resistant REC-1 cells were co-cultured on NT-CD40L and T-CD40L fibroblast 
monolayers and treated with Ibr at a range of doses (as indicated) and assessed for 
changes in apoptosis, proliferation and IRF4 expression. 
The below results show that survival and proliferation were not affected when the 
acquired BTKi resistant REC-1 cells were cultured on either of the NT-CD40L or T-CD40L 
fibroblast monolayers (Figure 4.6) and IRF4 expression was not downregulated (Figure 
4.7). 
 
 
 
 
 
 
 
Figure 4.6: Survival and proliferation of acquired Ibr resistant REC-1 cells co-cultured with 
NT-CD40L and T-CD40L stromal cells following treatment with Ibr. Resistant REC-1 cells were 
seeded at 5 x 106/mL onto two fibroblast monolayers; NT-CD40L and T-CD40L and treated with 
Ibr (FC: 100nM and 1µM). Cells were harvested from the monolayers after 48 hours incubation 
for analysis of survival and proliferation by flow cytometry. A) Assessment of apoptosis (%), B) 
Assessment of proliferation (%). 
 
 
A) B) 
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Figure 4.7: Immunoblot analysis of IRF4 expression in acquired resistant REC-1 cells co-
cultured with NT-CD40L and T-CD40L stromal cells following treatment with Ibr. Resistant 
REC-1 cells were seeded at 5 x 106/mL onto two fibroblast monolayers; NT-CD40L and T-CD40L 
and treated with a DMSO vehicle control or Ibr (100nM or 1µM). Protein was extracted after 
48 hours incubation for analysis of IRF4 expression. 10% SDS gel. 25.0µg protein, IRF4 (Cell 
Signalling technology #4964) 1 in 2000 dilution, GAPDH (Cell Signalling technology #2118) 1 in 
5000 dilution in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-HRP (Dako, P0448) 1 in 2000 
dilution (IRF4), 1 in 5000 dilution (GAPDH) in 5% BSA/TBST, 1 hr, RT. ECL (GAPDH), ECL prime 
(IRF4) (Pierce, Life Technologies). 
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4.4 Primary MCL cells cultured ex vivo demonstrate a functioning BCR 
and when co-cultured with CD40L, and behave similarly to REC-1 
cells following BTKi treatment. 
Primary MCL cells cultured ex vivo demonstrate a functional BCR with inhibition of 
phosphorylated BTK (Y223) following BTKi treatment. Primary MCL cells are 
heterogeneous, but generally behave similarly to REC-1 cells when co-cultured with 
stromal support and in response to BTKi. Co culture with CD40L induced survival, 
prevented BTKi-induced IRF4 downregulation and protected the primary cells from 
BTKi-induced death. 
4.4.1 Assessment of BCR signalling in response to BTKi treatment 
In all MCL cell lines (REC-1, G519, JEKO-1 and JVM2), Y223 BTK phosphorylation was 
reduced 1 hour following Ibr treatment. To determine whether the data was 
comparable in primary MCL cells, pre-treatment primary cells taken from four 
individual MCL patients were treated in vitro with Ibr or Acal (100nM), and incubated 
for 1 hour (MCL01, MCL02, MCL04) or 90 minutes (MCL03). Levels of BTK 
phosphorylation were assessed in both unstimulated and in anti-IgM stimulated cells 
(Methods section 2.3.2 and 2.2.8). 
As was seen in the MCL cell lines, phosphorylation of BTK-Y223 in primary cells was 
much greater following anti-IgM stimulation for 1 minute than at baseline (Figure 4.8). 
In BCR activated primary cells, phosphorylation of BTK-Y223 was significantly reduced 
by 100nM concentrations of Ibr (p=0.0047) after 1 hour, but not significantly by Acal 
(p=0.06) at this time point (Figure 4.9). Further reductions may have been seen after a 
longer incubation with BTKi but this could not be achieved in primary MCL cells 
unsupported in culture due to the rapid rates of apoptosis. 
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Figure 4.8: Increase in BTK-Y223 phosphorylation in patient samples after anti-IgM 
stimulation for 1 minute. Median Fluorescence Intensity ratios of BTK-Y223 phosphorylation in 
unstimulated cells vs anti-IgM stimulated primary cells (Units are arbitrary). 
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Figure 4.9: Reduction of pBTK-Y223 in patient samples after in vitro Ibr and Acal treatment 
(100nM) for 1 hour. The tables show the Median Fluorescence Intensity ratios of BTK-Y223 
phosphorylation in 4 primary MCL cell cases. Cells were stimulated with anti-IgM and treated 
in vitro with Ibr (upper panel) and Acal (lower panel) (100nM). * MCL03 cells were treated for 
1.5 hours. Data were analysed using a student’s paired t-test. 
 
 
 
 
 
 
 
Case  Untreated  Ibr 
(100nM) 
MCL01 6.585928 5.15917 
MCL02 15.18704 12.54907 
MCL03 11.47 8.86 
MCL04 9.3681592 6.6355721 
Case  Untreated  Acal 
(100nM) 
MCL01 6.585928 5.716263 
MCL02 15.18704 12.71481 
MCL03 11.47 11.07 
MCL04 9.3681592 7.9415423 
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4.4.2 Assessment of CD40L co-cultures on the survival of BTKi-treated MCL 
cells  
Due to the poor proliferative response of primary MCL cultured ex vivo,  even with 
CD40L stimulation (data from studies performed by Dr D Tucker as part of a completed 
MD from this group), the effects of BTKi  treatment on the proliferation of primary 
MCL cells was not assessed. However, those studies did demonstrate that CD40L 
protected primary MCL cells from apoptosis. Therefore we assessed whether CD40L 
also protected cells from BTKi- induced apoptosis.  Initially we assessed the effects of 
stromal cell support on primary MCL cell survival before BTK inhibition. Ex vivo primary 
cells from five MCL cases were seeded into wells in culture media alone or with murine 
fibroblast cells, either NT-CD40L or T-CD40L. The primary cells were removed for 
assessment of apoptosis after 24 and / or 48 hours.   
Although the response was variable (Table 4.2), most MCL cases showed enhanced 
survival in the presence of CD40L. This is very clearly demonstrated in the cases 
analysed at 24 hours (p=0.0201  paired t-test) although less clear in those cases 
analysed at 48 hours (Figure 4.10) largely as a result of the low apoptotic rates of cases 
MCL03 and MCL09 which are clinically indolent cases (the disease characteristics for 
these samples are shown in Table 4.3). 
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Table 4.2: Survival of primary MCL cells after 24 and 48 hours co-culture on a stromal layer. 
Primary MCL cells were seeded at 4 x 106/mL onto two fibroblast monolayers; NT-CD40L and T-
CD40L. Cells were harvested from the fibroblast layer after 24 and 48 hours incubation, 
labelled with MCL surface markers and annexin V-FITC for 20 minutes at RT and assessed for 
apoptosis by flow cytometry. The table shows the percentage of apoptotic cells from 4 cases of 
primary MCL after 24 hours and from 5 cases of primary MCL after 48 hours of co-culture. 
 
 
 
 
 
 
 
 
 
 
 
  % Apoptosis 
NT-CD40L 
% Apoptosis 
T-CD40L 
 
MCL03 
 
24 hours 10.3 7.5 
48 hours 0.7 1.0 
    
MCL05 
 
24 hours 10.7 3.8 
48 hours 14 2 
    
MCL06 
 
24 hours 20.37 12.53 
    
MCL07 
 
24 hours 14.4 10.4 
48 hours 10.0 2.5 
    
MCL08 
 
48 hours 8.5 4.5 
    
MCL09 
 
48 hours 1.5 2.6 
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Figure 4.10: Survival of primary MCL cells after 24 and 48 hours co-culture on a stromal layer 
with and without CD40L. Paired t test comparing rates of apoptosis for 4-5 cases of primary 
MCL cells cultured with NT-CD40L and T-CD40L murine fibroblasts. A) Cases assessed at 24 
hours B) Cases assessed at 48 hours. Some cases analysed at 48 hours were different to the 
cases analysed at 24 hours. 
 
Case Indolent/ aggressive 
subtype of MCL disease 
MCL01 Aggressive 
MCL03 Indolent 
MCL06 Aggressive 
MCL07 Aggressive 
MCL08 Aggressive 
MCL09 Indolent 
 
Table 4.3: Disease characteristics of MCL cases whose cells were analysed for survival in 
section 4.4.2. 
 
 
 
 
 
 
A) B) 
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To determine whether the survival of primary MCL cells was reduced in response to 
BTKi, the cells co-cultured on NT-CD40L and T-CD40L fibroblasts were treated in vitro 
with Ibr or Acal at the doses indicated and analysed for apoptosis by flow cytometry. 
Again results are heterogeneous with overall low levels of apoptosis seen in all cases. 
However for cells co-cultured for 24 hours with CD40L, apoptosis was significantly 
reduced in response to BTKi (p=0.0004) (Table 4.4, Figure 4.11), suggesting that CD40L 
protects primary cells from apoptosis even in the presence BTK inhibition. This finding 
is similar to the results previously shown for REC-1 cells. As before, results are less 
clear at 48 hours mainly as a result of the outlaying MCL08 case in response to Acal 
(Table 4.5, Figure 4.11). 
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  Apoptosis (%) 
Case  NT-CD40L T-CD40L 
MCL03 Control 10.27 7.46 
 Ibr (100nM) 10.28 5.65 
 Acal (1µM) 13.72 6.46 
MCL05 Control 20.37 12.53 
 Ibr (100nM) 22.27 13.48 
 Acal (1µM) 20.09 15.69 
MCL 06 Control 10.70 3.82 
 Ibr (100nM) 15.28 4.22 
 Acal (1µM) 14.30 4.07 
MCL 07 Control 14.39 10.35 
 Ibr (100nM) 15.58 12.80 
 Acal (1µM) 16.56 11.68 
 
Table 4.4: Survival of primary MCL cells in response to BTKi after 24 hours co-culture on NT-
CD40L and T-CD40L fibroblasts. Primary MCL cells were co-cultured on a monolayer of NT-
CD40L and T-CD40L fibroblasts and treated with Ibr (100nM) or Acal (1µM). Approximately 1 x 
106 cells were removed after 24 hours and stained with annexin-V-FITC for analysis of 
apoptosis by flow cytometry.  
 
  Apoptosis (%) 
Case  NT-CD40L T-CD40L 
MCL03 Control 0.72 0.97 
 Ibr (100nM) 0.86 1.00 
 Acal (1µM) 0.79 0.97 
MCL06 Control 10.70 3.82 
 Ibr (100nM) 15.28 4.22 
 Acal (1µM) 14.30 4.07 
MCL07 Control 10.00 2.50 
 Ibr (100nM) 8.90 2.20 
 Acal (1µM) 6.30 1.40 
MCL08 Control 8.51 4.51 
 Ibr (100nM) 5.10 5.77 
 Acal (1µM) 7.44 13.43 
MCL09 Control 1.46 2.60 
 Ibr (100nM) 1.65 5.24 
 Acal (1µM) 1.45 4.21 
 
Table 4.5: Survival of primary MCL cells in response to BTKi after 48 hours co-culture on NT-
CD40L and T-CD40L fibroblasts. Primary MCL cells were co-cultured on a monolayer of NT-
CD40L and T-CD40L fibroblasts and treated with Ibr (100nM) or Acal (1µM). Approximately 1 x 
106 cells were removed after 48 hours and stained with annexin-V-FITC for analysis of 
apoptosis by flow cytometry.  
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Figure 4.11: Survival of primary MCL cells co-cultured with stromal cells with and without 
CD40L in response to in vitro BTKi treatment. Paired t-test comparing the rates of apoptosis in 
response to Ibr (100nM) and Acal (1µM) (treatment groups combined), in primary MCL cells 
co-cultured with NT-CD40L and T-CD40L murine fibroblasts. A) 24 hours, B) 48 hours. Some 
cases analysed at 48 hours were different to the cases analysed at 24 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) B) 
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4.4.3 Analysis of IRF4 expression in BTKi-treated primary MCL cells in 
response to CD40L co-culture 
In the BTKi sensitive REC-1 cell line, IRF4 expression was upregulated by CD40L and 
IRF4 levels were sustained in response to BTKi (both Ibr and Acal). To determine 
whether these findings were also features in primary MCL cells, ex vivo primary MCL 
cells from 8 untreated patients were co-cultured with murine fibroblasts; NT-CD40L 
and T-CD40L, and treated in vitro with BTKi (Ibr or Acal). The cells were removed from 
the fibroblasts after 48 hours incubation with BTKi and lysed to obtain protein for 
analysis of IRF4 expression.      
Results from those experiments are shown in Figure 4.12. A representative 
immunoblot is shown in Figure 4.12A.   In the absence of treatment, IRF4 expression 
was significantly upregulated by CD40L in all eight MCL patient samples (paired t-test 
p= 0.0012) (Figure 4.12B).  IRF4 expression was significantly down regulated by Ibr 
(p=0.0393) and almost significantly by Acal (p=0.0590) in all primary MCL cases co-
cultured without CD40L (Figure 4.12C). However, stromal co-culture with CD40L 
prevented BTKi-induced downregulation of IRF4 in all 8 primary MCL cases (Ibr 
p=0.3398, Acal p=0.3802) (Figure 4.12D). 
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Figure 4.12: Assessment of IRF4 expression in BTKi-treated primary MCL cells in response to 
CD40L co-culture. A) Representative immunoblot analysis of IRF4 expression (Case MCL07) co-
cultured with/without CD40L and treated in vitro with BTKi for 48h. B) CD40L upregulates IRF4 
expression in 8/8 patient samples (Paired t-test p= 0.0012). C) IRF4 is significantly down 
regulated by Ibr and almost significantly downregulated by Acal in 8 patient samples co-
cultured without CD40L (paired t-test). D) CD40L stimulation prevents downregulation of IRF4 
by BTK inhibitors (Paired t-test; Ibr p=0.3398, Acal p=0.3802). Blot details: 10% SDS gel. 30.0µg 
protein. Rabbit anti-human IRF4 (CST #4964) 1 in 1000 dilution, rabbit anti-human GAPDH (CST 
#2118) 1 in 5000 dilution, in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-HRP (Dako, P0448) 1 in 
2000 dilution in 5% BSA/TBST, 1 hr, RT. ECL (GAPDH), ECL prime (IRF4) (Pierce, Life 
Technologies). 
 
 
 
 
 
C) D) 
B) 
MCL07 
A) 
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4.5 IRF4 expression can predict response to BTKi treatment. 
In primary MCL patient samples, downregulation of IRF4 was associated with clinical 
response to BTKi therapy.  In these patients, downregulation of IRF4 expression was 
an early response to BTKi therapy and sustained over time.  Results suggest that 
sustained or loss of IRF4 downregulation in response to BTKi treatment can signify 
primary or acquired resistance. 
Results from cell line and ex vivo BTKi-treated primary MCL cells have shown that IRF4 
expression is downregulated in cells sensitive to BTKi treatment, but that IRF4 
expression can be affected by either primary resistance seen in BTK resistant MCL cell 
lines, or by factors within the microenvironment such as stimulation by CD40L. 
However data from in vivo BTKi-treated patient samples would provide further 
rationale of the use of IRF4 as a predictor of response to BTKi treatment. 
4.5.1 Assessment of IRF4 expression in MCL patient samples following BTKi 
treatment 
Blood samples from 8 patients on monotherapy with BTK inhibitor agents Ibr and Acal 
were collected over the course of the PhD and were compared with pre-treatment 
samples.  Samples were taken from patients responding to BTKi therapy, and from one 
patient who was treatment refractory and not responding to BTKi therapy. The specific 
BTK inhibitor monotherapy given to patients and their response to therapy is shown in 
Table 4.6. Following isolation of the PBMCs (Methods section 2.2.2), the primary MCL 
cells were lysed in a RIPA buffer (Methods section 2.4.1) to obtain protein for analysis 
of IRF4 expression. 
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Case BTKi Treatment Status 
MCL01 Acalabrutinib Responding  
MCL02 Acalabrutinib Responding 
MCL04 Acalabrutinib Refractory 
MCL10 Ibrutinib Responding 
MCL11 Acalabrutinib Responding 
MCL12 Acalabrutinib Responding 
MCL13 Ibrutinib Responding 
MCL14 Ibrutinib Responding 
 
Table 4.6: The specific BTK inhibitor monotherapy used in the clinical treatment of 8 primary 
MCL cases examined for IRF4 expression levels and their response to treatment. 
 
The results are shown in Figure 4.13. IRF4 expression was downregulated in 7 out of 8 
MCL patient samples tested. These samples were taken from patients clinically 
responding to BTKi treatment. Statistical analysis of those 7 samples (three patients on 
Ibr treatment and four patients on Acal treatment) show significant IRF4 down-
regulation (paired t-test; p=0.0009).  Sample MCL04 shows sustained levels of IRF4 
expression and was clinically refractory to BTKi treatment.  
 
 
 
 
 
 
 
156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: IRF4 expression levels in patient samples on clinical therapy with BTKi. A) IRF4 
expression in 8 patient samples on BTKi treatment compared to their matched pre-treatment 
sample, in all but one case there is a clear downregulation of IRF4. B) In the 7 cases which are 
responding to clinical BTKi treatment, IRF4 is significantly downregulated. Data was statistically 
analysed using paired t-test (p=0.0009).  Blot details: 10% SDS gel. 30.0µg protein. Rabbit anti-
human IRF4 (CST #4964) 1 in 1000 dilution, rabbit anti-human GAPDH (CST #2118) 1 in 5000 
dilution, in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-HRP (Dako, P0448) 1 in 2000 dilution in 
5% BSA/TBST, 1 hr, RT. ECL (GAPDH), ECL prime (IRF4) (Pierce, Life Technologies). 
 
 
 
A) 
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We next assessed the expression of IRF4 during time on BTKi-treatment to determine 
how quickly downregulation of IRF4 expression occurred. IRF4 expression was 
assessed in two clinically responding cases over several treatment cycles with Acal.  
The cycle- associated white cell count (WCC)/ lymphocyte count is shown in Table 4.7.  
Immunoblot analysis shows that downregulation of IRF4 expression occurs within the 
first treatment cycle and was sustained over time, (Figure 4.14 and 4.15), not 
surprisingly response was variable between and within patient samples but expression 
levels were independent of the reported WCC.   
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Figure 4.14: IRF4 expression over several Acal treatment cycles in a patient responding to 
therapy. A) Immunoblot analysis of IRF4 expression B) Densitometry analysis of IRF4 
expression relative to GAPDH expressed in arbitrary units. C= cycle, D = day. Blot details: 10% 
SDS gel. 30.0µg protein. Rabbit anti-human IRF4 (CST #4964) 1 in 1000 dilution, rabbit anti-
human GAPDH (CST #2118) 1 in 5000 dilution, in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-
HRP (Dako, P0448) 1 in 2000 dilution in 5% BSA/TBST, 1 hr, RT. ECL (GAPDH), ECL prime (IRF4) 
(Pierce, Life Technologies). 
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Figure 4.15: IRF4 expression over several Acal treatment cycles in a patient responding to 
therapy. A) Immunoblot analysis of IRF4 expression B) Densitometry analysis of IRF4 
expression relative to GAPDH expressed in arbitrary units. C= cycle, D = day. Blot details: 10% 
SDS gel. 30.0µg protein. Rabbit anti-human IRF4 (CST #4964) 1 in 1000 dilution, rabbit anti-
human GAPDH (CST #2118) 1 in 5000 dilution, in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-
HRP (Dako, P0448) 1 in 2000 dilution in 5% BSA/TBST, 1 hr, RT. ECL (GAPDH), ECL prime (IRF4) 
(Pierce, Life Technologies). 
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Case  Acal treatment cycle WCC (x109/L)  
MCL02 Pre 36  
 C1D8 345  
 C1D21 339  
 C1D28 258  
 C2D15 155  
 C2D28 118  
 C3D28 73.9  
 C4D28 43.8  
 C5D28 34  
 C8D28 15  
 C10D28 12.9 lymphocytes: 9.4 
 
Case  Acal Treatment cycle WCC (x109/L)  
MCL01 C1D1 89  
 C1D8 335  
 C1D15 196  
 C1D22 122  
 C2D8 32  
 C4D1 9.2 lymphocytes: 5.5  
 
Table 4.7: White blood cell counts obtained from two patients corresponding to individual 
Acal treatment cycles. Lymphocyte counts were obtained for the two samples demonstrating 
low WCC. 
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4.6 IRF4 expression can be used to monitor for BTKi-treatment 
resistance in primary MCL cases. 
All primary MCL cases whether sensitive or resistant to BTKi demonstrated a normal 
functional BCR with inhibition of phosphorylated BTK Y223 in treated samples, but 
showed differential expression of IRF4. Loss of clinical response to BTKi treatment 
corresponded to increasing IRF4 expression and lack of downregulation with 
sustained IRF4 levels corresponded to primary BTKi resistance. 
4.6.1 Assessment of BTK phosphorylation and IRF4 expression in MCL patient 
cells with primary and acquired resistance to BTKi treatment 
To validate whether IRF4 expression can be used as a biomarker to detect patients 
with primary or acquired BTKi resistance, further detailed studies on two individual 
MCL cases was undertaken.  One case (MCL04) was treatment refractory 
demonstrating primary resistance to BTKi and the other was an acquired resistance 
case from a previously responding patient (MCL02) who subsequently relapsed after 
23 months on BTKi therapy. The primary MCL cells isolated from these cases were 
assessed for BTK phosphorylation following IgM stimulation (Methods section 2.2.8 
and 2.3.2) by flow cytometry. In the acquired resistance case, BTK phosphorylation was 
assessed in a pre-treatment sample and compared to a BTKi-treatment sample with 
relapsed disease. In the primary resistance case, BTK phosphorylation was assessed in 
a pre-treatment sample following in vitro treatment with Ibr and Acal at the doses 
indicated. 
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In both cases of BTKi resistance, phosphorylation of BTK-Y223 was reduced by BTKi as 
shown by the reductions in the median fluorescence intensity ratios for pBTK-Y223-PE 
against a corresponding isotype control (Figure 4.16).  
 
 
 
 
 
 
 
 
 
Figure 4.16: Flow cytometry analysis of phosphorylated BTK-Y223 in MCL patient cells with 
primary and acquired resistance to BTKi. A) MFIR of pBTK-Y223 in a pre-treatment sample vs. 
a BTKi-treatment sample from a patient with acquired BTKi resistance (case MCL02). B) MFIR 
of pBTK-Y223 in a pre-treatment sample from a patient with primary BTKi resistance following 
in vitro treatment with Ibr and Acal (1µM) (case MCL04). MFIR denotes the median 
fluorescence intensity ratio of pBTK-Y223-PE / IgG-PE isotype control. Units are arbitrary. 
 
 
 
 
 
 
 
 
 
 
A) B) 
163 
 
IRF4 expression was assessed in both the acquired and primary resistant BTKi cases 
(MCL02 and MCL04, respectively).  
In the acquired BTKi resistance case, protein was extracted from PBMCs during BTKi 
treatment until relapse. IRF4 was initially downregulated over several treatment cycles 
with Acal as shown previously (Figure 4.14) and shown again in Figure 4.17A. However, 
comparison of the patient’s pre-treatment sample with their relapse sample showed 
that IRF4 was not downregulated at relapse (Figure 4.17B) and appeared as a band 
slightly lower than that seen pre-treatment.   
In the primary resistance case, protein was extracted from PBMCs pre-treatment and 
during the first 3 cycles on treatment.  IRF4 was consistently expressed over several 
treatment cycles with Acal therapy and was not downregulated even after three 
months on therapy (Figure 4.18). 
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Figure 4.17: Immunoblot of IRF4 expression in primary MCL cells in a patient with acquired 
BTKi resistance. A) Shows downregulation of IRF4 expression during treatment response, B) 
shows loss of IRF4 downregulation at disease relapse. Blot details: 10% SDS gel. 30.0µg 
protein. Rabbit anti-human IRF4 (CST #4964) 1 in 1000 dilution, rabbit anti-human GAPDH (CST 
#2118) 1 in 5000 dilution, in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-HRP (Dako, P0448) 1 in 
2000 dilution in 5% BSA/TBST, 1 hr, RT. ECL (GAPDH), ECL prime (IRF4) (Pierce, Life 
Technologies). 
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Figure 4.18: Expression of IRF4 in primary MCL cells in a patient with primary BTKi resistance. 
IRF4 expression is not downregulated over several Acal treatment cycles in a patient clinically 
not responding to treatment. A) Immunoblot analysis of IRF4 expression B) Densitometry 
analysis of IRF4 expression relative to GAPDH expressed in arbitrary units. C= cycle, D = day. 
Blot details: 10% SDS gel. 30.0µg protein. Rabbit anti-human IRF4 (CST #4964) 1 in 1000 
dilution, rabbit anti-human GAPDH (CST #2118) 1 in 5000 dilution, in 5% BSA/TBST, o/n at 4°C.  
Goat anti-rabbit-HRP (Dako, P0448) 1 in 2000 dilution in 5% BSA/TBST, 1 hr, RT. ECL (GAPDH), 
ECL prime (IRF4) (Pierce, Life Technologies). 
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4.7 Discussion 
The tissue microenvironment is recognised to contribute to the development of 
chemo-resistance, and has been proposed as a mechanism of Ibr resistance in MCL and 
other B cell malignancies.191-194 Like their normal B cell counterparts, MCL cells are 
attracted into the tissues by chemotactic factors secreted by accessory cells such as 
stromal cells in the microenvironment, where important interactions take place with 
other cell types including T cells. CD40L is expressed on T cells, and in normal cells has 
an important role in providing co-stimulatory signals following stimulation of the BCR 
which increase the survival and growth of specific B cell clones.  
In this study, REC-1 cells treated with either Ibr or Acal demonstrated enhanced 
survival and proliferation in the presence of CD40L-stromal support. We found it 
surprising that a cell-line model would show such dependency, mimicking the 
behaviour of MCL cells in vivo, but this behaviour provides further support for the use 
of REC-1 cells as a model to investigate mechanisms of BTKi resistance in MCL. 
Stromal cell support in the absence of CD40L did not affect functional or signalling 
responses of REC-1 cells to BTK inhibition. However, the presence of CD40L stroma 
prevented downregulation of ERK1/2 phosphorylation following BTKi treatment of the 
REC-1 cells, suggesting that there is a BTK-independent pathway for ERK1/2 activation 
that is induced by CD40L possibly by MAPK and PI3K pathways. In addition, IRF4 
expression in REC-1 cells following CD40L stimulation was sustained and not down-
regulated in response to treatment with either Ibr or Acal.  These data suggest that 
CD40L stimulation provides a pathway for REC-1 cells to resist effects of BTKi 
treatment. Increased levels of IRF4 expression are seen following CD40L stimulation, as 
we see with BCR stimulation. However, unlike effects of BCR stimulation, IRF4 
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expression is sustained following BTKi treatment in the presence of CD40L, reflecting a 
possible mechanism of resistance and/or a biomarker of resistance. Studies suggest 
that both the canonical and non-canonical NF-κB pathways can be activated by MCL 
stromal cell interaction, either alone or through secretion of B-cell activating factor 
(BAFF),53 and may be a possible pathway mediating the effect of IRF4. There was no 
evidence of increased IRF4 expression in REC-1 cells co-cultured with stromal cells in 
the absence of CD40L.  
Unsurprisingly, REC-1 cells with acquired BTKi resistance were independent of CD40L; 
they required no additional stimulation from CD40L to overcome BTKi effect 
suggesting that the increased survival, proliferation and the sustained levels of IRF4 in 
these cells was independent of the effects of CD40L. This suggests that acquired 
resistance to BTKi may occur through an intrinsic mechanism, such as mutations in the 
BTK molecule.  
Like the MCL cell lines  described in Chapter 3, primary MCL cells whether sensitive or 
resistant to BTKi all showed a normal functional BCR with increased pBTK-Y223 
following IgM stimulation which was reduced following BTKi treatment. 
Phosphorylated BTK-Y223 was significantly reduced by Ibr but not Acal, however given 
the near significance (p=0.06) this was possibly due to the low dosage of Acal 
treatment (100nM) used to treat the cells in vitro. It is likely that this result would be 
significant at higher dosage. These results are suggestive that in cells with innate 
resistance, resistance mechanisms may occur further downstream from BTK or via 
alternative pathway activation possibly by effects of the tissue microenvironment. 
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Primary MCL cells behaved similarly to REC-1 cells when co-cultured with fibroblast 
support and in response to BTKi treatment.  Survival was significantly increased after 
24 hours co-culture with CD40L although not at 48 hours, which could be due to 
patient variability given that some patient samples analysed at 48 hours were different 
to samples analysed at 24 hours, two of which were indolent cases which generally 
have lower rates of apoptosis. In addition, the data is only representative of 5 
individual MCL cases at 48 hours, it is likely therefore that significance would increase 
with a larger sample size.   
Similar results were shown in response to BTKi; CD40L significantly prevented 
apoptosis of primary MCL cells in response to BTKi after 24 hours co-culture but not 
after 48 hours which again may be influenced by the small sample size and indolent 
cases with low apoptosis rates. 
CD40L significantly upregulated IRF4 levels in all 8 MCL patient samples analysed (p= 
0.0012) (Figure 4.12B). In the absence of CD40L, IRF4 was downregulated by BTKi (both 
Ibr and Acal), but in the presence of CD40L, no downregulation of IRF4 expression was 
seen in response to BTKi (both Ibr and Acal). 
These findings suggest that signals from the tissue microenvironment may modulate 
drug response in MCL and that CD40L-CD40 signalling may have a role in primary 
resistance to BTK inhibitors by modulating expression of IRF4. To validate whether IRF4 
could be a biomarker of BTKi treatment response in MCL, ex vivo samples from 
clinically treated patients (n=8) were analysed before and during BTKi treatment. The 
results showed that IRF4 was downregulated in 7 samples from patients shown to be 
clinically responding to BTKi and was not downregulated in 1 refractory case. In 
responding patients, IRF4 downregulation was shown to be an early response to 
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therapy occurring within the first treatment cycle and was sustained over several 
treatment cycles until relapse when its downregulation was prevented and IRF4 
expression was sustained.  Here however, we noticed that the IRF4 band was detected 
lower than that predicted which may reflect a post translational 
modification/alteration in phosphorylation sites which could be explored further using 
2 dimensional SDS-gel electrophoresis.  Commercially available phospho- IRF4 
antibodies are not widely available. The group of Wang & Ning 195 have developed a 
polyclonal antibody specific to phospho-IRF4 (Y121/124) offering the opportunity for 
collaborative studies. 
Similarly, IRF4 was not downregulated over several treatment cycles in a primary 
resistance case. These findings provide further evidence that IRF4 expression is 
associated with response to BTKi treatment in MCL and could have potential use as a 
biomarker in a clinical setting. The mechanisms of IRF4 regulation by BTKi in MCL are 
discussed in Chapter 5.  
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5 Chapter 5 - Investigating IRF4 regulation, interactions and 
effects of BTKi. 
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5.1 Introduction 
The findings from this study have indicated that IRF4 is linked to the treatment 
response to BTKi, both in MCL cell lines and in primary cells. However, to understand 
the role that IRF4 has in cells treated with BTKi, it is important to understand its 
regulation and function in MCL.  Therefore, further studies were undertaken to test 
the control of IRF4 within MCL, and to investigate the complex relationship between 
protein translation and degradation through assessment of mRNA levels. Subsequent 
studies then went on to explore the interactions between IRF4 and other cell proteins: 
initially exploring known interactions (specifically the interaction with the ETS family 
member PU.1 - as discussed in the Introduction section 1.4.1). Then subsequently, and 
perhaps more importantly, interactions with previously unreported proteins were 
studied using co-immunoprecipitation studies and SWATH mass spectrometry.  Finally, 
since IRF4 is a known transcription factor, studies were performed to identify IRF4 
target genes through sequencing of IRF4-DNA chromatin precipitates from either BTKi 
sensitive or resistant cells, aiming to determine DNA binding sites of IRF4 which can be 
mapped to the human genome to further identify its interactions.  
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5.2 Methods employed 
The methods employed in this chapter involve the isolation of RNA (Methods section 
2.5.1) from REC-1 and G519 cells following BTKi treatment, conversion of the RNA to 
cDNA (Methods section 2.5.2) and analysis of IRF4 and PU.1 mRNA expression by 
quantitative real time PCR (qPCR) (Methods section 2.5.4).  
Co-expression of IRF4 and PU.1 was investigated using biochemical assays of co-
immunoprecipitation (Co-IP) (Methods section 2.4.4), western blotting (Methods 
section 2.4.6) and immunohybridisation (Methods section 2.4.6.1) of IRF4 protein 
precipitates from REC-1 cells. Further assessment of IRF4-protein interactions was 
determined using SWATH mass spectrometry of co-precipitated proteins (Methods 
section 2.4.5). Functional relationships of the proteins identified using SWATH were 
determined using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) 
database, using highest confidence analysis (predicted significance >0.9).  
Chromatin immunoprecipitation (ChIP) of IRF4 (Methods section 2.5.6) was optimised 
in REC-1 and G519 cells. The ChIP procedure was confirmed by amplification of the 
RPL30 locus using conventional methods of PCR (Methods section 2.5.3) and agarose 
gel electrophoresis (Methods section 2.5.5). The DNA sequences bound to IRF4 were 
detected by next generation sequencing (Methods section 2.5.7) on purified IRF4 DNA 
from G519 cells.  
The list of antibodies used in this chapter is shown below (Table 5.1), accompanied 
with the antibody dilutions relating to the applications in which they were used. 
The mRNA expression data (qPCR) was analysed using the delta delta Ct (2^-ddCt) 
method in Microsoft Excel™. Sequencing reads obtained from the IRF4 ChIP sample 
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were aligned to the human genome reference HG38 using CLC Workbench version 11 
software. 
 
Table 5.1: Antibodies used in Chapter 5. HRP= Horseradish peroxidase, WB= western blotting, 
IP = immunoprecipitation ChIP=chromatin immunoprecipitation, CST= Cell signalling 
technology. All antibodies used for ChIP were validated except for the MUM-1 antibody from 
Abcam. 
 
 
 
 
Antibody/probe Species  Application Ref Source Conc 
 
IRF4 primary antibody Rabbit anti human WB 
IP/ChIP 
#4964 CST 1/1000 
1/25 
MUM-1 primary antibody  Rabbit anti human WB 
IP/ ChIP 
ab133298 Abcam 1/5000 
1/25 
PU.1/Spi-1 primary 
antibody 
Mouse anti human WB MAB5870 R & D 
systems  
1/250 
 
GAPDH  primary antibody Rabbit anti human WB #2118 CST 1/5000 
 
Histone H3 (D2B12) XP 
primary antibody  
Rabbit anti human  ChIP  #4620 CST 1/50 
Normal Rabbit IgG  
primary antibody 
Rabbit anti human  IP/ChIP #2729 CST 1/250 
Secondary antibody-HRP Goat anti rabbit WB #P0448 Dako 1/2000 
 
Secondary antibody-HRP Goat anti mouse  WB #P0447 Dako 1/2000 
 
IgG light chain secondary 
antibody-HRP 
Mouse anti rabbit WB ab99697 Abcam 1/2000 
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5.3 Downregulation of IRF4 mRNA is an early and specific response to 
BTKi treatment in sensitive REC-1 cells, but not in resistant cells 
(innate or acquired). 
Downregulated expression of IRF4 mRNA was shown to be an early response to BTKi 
treatment in the BTKi sensitive REC-1 cells. However, downregulation was not 
demonstrated in the acquired resistant REC-1 cells or the G519 cells; these findings 
corresponded to the retained expression of IRF4 protein in these latter cells. 
5.3.1 Assessment of IRF4 mRNA expression in REC-1 cells following BTKi 
treatment 
Expression of IRF4 mRNA was first assessed in REC-1 cells following treatment with Ibr 
(10µM). RNA was extracted from the cells at regular time points over 48 hours and 
converted to cDNA. The cDNA was amplified by qPCR using primers specific for regions 
on IRF4 and the control gene HPRT.  
Expression of IRF4 mRNA was found to be downregulated (relative to HPRT) in REC-1 
cells as an early response to Ibr, and was maximally reduced after 4 hours of treatment 
(Figure 5.1). This timescale related well to the results already reported in chapter 3 
(Figure 5.2) where the downregulation of IRF4 protein expression occurred at 4-8 
hours following BTKi treatment. This suggested that the changed IRF4 protein 
expression might be due to altered mRNA transcription and biosynthesis rather than 
degradation, and the down regulation of IRF4 was therefore a specific 
transcriptionally-regulated response to treatment. However, IRF4 mRNA was not 
persistently downregulated at this level and appeared to increase with time (although 
relative to baseline expression was still lower). The IRF4 protein expression did not 
follow the same trend (Figure 5.2), suggesting alternative/additional mechanisms must 
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underlie the persistent downregulation of IRF4 protein expression seen in REC-1 
treated cells. 
 
 
 
 
 
 
Figure 5.1: Expression of IRF4 mRNA in REC-1 cells in response to Ibr. REC-1 cells were treated 
with Ibr (10µM). RNA was extracted from the cells at regular time points over 48 hours. IRF4 
and HPRT regions were amplified from cDNA using qPCR. A) 2^-ddCt of IRF4 mRNA levels 
normalised to HPRT (N=2). B) Agarose gel electrophoresis analysis of the qPCR amplicons for 
IRF4 (91bp) and HPRT (131bp) (representative image from one experiment). 
 
 
 
 
 
Figure 5.2: Expression of IRF4 protein in REC-1 cells in response to Ibr. REC-1 cells were 
treated with Ibr (10µM). Protein was extracted from the cells at regular time points over 48 
hours and separated by SDS-PAGE. 10% SDS gel. 25µg protein, Rabbit anti-IRF4 Ab (CST #4964) 
1 in 1000, GAPDH (CST #2118) 1 in 5000 in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-HRP 
(Dako, P0448) 1 in 2000 dilution (IRF4), 1 in 5000 dilution (GAPDH) in 5% BSA/TBST, 1 hr, RT. 
ECL (Pierce, Life Technologies) (GAPDH) ECL prime (IRF4). Expression of IRF4 protein after 48 
hours Ibr treatment is indicated by the red arrow. 
 
A) B) 
Ibr (10µM) 
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To determine whether the response to Ibr was similar with a more specific BTKi, 
expression of IRF4 mRNA was compared in REC-1 cells treated with either Ibr or Acal at 
1µM concentrations. IRF4 mRNA was again found to be downregulated by Ibr by 4 
hours (as previously); and slightly later (after 4 hours) following treatment with Acal 
(Figure 5.3). Despite the differences in the first 4 hours following treatment, there was 
a similar trend in IRF4 mRNA expression in response to either Ibr or Acal. 
Note that in this experiment, the time 0 control was excluded from analysis, since the 
PCR amplicons assessed by agarose gel electrophoresis showed reduced expression of 
the IRF4 cDNA in the time 0 control sample compared to the treated samples (Figure 
5.4), which was not seen in the previous experiment (Figure 5.1B). This was possibly 
due to poor quality RNA as shown in Table 5.2. Since there was no difference seen 
between IRF4 mRNA expression at 0 or 1 hour (as shown in Figure 5.1) and is in 
accordance with  what is generally considered to be the case with mRNA transcription, 
analysis of IRF4 mRNA was compared relative to the 1 hour treated samples for both 
Ibr and Acal. 
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Figure 5.3: Expression of IRF4 mRNA in REC-1 cells in response to Ibr and Acal. REC-1 cells 
were treated with Ibr or Acal (1µM). RNA was extracted from the cells at regular time points 
over 48 hours. IRF4 and HPRT regions were amplified from cDNA using qPCR.  IRF4 mRNA 
levels were normalised to HPRT (2^-ddCt). 
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Table 5.2: Nanodrop assessment of RNA concentration and purity. The time 0 sample 
(highlighted in red), shows poor RNA purity compared to treated samples. 
 
 
 
 
 
 
 
 
 
Figure 5.4: Agarose gel analysis of the PCR products showing poor expression of IRF4 cDNA in 
the time 0 sample. IRF4 and HPRT cDNA amplicons from the time 0 sample (indicated by 
orange arrow) compared to the samples treated with Ibr (1µM) after 1, 4, 8, 24 and 48 hours. 
 
 
 
 
 
Sample Concentration 
ng/µl 
A260/280 
(2.0) 
A260/230 
(2.0-2.2) 
Ctrl   0h 167.8 2.8 1.5 
Ibr     1h 202.3 2.1 1.9 
Ibr     4h 251.4 2.1 2.0 
Ibr     8h 308.9 2.1 1.9 
Ibr   24h 298.9 2.1 2.0 
Ibr   48h 357.9 2.1 1.7 
Acal  1h 190.1 2.1 1.7 
Acal  4h 275.1 2.1 1.8 
Acal  8h 335.7 2.1 1.7 
Acal 24h 247.4 2.1 1.9 
Acal 48h 328.7 2.1 1.7 
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5.3.2 Assessment of IRF4 mRNA in BTKi- treated MCL cells with innate or 
acquired resistance 
IRF4 mRNA expression was next assessed in cells with either innate or acquired BTKi 
resistance to provide evidence of whether the differences seen in protein expression 
between BTKi sensitive and resistant cells were consistent with changes to IRF4 
transcription.  
 
The innate resistant G519 cells were assessed following treatment with Ibr or Acal 
(1µM). RNA was extracted from the cells at regular time points over 48 hours. IRF4 
mRNA expression was  found to differ between treatment with Ibr and Acal (although 
again, the trends are similar but delayed with Acal); however both showed increased 
mRNA expression at 24 and 48 hours relative to the control time 0 sample (Figure 5.5).  
The pattern of IRF4 mRNA following Ibr treatment corresponds well to the IRF4 protein 
expression in G519 treated cells - although direct correlation cannot be made due to 
different doses used, it is clear that there is increased protein expression seen at 24 
and 48 hours (Figure 5.6).  Further analysis shows that IRF4 mRNA expression was 
significantly different in G519 cells compared to REC-1 cells in response to BTKi 
treatment (unpaired t test p=0.0006) (Figure 5.7) suggesting differences in IRF4 gene 
transcription between BTKi sensitive and innately resistant cells.  
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Figure 5.5: Expression of IRF4 mRNA in G519 cells in response to Ibr and Acal. G519 cells were 
treated with Ibr or Acal (1µM). RNA was extracted from the cells at regular time points over 48 
hours. IRF4 and HPRT regions were amplified from cDNA using qPCR. IRF4 mRNA levels 
normalised to HPRT (2^-ddCt). 
 
 
 
 
 
 
 
Figure 5.6: Protein expression of IRF4 in G519 cells following Ibr treatment. G519 cells were 
treated with Ibr (10µM). Protein was extracted from the cells at regular time points over 48 
hours and separated by SDS-PAGE. 10% SDS gel. 25µg protein, Rabbit anti-IRF4 Ab (CST #4964) 
1 in 1000, GAPDH (CST #2118) 1 in 5000 in 5% BSA/TBST, o/n at 4°C.  Goat anti-rabbit-HRP 
(Dako, P0448) 1 in 2000 dilution (IRF4), 1 in 5000 dilution (GAPDH) in 5% BSA/TBST, 1 hr, RT. 
ECL (Pierce, Life Technologies) (GAPDH) ECL prime (IRF4).   
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Figure 5.7: Comparison of IRF4 mRNA expression in REC-1 and G519 cells in response to BTKi. 
The average relative expression values (2^-ddCt) of IRF4 mRNA from 3 x data sets for REC-1 
and 2 x data sets for G519. Data was analysed using an unpaired t test on treated samples 
only. 
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To confirm whether differences in IRF4 gene transcription were additionally seen in 
acquired resistant MCL cells, the acquired resistant REC-1 cells (R (Ibr 1µM)) and 
parent REC-1 cells (P) were treated with a corresponding dose of Ibr (1µM) and 
incubated for 4 hours. RNA was extracted from each cell line along with untreated 
parent REC-1 cells (P control) at the same time point for assessment of IRF4 mRNA 
expression. In the acquired resistant REC-1 cells, IRF4 mRNA was upregulated relative 
to the untreated control cells at 4 hours which differed to that observed with parental 
treated cells (Figure 5.8). These findings are suggestive that differences in protein 
expression that we see in cells resistant to BTKi are additionally reflected at the level of 
IRF4 gene transcription. 
 
 
 
 
 
 
 
 
Figure 5.8: Expression of IRF4 mRNA in parent vs acquired resistant REC-1 cells in response to 
Ibr. REC-1 cells and acquired resistant REC-1 cells (R (Ibr 1µM)) were treated with Ibr (1µM). 
RNA was extracted after 4 hours treatment. IRF4 and HPRT regions were amplified from cDNA 
using qPCR. IRF4 mRNA levels were normalised to HPRT (2^-ddCt). 
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5.4 PU.1 does not interact with IRF4 in REC-1 cells and is not linked to 
the downregulation of IRF4 in response to BTKi. 
PU.1 was not detected in IRF4 protein precipitates from REC-1 cells following co-
immunoprecipitation. Assessment of protein expression showed that, in contrast to 
IRF4 expression, PU.1 was not downregulated in primary MCL cells treated in vitro 
with BTKi. In addition, expression of PU.1 mRNA in REC-1 cells was increased in 
response to BTKi which did not correlate with downregulation of IRF4 mRNA 
expression. These studies suggest that PU.1 does not interact with IRF4 in REC-1 cells 
and is not linked to the downregulation of IRF4 in response to BTKi. 
Having determined that IRF4 protein expression and transcription are specific changes 
seen in MCL cells in response to BTKi treatment, we wanted to understand more about 
the role IRF4 in MCL cells and how differences in IRF4 protein expression could 
influence the response of MCL cells to BTKi. Little is known about the interactions of 
IRF4 in MCL either at the protein or chromatin level. As described in the introduction 
we know that IRF4 activates transcription of its target genes by forming homo or 
hetero-dimers either with other IRF family members or with other proteins including 
AP.1 and ETS family members. The most recognised binding partners for IRF4 are ETS 
family members PU.1 and SPI-B.150 We therefore assessed the interaction of PU.1 with 
IRF4 in MCL cells through co-immunoprecipation assays, and through comparison of 
expression of IRF4 to PU.1 proteins and transcription in response to BTKi treatment.  
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5.4.1 Assessment of IRF4- PU.1 interaction in REC-1 cells 
To investigate whether PU.1 interacts with IRF4 in MCL, co-immunoprecipitation was 
performed. Briefly, REC-1 cells were lysed in a low stringency (LS) lysis buffer (100µl / 1 
X 107 cells). Protein was extracted for immunoprecipitation (IP) of IRF4 using a 1 in 25 
dilution of rabbit anti-human IRF4 antibody (CST #4964) and an IgG control IP using a 
normal rabbit IgG antibody (CST #2729) (Methods section 2.4.4).  
Samples of the IRF4 precipitated protein, the post IP sample, the normal IgG control 
and the REC-1 whole cell lysate were run on a 10% SDS gel and transferred onto a 
PVDF membrane. The membrane was cut into two pieces. One half was incubated with 
rabbit anti-human IRF4 primary Ab (1:1000) and the other, with mouse anti-human 
PU.1/Spi-1 primary Ab (1:250) in 5% BSA/TBST over night at 4°C. Both membranes 
were incubated for 1 hour with a light chain specific secondary antibody-HRP (abcam 
#ab99697) diluted 1:2000 in 5% BSA/TBST. 
As shown in Figure 5.9, both IRF4 and PU.1 were present in the whole cell lysate 
confirming their expression by REC-1 cells. IRF4 was also shown to be present in the 
IRF4 precipitated sample and was enriched compared to the whole cell lysate; IRF4 
was not expressed in the IgG precipitated control sample confirming the absence of 
non-specific binding. Expression of PU.1 was not detected in the IRF4 test IP sample, 
although IRF4 and PU.1 were weakly expressed in the IRF4 post-IP sample suggesting 
that not all of the IRF4 protein was successfully precipitated from the lysate. As IRF4 
showed enrichment in the test IP sample and with the effectiveness of the PU.1 
antibody at detecting PU.1, there should have been sufficient IRF4 protein present to 
identify any co-precipitated PU.1. These results therefore suggest that PU.1 and IRF4 
were not physically associated in REC-1 cells. 
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Figure 5.9: Co-immunoprecipitation of IRF4 and PU.1 in REC-1 cells. REC-1 cells were lysed in 
LS buffer (100µl per 1 x 107 cells). For each IP, 600µg protein was diluted in 200µl of 
immunoprecipitation buffer and incubated with Rabbit anti human IRF4 antibody (CST #4964) 
(1/25 dilution), or Normal rabbit IgG antibody (CST #2729) (1:250) o/n at 4°C. Membranes 
were incubated with Rabbit anti-human IRF4 primary Ab (1:1000) or mouse anti-human 
PU.1/Spi-1 primary Ab (1:500) in 5% BSA/TBST o/n at 4°C. Membranes were incubated with a 
light chain specific secondary antibody-HRP (Abcam) (1:2000) in 5% BSA/TBST for 1 hour. IRF4 
(MW: 50kD) PU.1 (MW: 42kD). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
186 
 
5.4.2 Assessment of PU.1 protein expression in primary MCL cells treated in 
vitro with BTKi 
Primary MCL cells co-cultured on a stromal layer (both NT-CD40L and T-CD40L), were 
treated in vitro with Ibr and Acal. Protein was extracted after 48 hours and analysed 
for expression of IRF4 and PU.1. As shown previously (Chapter 4), in primary cells 
cultured on the NT-CD40L stromal layer, IRF4 was downregulated by BTKi (both Ibr and 
Acal) and both upregulated and sustained when cultured on a CD40L stromal layer. 
This differs to the expression of PU.1 which shows stable expression in response to 
BTKi treatment and appears downregulated in response to CD40L co-culture (Figure 
5.10). 
 
 
 
 
 
 
 
Figure 5.10: Expression of IRF4 and PU.1 in primary MCL cells. Immunoblot analysis of IRF4 
and PU.1 in primary MCL cells (Case MCL07) co-cultured on a stromal layer (both NT-CD40L 
and T-CD40L) and treated in vitro with BTKi for 48 hours. 10% SDS gel. 30µg protein. 
Membranes were incubated with Rabbit anti human IRF4 primary Ab (CST #4964) 1 in 1000 
dilution and GAPDH (CST #2118) 1 in 5000 dilution, o/n at 4°C and detected using Goat anti 
Rabbit-HRP secondary 1 in 2000 dilution following 1 hour incubation at room temperature. The 
membrane was washed and re-incubated with Mouse anti human PU.1/Spi-1 primary Ab 
(1:500) o/n at 4°C and detected using Goat anti mouse –HRP secondary antibody. 
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5.4.3 Assessment of PU.1 mRNA levels following BTKi treatment in REC-1 
cells 
REC-1 cells were treated with Ibr (1µM) and incubated for 48 hours. RNA was extracted 
from the cells at regular time points (as indicated) and converted to cDNA. The cDNA 
was amplified by qPCR using primers specific for regions on IRF4, PU.1 and the control 
gene HPRT for assessment of both IRF4 and PU.1 mRNA expression. 
As shown earlier (section 5.3.1) IRF4 mRNA expression relative to the control HPRT 
gene was downregulated by Ibr in REC-1 cells. However an almost inverse pattern was 
seen with PU.1 mRNA expression. PU.1 mRNA expression appeared to increase with 
almost a log greater difference in PU.1 mRNA expression compared to IRF4 mRNA seen 
at 48 hours (Figure 5.11). These results are again suggestive that PU.1 and IRF4 are not 
binding partners. 
 
 
 
 
 
 
 
 
 
Figure 5.11: Expression of IRF4 and PU.1 mRNA in REC-1 cells in response to Ibr. REC-1 cells 
were treated with Ibr 1µM. RNA was extracted from the cells at regular time points over 48 
hours for assessment of both IRF4 and PU.1 mRNA. IRF4, PU.1 and HPRT regions were 
amplified from cDNA using qPCR. IRF4 and PU.1 mRNA levels were normalised to HPRT (2^-
ddCt). 
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5.5 IRF4 interactions identified by mass spectrometry reveals a role for 
IRF4 in mitochondrial ribogenesis  
Proteomic study of IRF4 immunoprecipitation of REC-1 cells reveals a particular 
association with mitochondrial ribosomal proteins and related functional processes. 
Previous studies revealed that it was unlikely that one of IRF4’s known binding 
partners, PU.1, was associated with IRF4 in MCL cells.  We therefore went on to 
explore other potential protein interactions of IRF4 in REC-1 cells through studies of 
co-immunoprecipitation using SWATH mass spectrometry. This study employed the 
same IRF4 antibody used in earlier precipitation (CST #4964), but also a second IRF4 
antibody (rabbit anti-human MUM-1 (abcam #ab133298)) for immunoprecipitation to 
allow better comparison of precipitated proteins (Figure 5.12).    
 
 
 
 
 
 
Figure 5.12: Testing the efficiency of the abcam MUM-1 antibody for the 
immunoprecipitation of IRF4 from REC-1 cells. REC-1 cell lysate (600µg) was incubated with 
rabbit anti-human MUM-1 antibody (abcam #ab133298) 1:25 in 5% BSA/TBST, o/n at 4°C. A 
volume of 50µl of protein G beads was added for 1 hour at 4°C. Membrane was incubated with 
abcam rabbit anti-human MUM-1 antibody (1:1000) o/n at 4°C. Membrane was then 
incubated with mouse anti-rabbit light chain specific secondary antibody- HRP (1:5000) for 1 
hour. WCL = whole cell lysate, BME = β-mercaptoethanol. 
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Briefly, IRF4 protein precipitations were prepared from REC-1 cell lysate using both CST 
IRF4 and abcam MUM-1 antibodies and an IgG control antibody. The denatured 
precipitates were run on a 10% resolving gel prepared under sterile conditions, and 
each IP lane was cut into 8 individual gel slices (Methods section 2.4.5, Figure 2.5). The 
gel was left unstained to prevent any staining interference with the mass 
spectrometry. 
The proteomic analysis was performed in Manchester by Drs Cieran and Bobby 
Graham, and data analysis was then performed with the help of Dr Karen Rees-Unwin 
and Dr John Burthem in Manchester.   
In brief, sequential window acquisition of all theoretical fragment ion spectra (SWATH) 
was used to identify proteins in the IP samples and to allow quantitative comparison of 
the protein abundance. Essentially, the technique simply acquires all ions from 
proteins in the samples using an isolation window that covers the whole mass/charge 
range. The fragmentation spectra then enable retrospective identification of the 
peptides allowing the parent proteins to be identified. Quantitation is derived from the 
quantity of ions related to each protein in relation to the total amount of protein in the 
sample. SWATH therefore generates a list of proteins within a sample and a supports a 
relative comparison of protein abundance between samples. Proteins present can then 
be further analysed by data analysis tools to determine likely significance, and can be 
further analysed using bioinformatics approaches (in this case analysis using STRING) 
to determine likely functional relationships. 
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The results below describe in more detail the analysis of these studies and the 
significance of the results. The initial analysis focussed on proteins that were 
precipitated by both IRF4 and MUM-1 antibodies and were not seen in the IgG control 
IP.  The specificity was confirmed since the IRF4 protein itself was found only in 
precipitates where the specific antibodies were used and not seen in the control 
precipitates. In addition, both these antibodies co-precipitated a range of proteins that 
were not found in the control. Analysis showed that the probability that the proteins 
had been co-precipitated by chance by the specific antibodies but not the control was 
< 0.00001 (Chi Squared test). This confirmed that many of the precipitated proteins 
were likely to be associated with IRF4 in some form, although some would be non-
specific.  
To further analyse the data and identify the major associated proteins with IRF4, the 
functional relationships of these proteins were assessed by exporting to STRING 
analysis database. This database combines a range of data mining and experimental 
sources to establish linked functional characteristics of proteins.  All high confidence 
interactions were initially considered in the analysis, but due to the extensive level of 
interaction (Figure 5.13) only the highest confidence interactions (STRING algorithm 
confidence >0.9) were examined in more detail (Figure 5.14).  Single proteins without 
linkage which more likely represented non-specific interactions or unknown 
associations were excluded to simplify the analysis.  The identities of proteins present 
in each string cluster were determined and used to ascribe the functional group to that 
cluster (Figures 5.15). These functional proteins clustered to Ribosomal proteins and 
translation and ribosomal assembly (Figure 5.16), Mitochondrial ribosome proteins 
and mitochondria and mitochondrial RNA (Figure 5.17), DNA processing and 
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transcription (Figure 5.18), RAS and signalling functions (Figure 5.19) and Metabolism 
(general) (Figure 5.20). 
 
 
 
Figure 5.13: STRING analysis of high confidence relationships.  Results suggested high level of 
interaction for the majority of precipitated proteins, but was too complex for detailed 
functional analysis. 
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Figure 5.14: Profile of relationships analysed with highest confidence (STRING algorithm 
confidence >0.9). Single proteins are shown without linkage and may be non-specific or 
unreported interactions. 
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Figure 5.15: Profile of relationships analysed with highest confidence with functional 
annotation. Data analysed with highest confidence with all single proteins or doublets 
excluded from the analysis. The groups are assigned function according to protein function of 
the majority of precipitated elements.  Group (1) Ribosomal proteins and translation, (2) 
Mitochondrial ribosome proteins, (3) Ribosome assembly, (4) DNA processing and 
transcription (5) RAS and signalling functions, (6) Mitochondria and mitochondrial RNA, (7) 
Metabolism (general). 
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Figure 5.16: Ribosome proteins and proteins of translation and ribosomal assembly. Proteins 
identified in functional groups 1 and 3. 
 
 
 
 
 
 
 
 
WDR77 
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Figure 5.17: Mitochondrial ribosome proteins and mitochondria and mitochondrial RNA 
proteins. Proteins identified in functional groups 2 and 6. 
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Figure 5.18: Proteins of DNA processing and transcription. Proteins identified in functional 
group 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19: RAS and signalling function proteins. Proteins identified in functional group 5. 
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Figure 5.20: Proteins of Metabolism (general). Proteins identified in functional group 7. 
 
Further validation steps were undertaken to determine whether these IRF4 
associations were specific, since a possible criticism would be is that there are a large 
number of co-precipitated proteins detected in both test and control samples. The aim 
of this validation step was to see if the types of protein that were non-specifically 
precipitated (i.e. seen with control antibody alone or control antibody and IRF4 
antibodies) differed from the specific proteins (precipitated by the IRF4 antibody only). 
This analysis used a slightly extended dataset including both those that were solely 
present in control or IRF4 precipitates, but also proteins that were significantly 
enriched (>2-fold) in either sample. Comparison of the functional protein groups 
precipitated by control vs. test antibodies (as revealed by the STRING analysis 
database) is shown in Figure 5.21 and 5.22. 
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This analysis showed that ribosomal elements including RNA translational factors were 
a frequent finding in both the control and the IRF4 fractions suggesting that some of 
these protein types might be non-specific elements. However, one of the major 
aspects from the initial findings was confirmed – only the IRF4 antibodies precipitated 
mitochondrial RNA, shown as the distinct cluster in Figure 5.22 and enhanced in Figure 
5.23. The presence of mitochondrial ribosomal components only in IRF4 samples was 
highly significant (p<0.01 Chi square test). In comparison to a STRING analysis of 
known IRF4 interactions (Figure 5.24), the findings identified in this study are currently 
unknown and warrant further investigation. In addition, analysis of known IRF4, BTK 
and BCR interactions revealed a direct link for BTK and BCR but only an indirect link 
with IRF4 (Figure 5.25). 
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Figure 5.21: Profile of the relationships of the non-specific proteins precipitated by the 
control sample. Of note there are 2 significant functional clusters which both relate to cellular 
ribosomal RNA or RNA translation. 
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Figure 5.22: Profile of the relationships of the specific proteins precipitated by the IRF4 test 
antibodies. The two big clusters contain different proteins to the control, but they are 
functionally similar – relating to cellular RNA and RNA processing. However the highly distinct 
group (red circle) are mitochondrial ribosome elements which were not present in the control 
IP. 
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Figure 5.23: Enhanced detail of the distinct cluster of mitochondrial ribosome elements 
bound to IRF4. IRF4 precipitated proteins included MRPS5, MRPS9, MRPS22, MRPS26, 
MRPS23, MRPS31, MRPL3, MRPL38 and MRPL44 (mitochondrial ribosomal proteins), PTCD3 
(mitochondrial RNA-binding protein), TUFM (mitochondrial elongation factor Tu), DAP3 
(mitochondrial 28S ribosomal protein S29), and GADD45GIP1 (Growth arrest and DNA damage-
inducible proteins-interacting protein 1). 
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Figure 5.24: STRING analysis of known IRF4 interactions. The figure shows networks that are 
already known for IRF4 (Uniprot ID: Q15306). The findings from this study were not identified. 
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Figure 5.25: STRING analysis of known interactions for IRF4, BTK and BCR. Results showed a 
direct link for BTK (Uniprot ID: Q06187) and BCR (Uniprot ID: P11274), but no direct link with 
IRF4 (Uniprot ID: Q15306) (only indirect links). 
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5.6 Chromatin immunoprecipitation of IRF4 and detection of IRF4 
transcriptional targets can be achieved in MCL cell lines. 
Assessment of DNA interactions associated with IRF4 may indicate novel targets with 
the potential to overcome resistance to BTKi. Chromatin immunoprecipitation (ChIP) 
followed by high throughput DNA sequencing (ChIP-seq) is a useful method to identify 
binding sites for transcription factors on a genome-wide scale.  
The initial purpose of this section was to sequence DNA purified from chromatin 
precipitates of IRF4 and identify DNA sequences bound to IRF4 in MCL cell lines 
demonstrating sensitivity and resistance to BTKi. However, work was complex due to 
the extensive quality control steps required by the ChIP assay limiting the experimental 
results that could be analysed. Therefore the following section describes the work flow 
of the intended experiment, highlighting the problems encountered along the way and 
finishes with a summary of the optimised conditions required for ChIP-seq of IRF4 
which will be useful in future studies.   
Chromatin immunoprecipitation of IRF4 from MCL cell lines was performed using the 
Simple Chip Enzymatic Chromatin IP kit (CST #9003). This kit was chosen since the 
company had previously validated the rabbit anti-IRF4 antibody (CST #4964) (used 
throughout this study) for ChIP, in experiments with Hela cells. For details on the 
materials and reagents refer to methods section 2.1.5 and 2.5.6. 
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5.6.1 Introduction and general principle  
ChIP-Seq uses antibodies to detect proteins that are bound to DNA directly or that 
interact within DNA-bound protein complexes.  Protein- DNA interactions are first 
preserved using a formaldehyde solution for cross-linking. A series of lysis steps then 
disrupt cell and nuclear membranes, isolating only the nuclear contents for the ChIP. 
The chromatin is then digested using an enzyme and / or sheared into smaller 
fragments using sonication. An antibody specific to the protein of interest is then 
incubated with the cross-linked protein-DNA complexes and then bound to magnetic 
beads, which pulls the relative chromatin fragments out of solution. The cross-links are 
then reversed, and the resulting purified DNA can be used in subsequent DNA 
fragment library construction for DNA sequencing. Following sequencing, the sequence 
reads are analysed using peak-calling tools that align reads to a reference sequence 
and identify known DNA regions associated to proteins.   
5.6.2 Optimisation of chromatin digestion and fragmentation 
The first step in a ChIP assay is to optimise the chromatin digestion and fragmentation. 
This will depend on the size of the fragments required for the downstream application. 
Appropriate length fragments required for ChIP can be anywhere in the range of 150-
900bp. However DNA sequencing requires shorter fragments normally between 200-
400bp. 
Chromatin was first prepared from REC-1 cells at a concentration of 5 X 106 in 20mL 
culture media dispersed within a 15cm culture dish. Proteins were cross-linked to DNA 
by fixing cells in paraformaldehyde to a final concentration of 1%. Glycine was added 
to quench the formaldehyde and the cells were lysed in enzymatic 1 X lysis buffer A. 
The nuclei was pelleted and re-suspended in 1 X buffer B.  
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The protocol provided evidence that chromatin from Hela cells was digested to the 
appropriate length fragments (1-5 nucleosomes in length (900-150bp)) using 0.5µl of 
micrococcal enzyme and 3 sets of 20 second pulses with a sonication probe.  
To test these conditions in REC-1 cells, the chromatin was digested with 0.5µl of 
micrococcal enzyme for 20 minutes, washed and re-suspended in 1 X ChIP buffer and 
sonicated 3 times for 20 seconds using a Vibra-cell ultrasonic probe (SONICS).  
The crosslinks were reversed and the DNA from the chromatin was purified and 
analysed on 2% agarose gel. Most of the chromatin was digested to 3 nucleosomes in 
length (between 75bp and 500bp) (Figure 5.26) indicating that the length of time 
incubated with the enzyme or the volume could be reduced slightly in subsequent 
experiments to prevent over digestion. However these conditions were considered as 
optimal for this study since the downstream application was to sequence the ChIP 
samples.   
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Figure 5.26: Optimisation of chromatin digestion and fragmentation in REC-1 cells. Chromatin 
was digested with 0.5µl of micrococcal enzyme for 20 minutes and sonicated 3 times for 20 
seconds using a Vibra-cell ultrasonic probe. Chromatin was digested to 3 nucleosomes in 
length (between 75bp and 500bp). M= DNA ladder/marker. 
 
 
5.6.3 Preparation of chromatin samples for ChIP 
Using the same culture conditions and digestion and sonication conditions outlined 
above, chromatin samples were prepared from the following cell lines; REC-1, G519, 
and the acquired BTKi resistant cell lines REC-1/R (Ibr 1µM) and REC-1/R (Acal 1µM). A 
50µl aliquot was taken from each sample, the cross links were reversed (as before) and 
DNA was purified and quantified using a NanoDrop 2000 spectrophotometer. The DNA 
quantification values are shown in Table 5.3 and were used to standardise 
concentration of each sample in preparation for IP.  
Next, the original chromatin preparations from each cell line were diluted to 2µg in 
500µl of 1X ChIP buffer. This was recommended by the ChIP protocol to provide 
sufficient chromatin for immunoprecipitation and an optimal concentration for 
antibody binding using their CST ChIP validated antibodies. Ten microliters of each 2µg 
500bp 
75bp 
M 
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suspension was removed to a separate Eppendorf tube for the 2% input samples which 
were frozen at -20°C until a later stage of the protocol. The input DNA is used as a 
control for PCR effectiveness and is important in ChIP-sequencing data analysis. 
5.6.4 Immunoprecipitation of IRF4 from chromatin samples 
ChIP was performed using histone (H3), IRF4, and species-matched (normal rabbit) IgG 
antibodies (Table 5.1) on REC-1, G519 and acquired BTKi resistant REC-1 chromatin. 
The histone (H3) antibody was used as a positive control and the normal rabbit IgG was 
used as a negative control for establishment of the ChIP protocol. 
The indirect method of immunoprecipitation was performed by adding the appropriate 
volume of ChIP validated antibody to the 500µl of digested cross-linked chromatin. The 
amount of histone (H3) and normal IgG antibodies to add to the chromatin was 
specified by the kit protocol. The amount of ChIP validated IRF4 antibody added to the 
chromatin was a 1 in 25 dilution (specified on the product datasheet). 
The antigen/antibody complexes were separated from the solution on a magnet 
following incubation with ChIP grade protein G magnetic dynabeads. The beads 
containing the complex were then washed, the cross links were reversed and the DNA 
was purified. The efficiency of the ChIP was assessed by successful amplification of the 
ribosomal protein L30 (RPL30) locus using conventional PCR.  
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Table 5.3: Nanodrop assessment of DNA concentration and purity following DNA purification 
of various chromatin preparations pre immunoprecipitation.  
 
5.6.5 Assessment of the efficiency of immunoprecipitation from chromatin 
samples 
Histone H3 is an essential component of chromatin in the cell and is bound to most 
DNA sequences throughout the genome, including the RPL30 locus. Thus, IP of 
chromatin with the histone H3 antibody will enrich for the RPL30 gene and can be used 
as a positive control IP for almost any locus, including IRF4, while IP with the normal 
rabbit IgG will not result in RPL30 enrichment and is used as a negative control. 
 A volume of 5µl of each sample including the 2% input samples for REC-1 and G519 
was added to a PCR mix containing RPL30 primers and amplified with 40 rounds of 
PCR. A volume of 10µl of each sample was run on 2% agarose gel.  
Clear bands were present for the REC-1 2% input sample (taken from 2µg DNA) and 
the Histone H3 (positive control) sample but not the normal IgG sample (negative 
control) thereby confirming the efficiency of the ChIP procedure (Figure 5.27). The 
Sample  A260/280 (1.8-2.0) DNA Conc (ng/µl) 
REC-1 control 1 1.91 91.3 
REC-1 control 2 1.89 140.2 
REC-1 control 3 1.88 151.1 
REC-1/R (Ibr 1µM)  1.87 106.1 
REC-1/R (Acal 1µM)  1.86 91.2 
G519 1.86 146.0 
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RPL30 locus was amplified in all the IRF4 samples but to varying degrees. A very clear 
band was seen in the REC-1/R (Ibr 1µM) sample suggesting that the 2µg concentration 
of chromatin incubated with the IRF4 antibody was sufficient for effective IP of IRF4. 
Since all the chromatin samples were diluted to 2µg, it was suggested that some of the 
chromatin may have been lost during the wash steps in some of the samples. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.27: PCR validation of the ChIP samples. Chromatin immunoprecipitations were 
performed using digested chromatin from REC-1, G519 and REC-1/R cells and either Histone 
H3, IRF4 or Normal Rabbit IgG. Purified DNA was analysed by standard PCR methods using 
Human RPL30 Exon 3 Primers. PCR products were observed for RPL30 in the input samples for 
REC-1 (lane 1) and for G519 (lane 7) and for the IRF4 ChIP samples with and without BTKi, but 
not in the Normal Rabbit IgG ChIP sample (lane 3) or NTC (lane 9). RPL30 (161bp). M= DNA 
ladder/marker. 
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The ChIP samples underwent a number of pre-sequencing tests to confirm 
concentration and fragment length using high sensitivity DNA kits. A DNA 
concentration of 50ng is required for sequencing on the Ion Torrent, Ion personal 
genome machine (Ion PGM). Due to slight non-selective variation in results associated 
with UV spectrophotometry on the Nanodrop, final DNA concentrations before 
sequencing were determined using the Qubit® dsDNA High Sensitivity assay kit (Life 
Technologies).  
Despite the presence of DNA from all samples after 40 rounds of PCR, analysis of DNA 
concentration obtained using a qubit fluorimeter showed that the concentration of 
DNA in the original sample was too low for sequencing in 4 of the samples (Table 5.4). 
Furthermore, analysis of the 4 samples containing DNA using a bio-analyser showed a 
big peak of DNA in all samples at around 2kb. These fragments were too large to 
sequence on the Ion PGM. Smaller fragments were also present but were very faint 
suggesting the chromatin was not fully digested to the required length. Figure 5.28 
shows a gel like image of the DNA fragment size for each sample and Figure 5.29 
shows the Electropherograms, both obtained following analysis on the bio-analyser. 
 
 
 
 
 
 
212 
 
 
 
Table 5.4: High sensitivity analysis of DNA concentration for each ChIP sample and 2% inputs. 
Samples were re quantified using a Qubit high sensitivity DNA detection kit. Results show an 
adequate quantity of DNA in the input samples for REC-1 and G519 and in one of the IRF4 IP 
samples, but insufficient DNA quantity in four other IP samples precipitated from 2µg of 
chromatin. 
 
 
 
 
 
 
 
 
 
 
 
 
Sample  DNA Conc (ng/µl) Amount of DNA (µl) 
for sequencing (50ng) 
dH2O to 
39.5µl 
REC-1 2% Input 4.6 10.9 28.6 
REC-1 H3 10.2 4.9 34.6 
REC-1 IgG - 39.5 - 
REC-1 IRF4 - 39.5 - 
REC-1/R (Ibr 1µM) IRF4 2.7 18.5 21 
REC-1/R (Acal 1µM) IRF4 - 39.5 - 
G519 2% input  5.34 9.4 30.1 
G519 IRF4 - 39.5  
213 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.28: Electrophoresis gel-like image of each ChIP sample and the input samples. The 
four samples in Lane 3 (REC-1 IgG IP), Lane 4 (REC-1 IRF4 IP), Lane 6 (REC-1/R (Acal 1µM) IRF4 
IP)) and Lane 8 (G519 IRF4 IP) demonstrated complete absence of DNA. The four samples in 
Lane 1 (REC-1 2% input), Lane 2 (REC-1 Histone H3 IP), Lane 5 (REC-1/R (Ibr 1µM) IRF4 IP)) and 
lane 7 (G519 2% input) show presence of DNA however strong bands were present at around 
2000bp (2kb) as indicated. M= DNA ladder/marker. 
 
 
 
 
 
 
 
2Kb 
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Figure 5.29: Electropherograms obtained from the Bio-analyser showing DNA fragment size 
of each ChIP sample including the 2% inputs. The size of the DNA fragments is indicated by 
the numbers on the peaks. Red arrows point toward peaks of around 2Kb. 
 
 
REC-1 2% Input 
G519 2% Input 
REC-1 Histone H3 IP 
REC-1 normal IgG IP REC-1 IRF4 IP 
REC-1/R (Ibr 1µM) IRF4 IP REC-1/R (Acal 1µM) IRF4 IP 
G519 IRF4 IP 
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Given that there was no DNA in four of the samples, the experiment was repeated 
with the following optimisation steps. 
The seeding concentration of cells from each cell line remained the same at 5 X 106 in 
20ml culture media. However this time, the chromatin was digested using 0.8µl of 
micrococcal enzyme for 20 minutes with additional sonication in a water based 
bioruptor (Diagnode). For assessment of chromatin digestion and fragmentation, a ‘no 
sonication’ REC-1 control sample was added for comparison. Ten cycles of 30 seconds 
ON, and 30 seconds OFF produced appropriate length fragments (Figure 5.30). The 
purified DNA concentrations are shown in Table 5.5. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.30: Analysis of chromatin digestion and fragmentation pre immunoprecipitation- 
Experiment 2. Chromatin from 5 X 106 cells per sample was digested with 0.8µl of micrococcal 
nuclease and 10 rounds of sonication. The DNA was purified and 10μl was separated by 
electrophoresis on a 1% agarose gel. Lane 1 shows absence of DNA in the un digested/no 
sonication control, while lanes 2 – 7 show that the majority of chromatin from each sample 
was digested to 1 to 4 nucleosomes in length (150 to 500bp). M= DNA ladder/marker. 
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Table 5.5: Nanodrop assessment of DNA concentration and purity following DNA purification 
of various chromatin preparations pre immunoprecipitation- Experiment 2. 
 
Each chromatin sample was diluted to 2µg in 1X ChIP buffer. The same concentrations 
of antibodies were incubated with the chromatin. PCR validation of the ChIP procedure 
showed a clear band was present for the REC-1 and G519 input samples and the REC-1 
Histone H3 (positive control) but not the IgG sample, again confirming the efficiency of 
the ChIP procedure (Figure 5.31). However bands were very faint in all of the IRF4 
samples using the CST antibody at a concentration of 1 in 25. The DNA concentrations 
following IRF4 IP from 2µg of DNA were very low. The integrity of the DNA was also 
poor (Table 5.6). This suggested that concentration of chromatin to the specific IRF4 
antibody required further optimisation. 
 
 
 
 
 
 
 
Sample  A260/280 DNA Conc (ng/µl) 
REC-1  1.92 62.6 
REC-1  1.91 56.9 
REC-1  1.92 78.7 
REC-1/R (Ibr 1µM)  1.90 92.1 
REC-1/R (Acal 1µM)  1.89 195.8 
G519 1.90 118.8 
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Figure 5.31: PCR validation of ChIP procedure- Experiment 2. Chromatin 
immunoprecipitations were performed using digested chromatin from REC-1 and G519 cells 
and either Histone H3, IRF4 or Normal Rabbit IgG. Purified DNA was analysed by standard PCR 
methods using Human RPL30 Exon 3 Primers. PCR products were observed for RPL30 in the 
input samples for REC-1 (lane 1) and for G519 (lane 7), and the Histone H3 positive control 
(lane 2), but not in the Normal Rabbit IgG ChIP sample (lane 3), NTC (lane 9), or any of the IRF4 
ChIP samples (lanes 4, 5, 6 and 8). M= DNA ladder/marker. 
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Table 5.6: Nanodrop assessment of DNA concentration and purity following DNA purification 
of ChIP samples and 2 % inputs post immunoprecipitation- Experiment 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample  A260/280 DNA Conc (ng/µl) 
REC-1 (2% input)  1.97 10.2 
REC-1 (H3) 2.05 9.4 
REC-1 (IgG) 2.00 7.9 
REC-1 (IRF4) 2.20 3.0 
REC-1/R (Ibr 1µM) (IRF4) 3.62 1.6 
REC-1/R (Acal 1µM) (IRF4) 1.92 3.0 
G519 (2% input)  2.20 5.4 
G519 (IRF4) 2.23 3.6 
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A third experiment was performed using chromatin prepared from REC-1 and G519 
cells. This time, the chromatin was not diluted and the antibodies were added directly 
to the chromatin preparations at their original concentrations (also suggested by the 
protocol), therefore the chromatin concentration was increased but the antibody 
concentration was kept the same. In addition to using the CST IRF4 antibody, the 
alternative abcam MUM-1 antibody was tested. 
Immunoprecipitation of IRF4 was more defined using the anti-MUM-1 antibody and a 
chromatin concentration of 12µg (Figure 5.32, blue arrow), however whether this was 
due to the antibody or the higher concentration of chromatin was unclear.  
To determine whether the CST IRF4 antibody would be more effective at higher 
chromatin concentration, a 1 in 25 dilution of the antibody was incubated with 10µg of 
G519 chromatin and compared with results at 2µg.   
At 2µg, IRF4 was not successfully pulled out, however at 10µg, IP of IRF4 was much 
more defined (Figure 5.32, orange arrow).  
The DNA concentrations following IP from 10µg and 12µg chromatin were much higher 
than at 2µg, the quality of the DNA was also better (Table 5.7). 
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Figure 5.32: Immunoprecipitation of IRF4 at higher chromatin concentration. Chromatin 
immunoprecipitations were performed from different concentrations of digested chromatin 
from REC-1 and G519 cells and either Histone H3, Normal Rabbit IgG or IRF4 from cell 
signalling technology or MUM-1 from abcam. PCR products were observed for RPL30 in all 2% 
input samples including REC-1 (2µg), REC-1 (12µg), G519 (2µg) and G519 (10µg). PCR products 
were not present for IRF4 IP from REC-1 (2µg), or G519 (2µg). Products were clear for IRF4 IP 
from REC-1 chromatin (12µg) using the abcam anti MUM-1 antibody (blue arrow), and from 
G519 chromatin (10µg) using the CST anti-IRF4 antibody (orange arrow). No amplification of 
RPL30 was present in the Normal Rabbit IgG IP sample or NTC. M= DNA ladder/marker. 
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Table 5.7: Nanodrop assessment of DNA concentration and purity following ChIP at higher 
chromatin concentration. IRF4 was precipitated from higher concentrations of chromatin; 
10µg from G519, and 12µg from REC-1 chromatin. 
 
The DNA fragments from the G519 samples were analysed and re-quantified on the 
Bio-analyser using the high sensitivity DNA detection kit.  DNA was detected in the 
G519 2% input sample and most of the DNA fragments indicated on a gel-like image 
were between 150 and 200bp (Figure 5.33) and were sufficient for sequencing. Larger 
fragments were also present as shown on the electropherogram (Figure 5.34) but can 
be cleaned up using beads for size selection. The quantity of DNA detected in the G519 
2% input sample from the Bio-analyser using the high sensitivity kit was 10.9ng/µl, 
different to the nanodrop quantification 34.4ng/µl (Table 5.7). However, as shown in 
the gel-like image and electropherogram (Figure 5.33 and 5.34, respectively) no DNA 
was detected in the G519 IRF4 IP prepared from 10µg chromatin, despite the better 
DNA quantification and quality results obtained from the nanodrop. Again, it appeared 
that there was not sufficient DNA for sequencing. However, given the presence of DNA 
for the RPL30 locus following 40 rounds of PCR as shown on the agarose gel image 
(Figure 5.32, orange arrow), the G519 IRF4 sample was sequenced with the idea that 
the DNA would also be amplified in the process. 
Sample  A260/280 DNA Conc (ng/µl) 
 
REC-1 2% input 1.94 61.9 
 
REC-1 (abcam MUM-1 IP) 1.91 40.5 
 
G519 2% input 1.95 34.4 
 
G519 (CST IRF4 IP) 1.86 21.1 
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Figure 5.33: Electrophoresis gel-like image of the G519 2% input sample and the G519 IRF4 
sample following ChIP at higher chromatin concentration. ChIP of IRF4 was performed from 
10µg of G519 chromatin. DNA was detected by the Bio-analyser in the G519 2% input sample 
and most of the DNA fragments were between 150 and 200bp (lane 1). No DNA was detected 
in the G519 IRF4 IP prepared from 10µg chromatin (lane 2). M= DNA ladder/marker. 
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Figure 5.34: Electropherograms obtained from the Bio-analyser showing DNA fragment size 
for the G519 2% input sample and the IRF4 IP sample. The size of the DNA fragments is 
indicated by the numbers on the peaks. Small fragments were indicated by peaks of around 
100-250bp (red arrow) for the G519 2% input sample. No fragments were detected for the 
G519 IRF4 IP sample. Bio-analyser assessment of DNA concentration for the G519 2% input 
sample and the G519 IRF4 IP sample was 10.9ng/µl and 0.1ng/µl (respectively). 
 
 
 
 
 
 
G519 2% Input 
G519 IRF4 IP 
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The G519 IRF4 sample (10µg) was sequenced on the Ion PGM by Dr Michele Kiernan 
(University of Plymouth). Despite the absence of DNA obtained from the Bio-analyser, 
a successful library was generated from the sample and 79,000 reads were obtained.  
At this stage, the G519 IRF4 ChIP sample was only sequenced to see if sequencing 
reads could be obtained from the low amount of DNA. 
Therefore, the G519 IRF4 sample reads were aligned to the human genome with peak 
annotation (Figure 5.35). This generated a list of all peaks of > 0.0001 significance to 
either the 3’ or 5’ of genes and the distance the peak was from these genes (Table 5.8). 
However, in order to properly identify DNA sequences specifically bound to IRF4 in 
G519 cells, the normal IgG sample and the 2% G519 input sample should have been 
included to eliminate non-specific bias. Therefore detailed analysis was not 
undertaken, although given the interesting results from the protein co-
immunoprecipitation studies, a comparison of mitochondrial associated proteins 
(proteins from function group 2 and 6) was undertaken with potential IRF4 associated 
genes (Table 5.9).  This showed that IRF4 in G519 cells can be associated with DNA 
fragments from some of those proteins identified. 
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Figure 5.35: Peak annotations generated from the G519 ChIP sequencing reads. 
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Table 5.8: Sample of G519 sequencing read data. The list shows the results for the first 10 
IRF4 DNA targets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chr Region 
Center of 
peak Length 
Peak 
shape 
score P-value 5' gene 
5' 
distance 3' gene 
3' 
distance 
1 
125180106..
125180314 1.25E+08 209 26.53298 2E-155 RP11-344P13.1 3599581 CH17-333M13.2 18162865 
5 
49661458..4
9661574 49661504 117 23.14485 8.2E-119 CTD-2013M15.1 3765487 EMB 734617 
4 
49153148..4
9153288 49153198 141 17.90544 5.35E-72 TPI1P4 135993 RP11-1281K21.2 49882 
16 
46388681..4
6388807 46388743 127 17.09306 8.36E-66 PPP1R1AP2 10476164 ANKRD26P1 80533 
18 
108404..108
557 108470 154 15.32276 2.69E-53 RP11-683L23.6 14073 ROCK1P1 507 
3 
93470653..9
3470775 93470728 123 13.63451 1.25E-42 ABBA01000934.1 1956877 RNU6-488P 372988 
3 
93470416..9
3470545 93470449 130 13.57463 2.83E-42 ABBA01000934.1 1956640 RNU6-488P 373218 
16 
34583066..3
4583185 34583141 120 13.50516 7.29E-42 BCLAF1P2 314416 CTD-2144E22.9 358791 
Y 
11747623..1
1747716 11747669 94 12.75345 1.49E-37 RP11-295P22.2 273385 RCC2P1 33335 
5 
49659765..4
9659900 49659820 136 12.0967 5.5E-34 CTD-2013M15.1 3763794 EMB 736291 
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Mitochondrial and ribosome proteins IRF4-DNA 
binding sites 
Comments 
MRPS22 Mitochondrial Ribosomal Protein S22 0  
MRPS26 Mitochondrial Ribosomal Protein S26 0  
MRPS23 Mitochondrial Ribosomal Protein S23 0  
MRPS9 Mitochondrial Ribosomal Protein S9 0  
MRPL38 Mitochondrial Ribosomal Protein L38 0 Sites were found for MRPL 
32,33,35,37 and 39 
MRPL3 Mitochondrial Ribosomal Protein L3 1  
DAP3 Death-associated protein 3 1  
GADD45GIP1 Growth arrest and DNA-damage-
inducible proteins-interacting protein 1 
0  
Mitochondria and mitochondrial RNA   
ATP6V0D1 ATPase H+ transporting V0 subunit D1 2  
ATP5H ATP synthase, H+ transporting, 
mitochondrial Fo complex, subunit D 
0 Sites were found for 
ATP5HP2, P3, P4 
PPA2 Pyrophosphatase (Inorganic) 2 4  
ATP5O ATP Synthase Subunit O 0  
UQCRFS1 Ubiquinol-Cytochrome C Reductase, 
Rieske Iron-Sulfur Polypeptide 1 
3  
UQCRC2 Ubiquinol-Cytochrome C Reductase Core 
Protein 2) 
0 Sites were found for 
UQCRC2P1 
PMPCB Peptidase, Mitochondrial Processing Beta 
Subunit 
5  
TIMM44 Translocase Of Inner Mitochondrial 
Membrane 44 
2  
GRPEL1 GrpE Like 1, Mitochondrial 1  
KIAA1967 Deleted in Breast Cancer 1 0  
DNAJB1 DnaJ Heat Shock Protein Family (Hsp40) 
Member B1 
0 Sites were found for 
DNAJB8, 11, 12, 13, 14 
C11orl73 Chromosome 11, open reading frame 73 0 Sites were found for 33 
other Cllorf's 
DNAJ HSP40 (heat shock protein 40) 0  
 
Table 5.9: Comparison of mitochondrial associated proteins with potential IRF4 associated 
genes. 
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5.7 Discussion 
The results shown in this chapter attempt to characterise the role IRF4 has in 
neoplastic MCL cells. Results shown in chapter 3 and 4 demonstrate that the protein 
expression of IRF4 in MCL cells is downregulated in the neoplastic cells of both BTKi-
sensitive cell lines and primary cells, and that BTKi- resistance either innate or acquired 
either from pronged exposure to BTKi or through the influence of microenvironmental 
interactions do not show IRF4 downregulation. The initial question we asked was 
whether this downregulation was as a result of reduced gene transcription rather than 
because of increased protein degradation.  In REC-1 cells, IRF4 mRNA levels were 
found to be downregulated following Ibr treatment after 1 hour and maximally by 4 
hours correlating with the downregulation of IRF4 protein expression at 4-8 hours 
shown in previous chapters, suggesting that initial IRF4 expression-changes result from 
change to mRNA transcription as a specific response to treatment. However, IRF4 
mRNA levels were not maintained at this lower level with an increase seen over time 
although remaining lower relative to control. This differs to the protein expression of 
IRF4 in response to BTKi treatment which appears more downregulated with time 
suggesting additional/alternative mechanisms such as protein degradation are also 
involved in the control of IRF4. This response in mRNA levels was mirrored with Acal 
treatment although the response appeared delayed and may reflect the increased 
specificity of Acal and the higher reported IC50 dose.  
Further experiments indicated considerable differences in IRF4 mRNA expression in 
response to BTKi between sensitive and resistant cells. In the G519 cells IRF4 mRNA 
levels were shown to increase over time relative to the control cells with both Ibr and 
Acal BTKi, with an almost 10 fold increase seen at 48 hours in response to Ibr. This is 
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consistent with the observed changes to IRF4 protein expression in G519 cells 
particularly after 24 and 48 hours treatment.  This analysis clearly showed that the 
pattern of mRNA expression by G519 cells differed from that seen in BTKi treated REC-
1 cells. Similarly, in cells with acquired Ibr resistance (Ibr resistant REC-1 cells) IRF4 
mRNA was upregulated relative to the untreated control cells at 4 hours which differed 
to that observed with parental treated cells. 
These results suggest that the changes observed in IRF4 protein expression , at least at 
early stages, are at the level of transcription and differences exist in the transcription 
of IRF4 mRNA between cells with BTKi sensitivity and  resistance  which reflect IRF4 
protein expression. However, although these results are suggestive of a transcriptional 
control mechanism for IRF4, particularly given that IRF4 mRNA expression generally 
matched protein expression in each case, the fold change difference seen in REC-1 
cells following BTKi treatment was small and the sample size was small.  Therefore 
more replicates with the addition of  measurement of mRNA in control cells at the 
same time points (mRNA levels can vary under normal conditions ) would be required 
in order to confirm the significance of the data.   
To further determine the role IRF4 may have in response to BTKi treatment we looked 
for the protein associations of the molecule using co-immunoprecipitation. Initially this 
focussed on investigating the known interactions with the ETS family member PU.1 
which on binding with IRF4, results in release of the auto-inhibitory effect on the DNA 
binding region allowing IRF4 to bind its target sequence with much greater affinity 
(introduction section 1.4.1).  These interactions play an important role in B-cells 
maturation and development. However PU.1 was not detected in IRF4 protein 
precipitates from REC-1 cells following co-immunoprecipitation studies or in the mass 
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spectrometry analysis. In addition, we appreciate that failing to detect PU.1 in IRF4 
precipitates doesn’t prove lack of interaction. We therefore performed some further 
assessments of PU.1 expression in response to BTKi treatment. In assessing the 
response of PU.1 to BTKi treatment we found that in primary MCL cells co-cultured on 
stromal cells, unlike IRF4 expression,  protein PU.1 expression was not downregulated 
in response to BTKi when CD40L was absent and that PU.1 expression following MCL 
cell stimulation with CD40L remained stable (again the converse to what was seen with 
IRF4 protein expression). We would have expected if IRF4 and PU.1 were associated 
that they would show similar levels of expression. Assessment of levels of PU.1 mRNA 
in REC-1 cells further supports this contention. Expression of PU.1 mRNA in REC-1 cells 
in comparison to IRF4 mRNA levels was increased in response to BTKi with almost a log 
greater difference in PU.1 mRNA expression compared to IRF4 mRNA seen at 48 hours.  
Taken together these studies are suggestive that PU.1 is not a principal binding partner 
of IRF4 in our MCL cell lines, and that IRF4 regulates expression of its target genes 
through binding to other protein partners. 
Having explored the proteins of known associations with IRF4 we undertook further 
experiments to explore protein associations that had not previously been reported 
which might give insight into the role IRF4 plays in MCL biology.  
This element of the study employed immunoprecipitation as before, but in this case 
used mass spectrometry to determine protein association. The analysis identified a 
large number of co-precipitated proteins, the IRF4 protein itself was found only in 
precipitates where the specific antibodies were used and not seen in the control 
precipitates, confirming that the IP had worked. Further analysis of the co-precipitated 
proteins was therefore undertaken.   
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Initial analysis focussed on the subset of proteins (190 proteins) that were precipitated 
by both IRF4 test antibodies, but were not present in the control IP. This was done to 
focus on the proteins that were most likely to be significant. The proteins precipitated 
by both specific antibodies showed high similarity and data confidence analysis 
suggested that the probability of these proteins being co-precipitated by IRF4 but not 
control was p<0.00001 (chi squared test). Furthermore, analysis of functional 
relationships using STRING demonstrated that the proteins that were precipitated 
were linked at a functional level being mainly proteins with positive biosynthetic 
function: anabolic elements and were functionally consistent with a known function of 
IRF4 – to enhance anabolic processes196,197 and therefore the findings were biologically 
plausible. In particular, the link with mitochondrial proteins is interesting, this finding 
was not expected, however mitochondria have a recognised link to IRF4 196,197 and one 
that can be linked to chemo-resistance.198,199 
Further analysis to evaluate the specificity of IRF4 protein participates was undertaken. 
This analysis compared proteins which were present in control and IRF4 samples 
(presumed non-specific) with those present in both IRF4 precipitates (presumed 
specific), including proteins that were present or absent but also those that were 
significantly enriched (>2-fold) in either sample. This wider protein group was again 
analysed by STRING.  This analysis showed that ribosomal elements including RNA 
translational factors were a frequent finding in both the control and the IRF4 fractions, 
suggesting that some these protein types might be non-specific elements. However, 
one of the major aspects from the initial findings was confirmed – only the IRF4 test 
antibodies precipitated mitochondrial ribosomal elements. The presence of 
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mitochondrial ribosomal components only in IRF4 samples was highly significant 
(p<0.01 Chi square test). 
Therefore, the Proteomic study of IRF4 immunoprecipitation of REC-1 cells strongly 
suggests a particular association of IRF4 in REC-1 cells with mitochondrial ribosomal 
and functional processes. These results require confirmation by additional analysis, but 
are interesting. Mitochondrial proteins (while forming part of mitochondria) are 
encoded and synthesised by the main cellular DNA, not mitochondrial DNA, and are 
then exported to the cytoplasm where they are imported into the mitochondria and 
assembled. In short, it is plausible that IRF4 may associate with these proteins in 
nucleus, nucleolus or cytoplasm, the IRF4 does not have to enter the mitochondria to 
encounter them. We cannot say at what point the IRF4 binds to mitochondrial 
ribosomal proteins but given the functional link as referenced above it is certainly 
plausible that it might do so and that activation of mitochondrial function may 
contribute to the chemo-resistance associated with IRF4 expression.    
Experiments aiming to identify IRF4 target genes in BTKi sensitive and resistant MCL 
cell lines using ChIP analysis were limited due time constraints of this PhD and the 
extensive optimisation steps required for successful precipitation of IRF4 using the CST 
Simple ChIP enzymatic chromatin IP protocol.  
It was determined that a 20 minute incubation using 0.8ul of micrococcal nuclease 
with an additional 10 rounds of sonication was required in order to generate 
appropriate length fragments for ChIP-seq. This was confirmed by agarose gel 
electrophoresis and following assessment of the input DNA sample on the bio-
analyser. A concentration of 2µg of REC-1 chromatin was enough for successful ChIP of 
the histone H3 positive control as confirmed by amplification of the RPL30 locus, but 
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not for IRF4. At least 10µg of chromatin was required for immunoprecipitation of IRF4 
which showed a clear band for the RPL30 locus, however DNA from the G519 ChIP 
sample could not be detected using high sensitivity DNA quantification kits.  
Despite the absence of DNA, a successful library was generated from the G519 IRF4 
ChIP sample which may be due to the additional rounds of PCR required during DNA 
library preparation. In addition, a total of 79,000 reads were produced from the 
sample following sequencing of the DNA on the Ion Torrent PGM.  
Although the purified DNA from the G519 IRF4 ChIP sample was successfully 
sequenced, the resulting peaks are only relevant with an input DNA control. This would 
normally be sequenced in parallel with the ChIP sample. 
Furthermore, even though the reads generated were aligned to the human genome, 
the DNA sequences bound to IRF4 could not be accurately determined due to the 
absence of an appropriate IgG control. However it was noted that Spi-1 (the gene 
which gives rise to PU.1), was not detected in the G519 IRF4 DNA, providing further 
evidence for the lack of association with IRF4 in MCL. In addition, within the limitations 
outlined above and that this analysis was performed in G519 cells , it is interesting to 
note that genes which denote mitochondrial /ribosomal function were detected  in the 
G519 IRF4 DNA again suggesting a link of IRF4 to mitochondrial function. 
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MCL is a rare B-cell lymphoproliferative disorder that generally has poor outcome 
following conventional therapy. Inhibitors of BTK have significantly improved 
treatment outcomes for MCL patients. However it remains that a significant fraction of 
patients have primary resistance to BTKi and responding patients inevitably develop 
acquired resistance with aggressive relapse of the disease. Resistance to BTKi is 
therefore a major challenge in the management of MCL. 
This thesis builds on from existing knowledge of the mechanisms underlying the 
sensitivity of MCL cells to the first in class BTKi Ibr, and contributes further knowledge 
using the more selective BTKi Acal.  
In addition, this thesis contributes a significant body of evidence implicating IRF4 in 
BTKi response in both MCL cell lines and in primary cells possibly arising from 
activation of alternative survival pathways which modulate ERK1/2 phosphorylation.  
The findings with respect to IRF4 suggest it may have a role as a mediator of BTKi 
treatment-resistance in MCL and as a biomarker to predict response to BTKi therapy in 
the clinical setting. 
The downregulation of IRF4 in response to BTKi was significantly opposed following 
CD40L stimulation, therefore implicating CD40 signalling as a possible mechanism of 
resistance to BTKi within the cellular microenvironment of MCL. Further assessment of 
IRF4 protein interactions using the MCL cell line REC-1 identified a novel group of 
proteins associated with mitochondria which may be involved in mediating the IRF4-
mediated resistance to treatment with BTKi. Further investigation of these interactions 
may indicate novel targets for the design of therapeutic combinations which can 
overcome BTKi resistance in MCL.  
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6.1.1 Cellular responses to BTKi in MCL 
Given the spontaneous apoptosis of primary MCL cells in vitro, this study set out to 
characterise MCL cell line models of BTKi sensitivity and resistance. Previous studies 
have reported that the REC-1 cell line is valuable for the analysis of BTKi in MCL 26,106,200 
and this was confirmed and extended in this study: The REC-1 cells demonstrated 
sensitivity to BTKi showing dose dependant apoptosis in response to Ibr and a 
reduction of proliferation in response to both Ibr and Acal. In contrast, BTKi had no 
effect on G519 cells, again supporting other studies which have characterised these 
cells as BTKi resistant.145,201  
The JEKO-1 and JVM2 cells were also characterised as BTKi resistant as they only 
responded to Ibr at high dosage (10µM) which is likely to cause off-target activity in 
the cells due to the broad specificity of the Ibr kinome and indicates that effects 
observed at high dosage may not be a direct effect of BTK inhibition. This was 
supported by results using the more selective BTKi Acal, which compared with Ibr, did 
not induce substantial apoptosis in REC-1 cells or show any evidence of off-target 
effects even at exceptionally high dose.  
The findings with REC-1 are in accordance with another study reporting that minimal 
apoptosis was observed in REC-1 cells in response to the second generation BTKi, 
Spebrutinib (CC-292).106 Rather, inhibition of BTK in this study and others identify 
predominant effects on proliferation.145 In our studies, the effects on proliferation 
were not only induced by Ibr but also by Acal and both inhibitors reduced proliferation 
of REC-1 cells equally at low dosage (100nM). 
The observed low levels of apoptosis seen with treatment of MCL cells with BTKi is 
supported  by  both others in the field and by clinical observations -  in patients treated 
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with BTKi,  rapid apoptosis of circulating neoplastic cells  is not seen. However one of 
the known mechanisms of action of BTKi is to disrupt integrin mediated adhesion to 
the tissues rather than to directly inhibit survival. Again this is supported by clinical 
observations of the lymphocytosis seen in MCL and CLL patients directly following BTKi 
therapy which is accompanied by lymph node shrinkage.  This lack of cell attachment 
to the extracellular matrix (ECM)132,202 has been suggested to result in anoikis (a form 
of programmed cell death) of the leukaemia cells.   Certainly the mechanisms resulting 
in MCL cell death following BTKi treatment are not fully understood and could be a 
consideration for future work. 
6.1.2 Effect of the MCL microenvironment on the cellular response to BTKi 
MCL cells are recognised to be supported by accessory cells within a 
microenvironment providing signals for growth and survival, and known to be a major 
factor in causing resistance to chemotherapy. To investigate whether this MCL 
microenvironment influences responses to BTKi, this study developed a 2D in vitro 
model using two murine fibroblasts cell lines, one expressing CD40L and the other not 
expressing CD40L.  
It was rather surprising to find that REC-1 cells demonstrated dependency on CD40L; 
co-culture with fibroblast cells in the absence of CD40L did not alter the cellular 
response to BTKi, but co-culture in the presence of CD40L prevented the reduction in 
proliferation and attenuated cell death in response to BTKi. The murine fibroblasts 
expressing CD40L were also shown to support the survival of ex vivo primary MCL cells. 
The aggressive MCL subtypes demonstrated increased dependence on CD40L over the 
indolent subtypes, which has been shown in previous unpublished results by our group 
(Dr David Tucker, MD awarded 2017).  In response to BTKi, the primary MCL cells 
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behaved similarly to REC-1 cells showing increased apoptosis in response to Ibr while 
apoptosis was prevented in the presence of CD40L.    
In summary, these results demonstrated that REC-1 cells have a dependency on the 
tissue microenvironment in response to CD40L which mimics the behaviour of the cells 
in vivo and therefore represents a useful model to explore BTKi resistance pathways in 
MCL, and also suggests that CD40 signalling may play an important role in resistance to 
BTKi by increasing survival. 
6.1.3 Signalling responses to BTKi in MCL  
All MCL cell lines whether sensitive or resistant to Ibr, showed increased 
phosphorylation of BTK (pBTK-Y223) following IgM stimulation which was reduced 
following BTKi treatment. Similar results were seen in primary MCL cells although the 
degree of pBTK-Y223 following IgM stimulation was variable between cases.  
Again, in all cell lines, activation of the downstream effector molecule ERK1/2, 
appeared to be dependent on BTK signals as it was inhibited following Ibr treatment. 
These findings do not correlate with the cellular responses of each cell line following 
BTKi treatment and indicate that resistance mechanisms occur further downstream 
from ERK1/2. However, in the presence of BCR activation and CD40 stimulation, 
ERK1/2 phosphorylation was only partially reduced, suggesting that there is an 
additional route for ERK1/2 activation induced by BCR or CD40 signalling, possibly 
through activation of MAPK and PI3K pathways. A previous study by Ma et al 145 
showed that reduced phosphorylation of ERK and AKT levels after Ibr treatment 
correlated with cytotoxic sensitivity of MCL cells. It has been suggested by others that 
activation of PI3K-AKT causes primary resistance to Ibr in MCL.138,145 Therefore it would 
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seem mechanistically plausible for clinical studies to use BTKi in combination with PI3K 
inhibitors. 
6.1.4 IRF4 expression in response to BTKi in MCL  
The role of IRF4 in the pathogenesis of other NHLs such as DLBCL and MM is well 
understood. Both DLBCL and MM respond well to treatment which downregulates 
IRF4 expression. IRF4 also has defined roles in CLL, HL and ALL and is believed to 
contribute to disease pathogenesis. Evidence supporting a role for IRF4 in MCL biology 
is lacking, so given the preliminary results by the group indicating downregulation of 
IRF4  in CLL patients treated with BTKi, it was of  particular interest to investigate its 
expression in response to BTKi treatment in MCL. 
This study showed that IRF4 was downregulated by BTKi (both Ibr and Acal) in sensitive 
REC-1 cells, but not in REC-1 cells with acquired Ibr resistance or any of the innate 
resistant cell lines. Expression of IRF4 mRNA showed that downregulation of IRF4 was 
an early response to BTKi treatment in REC-1 cells and was prevented / increased in 
REC-1 cells with acquired Ibr resistance. These findings were validated in primary MCL 
cell samples from treated patients (n=8) analysed before and during BTKi treatment 
showing that IRF4 was downregulated in 7 samples from patients shown to be 
clinically responding to BTKi and was not downregulated in 1 refractory case.  
Consistent with the protein and mRNA expression of IRF4 in sensitive REC-1 cells in 
response to Ibr, IRF4 downregulation was also shown to be an early response to 
therapy occurring within the first treatment cycle and was sustained over several 
treatment cycles until relapse when its downregulation was prevented. Furthermore, 
IRF4 was not downregulated over several treatment cycles in a patient demonstrating 
primary resistance to BTKi (determined clinically).  
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These findings indicated that IRF4 may be involved in the development of both primary 
and acquired resistance to BTKi in MCL. In addition the observation that IRF4 was 
involved in treatment response to BTKi indicated it may have potential use as a 
biomarker in a clinical setting.  
Although only representative of 8 cases, these results represent the largest study of 
IRF4 expression in matched pre and post BTKi treatment patient samples thus far and 
show encouraging results. A larger panel of MCL patient samples would however 
strengthen the data. 
Modulation of IRF4 by CD40 signalling, a potential mechanism of BTKi resistance 
Unlike pERK, the downregulation of IRF4 was not altered in response to BCR activation 
in sensitive REC-1 cells; IRF4 was however modulated by CD40L stimulation which 
prevented its down-regulation in response to Ibr and Acal. This correlates with the 
enhanced survival and proliferation of the REC-1 cells and suggests an alternative 
route for IRF4 activation, possibly via CD40L induced activation of NFB which is a 
direct target of IRF4.147  In vitro experiments with primary MCL cells were consistent 
with results from REC-1 cells, IRF4 was downregulated by BTKi (both Ibr and Acal) in 
the absence of CD40L, but this effect was prevented in the presence of CD40L.   
Recently, it has been demonstrated that CD40L activation of the alternative NFB 
pathway has a major impact on the drug response in MCL. Rauert-Wunderlich et al 203  
showed that CD40L activation of the alternative NFB pathway in MCL led to 
independency of classical NFB signalling which resulted in resistance to BCR 
inhibitors. 
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Taken together these findings suggest that signals from the tissue microenvironment 
may modulate drug response in MCL and that CD40L signalling may have a role in 
resistance to BTK inhibitors by modulating expression of IRF4 through NFB. On the 
other hand, dependency on CD40L was lost in REC-1 cells with acquired BTKi resistance 
(both Ibr and Acal) suggesting that ‘acquired resistance’ to BTKi more likely occurs 
through an intrinsic mechanism. Furthermore, BTK activation was restored in these 
cells in the presence of both Ibr and Acal and correlated with the sustained 
proliferation of the cells. 
It is possible that the REC-1 cells with acquired BTKi resistance had developed a BTK 
mutation, as has been described in patients on BTKi in CLL and MCL and discussed in 
further detail in the introduction (section 1.3.7), causing ineffective binding of each 
inhibitor to the BTK C481 residue, and therefore BTK phosphorylation was no longer 
reduced in response to BTKi.  Indeed in these cells we saw an increased level of pBTK-
Y223 suggesting a more aggressive proliferative phenotype. This would also explain the 
sustained levels of IRF4 in REC-1 cells with acquired Ibr resistance which were not 
downregulated by Ibr and matched IRF4 expression seen in the untreated parent REC-
1 cells. 
However, this is different from the innate resistant cells (G519, JEKO-1 and JVM2) in 
which pBTK Y223 was reduced and IRF4 was not downregulated by BTKi suggesting the 
drug was still able to bind, only it was ineffective suggesting modulation via other 
mechanisms, such as alternative pathway activation via stimulation from the 
microenvironment, are involved in primary resistance. Detection of the BTK C418S 
mutation was not carried out in this study but would be a consideration in future 
studies in order to confirm the predictions made above. This could be carried out on 
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parent REC-1 cells and compared with the acquired BTKi resistant REC-1 cells and an 
MCL cell line with innate BTKi resistance such as G519.  
Assessment of IRF4-protein interactions in REC-1 cells  
It is well known that the most common binding partner for IRF4 in B-cells is ETS family 
member PU.1.150,151,159 This study showed no evidence of IRF4 interacting with PU.1 in 
BTKi sensitive REC-1 cells, and no link between PU.1 and IRF4 response to BTKi in 
primary MCL cells.  Interestingly, detailed assessment of IRF4- protein interactions by 
SWATH mass spectrometry revealed a strong relationship with mitochondrial proteins. 
This finding was novel, however mitochondria have a recognised link to IRF4 197 and 
one that can be linked to chemo-resistance. In studies of CLL, resistance to 
chemotherapy has been associated with increased mitochondrial mass which reduced 
sensitivity to fludarabine nucleoside 198 and correlated with the apoptotic response of 
the CLL cells. 
Further work will need to be carried out to prove the significance of these protein 
interactions and whether BTKi have effects on mitochondrial function. 
Use of IRF4 as a biomarker of BTKi response 
Findings from this study provide evidence that IRF4 is associated with response to BTKi 
treatment in MCL and could have potential use as a biomarker to predict response to 
BTKi therapy in a clinical setting.  
This would prevent unnecessary administration of BTKi to patients who do not respond 
to therapy (identified by absence of IRF4 downregulation within the first treatment 
cycle) and also those who are acquiring resistance to BTKi (identified by sustained IRF4 
expression following a period of downregulation). Early prediction of response to BTKi 
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would allow patients to be treated with alternative treatment options and thus 
improve treatment outcomes. 
Other studies have suggested early detection of the relapse specific mutation during 
Ibr treatment by identification of an evolving minute mutant clone.135  At present, this 
can only be achieved using deep targeted sequencing of the BTK gene either through 
NGS, which is costly, or Sanger sequencing (less sensitive), this however would not 
benefit cases of primary BTKi resistance where  it has been shown in previous studies 
that the mutation is not present.138  
Therefore monitoring IRF4 protein levels by flow cytometry or ELISA (enzyme-linked 
immunosorbent assay), would be a cheaper alternative to sequencing and would 
determine both primary BTKi resistance as well as onset of secondary resistance to Ibr 
and other BTK inhibitors. The use of flow cytometry to assess IRF4 levels along with 
pBTK-Y223 expression in the neoplastic B-cells would be a rapid and cost effective 
method to monitor patients on BTKi treatment compared to screening all patient 
samples for the presence of BTK mutations by NGS.  
Using data generated from this study, our group are currently optimising a method for 
assessment of IRF4 expression by flow cytometry in paired pre-treatment / BTKi-
treated samples in patients with CLL where IRF4 expression specifically in the 
neoplastic B-cells can be determined. CLL cases were chosen for optimisation studies 
due to the more frequent condition and guaranteed peripheral lymphocytosis which 
can be validated against detection of IRF4 by western blotting and 
immunohybridisation studies.  It is however anticipated that this will be assessed in 
MCL patients on BTKi treatment once these initial optimisation and validation steps 
are confirmed. 
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6.1.5 Alternative therapy combinations 
It was hoped that results from the chromatin IP studies would have generated insights 
into the role IRF4 may have in BTKi treatment in MCL.  This work is on-going but having 
performed initial optimisation experiments with the generation of gene-annotated 
reads it can be continued.  The proteomic study revealed some interesting insights, 
again which need validation, but which confirmed, could potentiate the evaluation of 
drugs which target mitochondrial function. Venetoclax is an oral selective BCL2 
inhibitor which is known to target mitochondrial metabolism and indeed combinations 
of Ibr with Venetoclax are showing promise 204 and are currently being evaluated in on-
going clinical trials.  
Our studies also show that MCL cells can overcome sensitivity to BTK inhibition 
through alternative pathway activation. It has been shown by others that one 
consequence of relapse-specific mutation is the activation of PI3K and CDK4 pathways 
which promote cell survival and proliferation.138 MCL is driven by cyclin D1 
overexpression, and it has been shown that blocking CDK4 (which normally interacts 
with cyclin D1 to promote cell cycle progression) makes Ibr-resistant cells carrying the 
relapse-specific mutation sensitive to drugs that inhibit PI3K and also re-sensitises cells 
to Ibr. Therefore it has been suggested that targeting CDK4 with palbociclib plus a BTK 
inhibitor may be able to override acquired resistance in MCL.  
Given the knowledge that in both DLBCL and MM IRF4 expression is downregulated 
upon treatment with lenolidomide it was interesting to note that during the course of 
this study a clinical trial was initiated testing lenolidamide in combination with Ibr in 
MCL (Trial ID: NCT02446236) and has shown encouraging results. This again is 
suggestive of the role IRF4 may have in the BTKi-treatment response in MCL. 
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6.1.6 Conclusion  
This thesis contributes significantly to the understanding on the particular sensitivity of 
MCL cells to BTK inhibition. Overall, this study has identified that BTKi induces 
downregulation of IRF4 in sensitive but not resistant MCL cell lines, and that 
downregulation is opposed by CD40L. CD40L encountered in the cellular 
microenvironment supports the proliferation and survival of MCL cells, and protects 
them from the effects of BTK inhibition.  This suggests that the expression of IRF4 
following treatment with BTKi might be a biomarker for BTKi-sensitivity in MCL, and 
that mitochondrial proteins modulated by IRF4 may play an important role in MCL 
treatment response. 
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Analysis of flow cytometry data  
 
Results were acquired using a BD AccuriTM C6 flow cytometer (BD) and data were 
analysed using BD AccuriTM CFlow Plus software (BD Biosciences).  
For analysis of apoptosis, a two dimensional (2D) plot of forward/side scatter identified 
populations of apoptotic or dead cells (small with low-forward scatter and irregular 
with increased side scatter) (Figure_Apx 1). This population was confirmed to express 
Annexin V consistent with the occurrence of apoptosis. Using this plot, the viable and 
apoptotic/dead cells were separately gated to determine the percentage viability 
within the sample (Figure_Apx 2). 
For the remainder of analyses, a gate was placed only around the viable lymphocyte 
population and assessed in relation to fluorescence of an isotype control. Proliferation 
was assessed using the nuclear proliferation antigen Ki67 and expressed according to 
the percentage of permeabilised viable cells expressing Ki67 –FITC (Figure_Apx 3). The 
activation of BTK was assessed using an antibody recognising phosphorylation of one 
of the activation epitopes of BTK (pBTK-Y223-PE) in permeabilised cells. The activation 
of BTK in these cells was expressed as the median fluorescence intensity of the peak. 
The median rather than the mean was chosen as the peaks produced from primary 
cells would often be skewed (Figure_Apx 4).       
For experiments using primary MCL cells, a forward / side scatter plot was obtained 
and a gate was placed on the population of cells containing lymphocytes (similar to the 
cell line approach above).  The CD5 / CD19 dual-staining population of cells (mantle 
cell population) within this gate were identified according to their fluorescence 
(compared with isotype control antibody). Apoptosis, proliferation and BTK 
phosphorylation data was determined as previously described, but only from the 
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CD5/19 positive population of cells.  Example of analysis plots to determine the 
percentage of apoptosis of primary cells labelled with MCL surface markers is shown 
(Figure_Apx 5) or median fluorescence intensity of BTK Y223 phosphorylation in 
primary MCL cells (Figure_Apx 6). 
 
 
 
 
 
 
 
Figure_Apx 1: Populations of viable or apoptotic lymphocytes using a forward (FSC-A) vs side 
scatter (SSC-A) plot. Viable lymphocytes with high forward scatter are shown in black, 
apoptotic/dead cells with low forward scatter and high side-scatter are shown in red.  
 
 
 
 
 
 
 
 
Figure_Apx 2: Example of FACS analysis plots used to determine the percentage of apoptosis 
of MCL cell lines. Using a forward/side scatter plot, a gate was placed around the population 
of cells containing both viable and apoptotic lymphocytes (labelled P1) (left).  Analysis on 
these cells using a peak plot of FITC fluorescence determined two defined populations.  A 
threshold line was placed between these defined populations to determine the percentage of 
annexin V-positive cells, shown in V1-R (right). 
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Figure_Apx 3: Example of FACS analysis plots used to determine the percentage of 
proliferation of MCL cell lines. Using a forward/side scatter plot, a gate was placed around the 
population of cells containing only the viable lymphocytes (labelled P1) (left). Using a peak 
plot, fluorescence from FITC labelled Ki67 positive cells was gated on the P1 cell population. A 
threshold line was placed between the Ki67 negative and positive cells to determine the 
percentage of the peak containing Ki67 positive cells, shown in V1-R (right). 
 
 
 
 
 
 
 
 
 
Figure_Apx 4: Example of FACS analysis plots used to calculate the median fluorescence 
intensity for BTK phosphorylation in MCL cell lines. Using a forward/side scatter plot, a gate 
was placed around the population of cells containing only the viable lymphocytes (labelled P1) 
(left). The median fluorescence intensity was calculated for PE labelled BTK Y223 positive cells 
gated on P1. 
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Figure_Apx 5: Example analysis plots of apoptosis in primary MCL cells. Using a forward/side 
scatter plot, a gate was placed around the population of cells containing lymphocytes (labelled 
P1) (top left). An isotype control (top right) and CD5/CD19 positive population (bottom left) 
allowed MCL cells to be identified. The percentage of annexin V-positive cells was applied to 
the CD5/CD19 positive cells to obtain the level of apoptosis (bottom right). 
 
 
 
 
 
 
 
Unstained cells  Isotype control cells             
IgG1-PE/ IgG1-APC 
CD19-APC/CD5-PE 
positive cells 
Apoptosis of CD19/CD5 
positive cells only 
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Figure_Apx 6: Analysis to determine median fluorescence intensity of BTK Y223 
phosphorylation in primary MCL cells. Using the gating strategy described in Figure_Apx 5, the 
median fluorescence intensity of the BTK Y223-PE peak was determined for the CD5/CD19 
positive cells. 
  
Unstained viable cells shown in P1  Isotype control cells             
IgG1-FITC/ IgG1-PE/ IgG1-APC 
CD19-FITC/CD5-APC positive 
cells shown in Q5-UR 
Phosphorylation of BTK Y223-PE in 
CD19/CD5 positive cells only 
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